Novel genes encoding protein kinase/protein phosphatase

ABSTRACT

Selection of clones having the kinase and/or phosphatase-like structure from clones which had been isolated and the structures thereof had been determined in the Helix Research Institute (helix clones; Japanese Patent Application No.  2000 - 183767 ) was conducted. Twelve novel genes were provided by carrying out homology search for all the helix clones by using the amino acid sequences of known kinases and phosphatases as queries. The genes are expected to be involved in intracellular signal transduction. The physiological functions of the inventive genes can be tested by using reporter gene assay systems capable of detecting signal transduction. The proteins of the present invention are useful as target molecules in drug discovery and in the development of new pharmaceuticals.

[0001] This application is a continuation-in-part of PCT/JP00/05060, filed Jul. 28, 2000, which claims priority to U.S. Provisional Application Nos. 60/159,590, filed Oct. 18, 1999, and 60/183,322, filed Feb. 17, 2000; and Japanese Patent Application Nos. 11 -248036, filed Jul. 29, 1999; 2000-118776, filed Jan. 11, 2000; and 2000-183767, filed May 2, 2000.

TECHNICAL FIELD

[0002] The present invention relates to novel human protein kinases and protein phosphatases, as well as to genes encoding the proteins.

BACKGROUND

[0003] A variety of physiological functions of cells have to be regulated correctly and harmoniously according to need for cells to differtiate/proliferate into normal cells, and further to exert functions at the tissue level. It has been well known that the regulation of the state of protein phosphorylation by protein phosphorylation enzyme/protein kinase (hereinafter referred to as “kinase”) and protein dephosphorylation enzyme/protein phosphatase (hereinafter referred to as “phosphatase”) plays a central role in most of such regulatory mechanisms.

[0004] Many kinase and phosphatase genes have been identified to date. It has been clarified that they form a very large protein family with a well conserved structure (Semin. Cell Biol. 5(6):367-76, 1994; Cell 80(2):225-36, 1995; Genes Cells 1(2):147-69, 1996; Trends Biochem. Sci. 22(1):18-22, 1997; Proc Natl Acad Sci USA, 96(24):13603-10, 1999). The presence of numerous types of kinases and phosphatases in cells suggests that many types of intracellular physiological functions are precisely regulated by kinases and phosphatases. Thus, there is a possibility that agents acting on kinase or phosphatase can more precisely control physiological functions as compared with known agents represented by receptor agonist or receptor antagonist. Therefore, it is expected that agents acting on kinase or phosphatase are agents, which undesirable side effects can be much easily separated from the main effects, and accordingly, may function as highly useful pharmaceuticals.

[0005] In order to develop such agents acting on kinase or phosphatase, first, it is required to specify the intracellular physiological function associated with each of the kinases and phosphatases, and gain some information indicating the medical usefulness of suppressing or activating the function. Many types of kinases and phosphatases have been already isolated and studied. However, there may exist many unidentified molecules. Furthermore, with respect to kinases and phosphatases the genes of which have been isolated, it can be stated that information on intracellular physiological functions related with each kinase or phosphatase still are poor and has to be clarified. The identification of new kinase and phosphatase as well as clarification of physiological functions thereof is expected to make significant progress in the development of new pharmaceuticals and therapies.

SUMMARY

[0006] The object of the present invention is to provide novel human protein kinase and protein phosphatase proteins, genes encoding the proteins, as well as production and uses of the same.

[0007] To accomplish the object described above, the present inventors strenuously carried out researches as follows. First, the present inventors tried to select clones having the kinase/phosphatase-like structure (KP clones) from clones which had been isolated and the structures of which had been determined in the Helix Research Institute (hereinafter referred to as “helix clones”; Japanese Patent Application No. Hei 11-248036). These helix clones are highly expected to have the full-length sequence, which were obtained by the combined use of; [1] preparation of a cDNA library containing sequences of full-length at a high rate achieved by the oligo-capping method; and [2] evaluation system for the completeness in cDNA length based on the 5′-end sequence (the selection is achieved based on the evaluation using ATGpr after eliminating non-fall length clones as compared with an EST). In addition, they are highly advantageous since the cDNAs are already inserted into a mammalian expression vector, they can be used promptly in experiments for the expression in cells.

[0008] The present inventors carried out homology search for all the helix clones using the amino acid sequences of known kinases and phosphatases as queries, and selected 12 clones: “C-NT2RP2000668”, “C-HEMBA1002212”, “C-NT2RM4001411 ”, “C-NT2RM4001758”, “C-NT2RP2002710”, “C-NT2RP2004933”, “C-PLACE1011923”, “C-NT2RP2001839”, “C-HEMBA1006173”, “C-OVARC 1000556”, “C-PLACE2000034”, and “C-HEMBA1001019” (hereinafter referred to as “KP clones”). These KP clones contain full-length cDNAs encoding novel human proteins. It has been known that many of known kinases and phosphatases are associated with a variety of signal transduction pathways in cells. Therefore, there is the possibility that the newly found KP clones having the kinase/phosphatase-like structure are also associated with some signal transduction pathways. The potential of the KP clones as target molecules in drug discovery can be explored through evaluating these KP clones in various assay systems using reporter genes and deducing the physiological functions thereof.

[0009] As described above, the present inventors found novel kinase/phosphatase proteins, and thereby accomplished the present invention.

[0010] Specifically, the present invention relates to novel human protein kinase and protein phosphatase proteins, genes encoding the proteins, and production and uses of the proteins and genes. More specifically, the present invention provides the following:

[0011] [1] a DNA of any one of the following (a) to (d):

[0012] (a) a DNA encoding a protein consisting of the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22,

[0013] (b) a DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21,

[0014] (c) a DNA encoding a protein which (i) comprises the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22 in which one or more amino acids are substituted, deleted, inserted and/or added, and (ii) is functionally equivalent to the protein consisting of the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22, and

[0015] (d) a DNA hybridizing under a stringent condition to a DNA consisting of the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21, which encodes a protein functionally equivalent to the protein consisting of the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22;

[0016] [2] a DNA encoding a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22;

[0017] [3] a DNA comprising the nucleotide sequence of SEQ ID NO:24;

[0018] [4] a protein or partial peptide encoded by the DNA of [1] or [2];

[0019] [5] a polypeptide comprising the amino acid sequence of SEQ ID NO:25;

[0020] [6] a vector into which a DNA of any one of [1] to [3] has been inserted;

[0021] [7] a host cell containing a DNA of any one of [1] to [3], or the vector of [6];

[0022] [8] a method for producing the protein or peptide of [4] or [5], which comprises the steps of culturing the host cell of [7], and recovering the expressed protein from the host cell or the culture supernatant;

[0023] [9] an antibody binding to the protein or peptide of [4] or [5];

[0024] 5[10] a polynucleotide containing at least 15 nucleotides complementary to a DNA consisting of the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21 or the complementary strand thereof; and

[0025] [11] a method of screening for a compound that binds to the protein or peptide of [4] or [5], which comprises the steps of:

[0026] (a) contacting a test sample containing at least one compound with the protein or peptide,

[0027] (b) detecting the binding activity of the compound with the protein or peptide, and

[0028] (c) selecting the compound that has the activity of binding to the protein or peptide.

[0029] The present invention provides human-derived genes “C-NT2RP2000668”, “C-HEMBA1002212”, “C-NT2RM4001411”, “C-NT2RM4001758”, “C-NT2RP2002710”, “C-NT2RP2004933”, “C-PLACE1011923”, “C-NT2RP2001839”, “C-HEMBA1006173”, “C-OVARC1000556”, “C-PLACE2000034”, and “C-HEMBA1001019” that encode novel kinases/phosphatases. SEQ ID NOs of the nucleotide sequences of these human-derived cDNAs and the amino acid sequences encoded by the cDNAs are shown below. Gene name cDNA Protein C-NT2RP2000668 SEQ ID NO:1 SEQ ID NO:2 C-HEMBA1002212 SEQ ID NO:3 SEQ ID NO:4 C-NT2RM4001411 SEQ ID NO:5 SEQ ID NO:6 C-NT2RM4001758 SEQ ID NO:7 SEQ ID NO:8 C-NT2RP2002710 SEQ ID NO:9 SEQ ID NO:10 C-NT2RP2004933 SEQ ID NO:11 SEQ ID NO:12 C-PLACE1011923 SEQ ID NO:13 SEQ ID NO:14 C-NT2RP2001839 SEQ ID NO:15 SEQ ID NO:16 C-HEMBA1006173 SEQ ID NO:17 SEQ ID NO:18 C-OVARC1000556 SEQ ID NO:19 SEQ ID NO:20 C-PLACE2000034 SEQ ID NO:21 SEQ ID NO:22 C-HEMBA1001019 SEQ ID NO:23

[0030] Further, the nucleotide sequence of a partial fragment of CDNA “C-HEMBA100 119” of SEQ ID NO:23 is shown in SEQ ID NO:24, and the amino acid sequence of the protein encoded by the cDNA fragment is shown in SEQ ID NO:25.

[0031] Hereinafter, unless otherwise stated, the above-mentioned genes of the present invention, “C-NT2RP2000668”, “C-HEMBA1002212”, “C-NT2RM4001411 ”, “C-NT2RM4001758”, “C-NT2RP2002710”, “C-NT2RP2004933”, “C-PLACE1011923”, “C-NT2RP2001839”, “C-HEMBA1006173”, “C-OVARC1000556”, “C-PLACE2000034”, and “C-HEMBA1001019” are collectively called “KP genes”, and proteins encoded by respective genes are collectively called “KP proteins” (“C-HEMBA1001019” is a protein consisting of the amino acid sequence of SEQ ID NO:25).

[0032] The inventive KP proteins were selected as clones having the kinase/phosphatase-like structure from the clones isolated and whose structures had been already determined in the Helix Research Institute. The regulation of the phosphorylation state of proteins by kinase and phosphatase plays central roles in normal differentiation and/or proliferation of cells, as well as in physiological functions at the cellular level. Thus, the inventive proteins are expected to share important functions in living body, and therefore, are useful as target molecules in drug development. In addition, the inventive KP proteins can be used as reagents for phosphorylating or dephosphorylating proteins.

[0033] The helix clones were prepared by a special method, and are expected to contain cDNA of full-length chains in high probability (Japanese Patent Application No. Hei 11-248036; Japanese Patent Application No. 2000-118776; Japanese Patent Application No. 2000-183767). Furthermore, because the cDNAs are already inserted in a mammalian expression vector, they can be used promptly in experiments for the expression in cells. Thus, information on physiological functions of the genes can be gained by successively testing these vectors with various assay systems using reporter genes. It has been known that many of known kinases and phosphatases are associated with a variety of signal transduction pathways in cells, and thus, the inventive KP genes can be also associated with signal transduction. Various potential physiological functions of the inventive genes can be thoroughly examined by functional screening using reporter gene assay systems in which known types of signal transduction can be detected.

[0034] Assay systems using reporter genes are excellent experimental systems which enable assessment of a variety of intracellular physiological functions simply in a single format. Specifically, the functional screening is preformed by the following reporter gene assay. A vector containing the inventive KP gene is introduced into the host cell with reporter genes having a variety of enhancer elements, and the KP gene is expressed in the cell. When the expression level of the reporter gene is altered as compared to that of the control cells in which no vector containing the KP gene had been introduced, it can be concluded that the protein encoded by the KP gene acted on the enhancer element. Useful information on physiological functions of the inventive KP gene is expected to be provided by testing whether the inventive KP gene acts on a variety of enhancer elements or not. Large amount of information on signal transduction systems acting on the elements, functional genes regulated by the enhancer elements, and so on, are known for many enhancer elements. Thus, when a KP gene being tested is proved to act on an enhancer element, it is possible to deduce physiological functions in which the KP gene participates based on known information on the enhancer element.

[0035] In the functional screening, it is also beneficial to study not only actions of a KP gene expressed alone, but also influences of the KP gene on the action after some stimuli. More specifically, even if the KP gene alone does not exhibit any activity, there is the possibility that the activation of a particular element by a known type of stimulus is enhanced or suppressed by the coexpressed KP gene. Such a known type of stimulus includes, for example, ligands of a cell surface receptor (interleukins, growth factors, TGF-P family, TNF-A family, hormones, low-molecular-weight compounds, etc.); expression of factors associated with intracellular signal transduction (various kinases, various phosphatases, low-molecular-weight G protein binding protein family, Smad family, STAT family, TRAF family, cell surface receptors, etc.); stress stimuli (oxidation stress, mechanical stress, heat stress, etc.); and so on.

[0036] The assays using reporter genes can be conducted by those skilled in the art by using a variety of commercially available kits that are used conventionally. For example, Mercury™ Pathway Profiling Systems from Clontech, PathDetectR Trans-Reporting System and PathDetectR Cis-Reporting System from Stratagene, and such are included. The assays can be conducted according to standard methods as described in the literature (“Overview of Genetic Reporter Systems” In Current Protocols in Molecular Biology, Ed. Ausubel, F. M. et al., (Wiley & Sons, N.Y.) Unit 9.6 (1995); Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, N.Y. (1989)).

[0037] When the luciferase gene is used as the reporter gene, the luciferase activity can be measured, for example, by a standard method using Dual-Luciferase™ Reporter Assay System from Promega or the like.

[0038] Reporter genes that can be used in the above-mentioned functional screening include, for example, secretory alkaline phosphatase gene, chloramphenicol acetyltransferase (CAT) gene, β-galactosidase gene, and such in addition to luciferase gene. Further, enhancer elements that are used in the reporter assay can be exemplified by Serum Response Element (SRE), cAMP Response Element (CRE), TPA Response Element (TRE), NFKB (Nuclear factor of KB cell)-binding element, Heat shock Response Element (HRE), Glucocorticoid Response Element (GRE), AP 1 (Activator protein 1: c-jun/c-fos complex)-binding element, NFAT (Nuclear Factor of Activated T-cells)-binding element, p53-binding element, interferony activated element (Interferon Gamma Activated Sequence: GAS), Interferon-Stimulated Response Element (ISRE), E2F-binding element, STAT family-binding element, Smad family-binding element, TCF/LEF-binding element, GATA family-binding element, Sterol Regulatory Element (SRE), IRF (Interferon Regulatory Factor) family-binding element, PPAR Υ-binding element and AhR-binding element.

[0039] 293 cell, Hela, NIH3T3, CV-1, Jurkat, vascular smooth muscle cell, vascular endothelial cell, and cardiac muscle cell can be exemplified as host cells that are used in the reporter assay.

[0040] Functionally equivalent proteins to the human KP proteins (SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 25) are encompassed in the present invention. Such proteins include, for example, mutants, homologues, variants, and so on, of human KP proteins. The term “functionally equivalent” herein means that the protein of interest has a function of phosphorylating proteins and/or dephosphorylating proteins like the KP proteins. According to the following procedure, it can be judged whether or not the protein of interest phosphorylates a protein.

[0041] A kinase protein and a substrate protein are combined together in an appropriate reaction solution. After the reaction is conduced in the presence of ATP, the phosphorylation state of the substrate protein is measured to judge the phosphorylation activity. The kinase protein to be used can be purified from appropriate cell lines or extracts from tissue by commonly used biochemical methods. It is also possible to use kinase proteins obtained by the overexpression of introduced genes encoding kinase proteins into mammalian cells (COS7, CV-1, HEK293, HeLa, Jurkat, NIH3T3, etc.), insect cells (Sf9, etc.), E. coli, yeast, and so on. The phosphorylation state of the substrate protein can be measured in a liquid scintillation counter, autoradiography, and such, by using ATP labeled with radioisotope, such as [Υ-³²P] ATP.

[0042] Further, the phosphorylation state of the substrate protein can be measured by ELISA (enzyme-linked immunosorbent assay), Western blotting, etc. using phosphorylated protein specific antibodies or the like. Such substrate proteins to be used include proteins specific to particular kinases, as well as a variety of proteins, such as casein, histone, and myelin basic protein (MBP), which are known to be phosphorylated by non-specific kinases. Alternatively, synthetic peptides and such containing sequences that are phosphorylated may be also used.

[0043] Furthermore, the phosphorylation activity can be assessed by measuring the phosphorylation of the kinase proteinper se (autophosphorylation). More specifically, the assay can be performed according to conventional methods described in Protein Phosphorylation: A Practical Approach. First Edition (Hardie et al., Oxford University Press, 1993) or others.

[0044] It can be judged whether a protein of interest dephosphorylates a protein or not by using the following procedure.

[0045] A phosphatase protein and a pre-phosphorylated substrate protein are combined together in an appropriate reaction solution. Then, the decrease in the extent of phosphorylation of the substrate protein or the amount of phosphate released from the substrate protein is measured to assess the dephosphorylation activity. Those phosphatase proteins prepared by the same method as those described above for the assessment of the phosphorylation activity can be used as the phosphatase protein in this method. The same substrate protein mentioned above for the judgment of the phosphorylation activity can be used as the substrate protein herein. In addition, phosphorylase, phosphorylase kinase, and such can be also used as substrate proteins. The pre-phosphorylation of the substrate protein can be achieved by using appropriate kinase such as phosphorylase kinase, protein kinase A, tyrosine kinases including EGF receptor and so on. The phosphorylation state of the substrate protein can be assayed by the same method described above for the assessment of the phosphorylation activity. More specifically, the assay can be performed according to conventional methods described in “Protein Phosphorylation: A Practical Approach. First Edition (Hardie DG. et al., Oxford University Press, 1993)”, and so on.

[0046] Further, the substrate protein to be phosphorylated or dephosphorylated by a test protein can be identified by expressing a cDNA expression library composed of phage vectors or the like, and assessing whether a protein expressed from each clone can be a substrate for the test protein or not. More specifically, the identification can be carried out by referring to the method described in “EMBO J. (1997) 16:1921-1933”. Alternatively, the substrate protein can be identified through the identification of proteins binding to the test protein by the yeast two-hybrid screening or the like. More specifically, the identification can be carried out by referring to the method described in “EMBO J. (1997) 16:1909-1920”.

[0047] One method for preparing functionally equivalent proteins well known to those skilled in the art involves the introduction of mutations into the proteins. For example, one skilled in the art can prepare proteins functionally equivalent to the human KP protein (SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 25) by introducing appropriate mutations into the amino acid sequence of the protein using the site-directed mutagenesis method (Hashimoto-Gotoh et al., Gene 152:271-275, 1995; Zoller et al., Methods Enzymol. 100:468-500, 1983; Kramer et al., Nucleic Acids Res. 12:9441-9456, 1984; Kramer et al., Methods. Enzymol. 154:350-367, 1987; Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492, 1986; Kunkel, Methods Enzymol. 85:2763-2766, 1988) and such. Mutation of amino acids may occur in nature, too. The proteins of the present invention include proteins comprising the amino acid sequence of human KP protein (SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 25) in which one or more amino acids are mutated, so long as the resulting mutant protein is functionally equivalent to the protein. In such a mutant protein, the number of the amino acids to be mutated is usually 50 residues or less, preferably 30 residues or less, and more preferably 10 residues or less (e.g., 5 residues or less).

[0048] The amino acid residue to be mutated is preferably mutated into a different amino acid that allows the properties of the amino acid side-chain to be conserved. Examples of properties of amino acid side chains include: hydrophobic amino acids (A, I, L, M, F, P, W, Y, V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T), and amino acids comprising the following side chains: an aliphatic side-chain (G, A, V, L, I, P); a hydroxyl group containing side-chain (S, T, Y); a sulfur atom containing side-chain (C, M); a carboxylic acid and amide containing side-chain (D, N, E, Q); a base containing side-chain (R, K, H); and an aromatic containing side-chain (H, F, Y, W) (The parenthetic letters indicate the one-letter codes of amino acids).

[0049] It is well known that a protein having deletion, addition, and/or substitution of one or more amino acid residues in the sequence of a protein can retain the original biological activity (Mark et al., Proc. Natl. Acad. Sci. USA 81:5662-5666, 1984; Zoller et al., Nucleic Acids Res. 10:6487-6500, 1982; Wang et al., Science 224:1431-1433; Dalbadie-McFarland et al. Proc. Natl. Acad. Sci. USA 79:6409-6413, 1982).

[0050] A protein having the amino acid sequence of human KP protein to which one or more amino acid residues have been added, is exemplified by a fusion protein containing the human KP protein. Fusion proteins, in which the human KP protein is fused to other peptides or proteins, are included in the present invention. Fusion proteins can be made using techniques well known to those skilled in the art, for example, by linking the DNA encoding the human KP protein (SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 25) in frame with the DNA encoding other peptides or proteins, followed by inserting the DNA into an expression vector and expressing it in a host. There is no restriction as to the peptides or proteins to be fused to the protein of the present invention.

[0051] For instance, known peptides which may be used for the fusion include the FLAG peptide (Hopp et al., BioTechnology 6:1204-1210, 1988), 6x His that is made up of six histidine residues, 10x His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, lck tag, α-tubulin fragment, B-tag, and Protein C fragment. Also, glutathione-S-transferase (GST), influenza hemagglutinin (HA), the constant region of immunoglobulin, β-galactosidase, maltose binding protein (MBP), and the like may be used as a protein to be fused with the protein of this invention. Fusion proteins can be prepared by fusing the DNA encoding these peptides or proteins, which are commercially available, with the DNA encoding the protein of the invention, and expressing the fused DNA.

[0052] An alternative method for preparing functionally equivalent proteins known to those skilled in the art utilizes, for example, the hybridization technique (Sambrook et al., Molecular Cloning 2nd ed. 9.47-9.58, Cold Spring Harbor Lab. Press, 1989). Generally, one skilled in the art can isolate DNAs highly homologous to the whole or part of the DNA sequence encoding the human KP protein (SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23), and then isolate proteins functionally equivalent to the human KP protein based on those DNAs isolated. The present invention includes proteins that are (i) encoded by a DNA hybridizing to a DNA encoding the human KP protein and (ii) functionally equivalent to the human KP protein. Such proteins include, for example, homologues derived from human and other animals (for example, protein encoded by a DNA from mouse, rat, rabbit, cattle, etc.).

[0053] Those skilled in the art can properly select hybridization conditions to be used for the isolation of DNAs encoding proteins functionally equivalent to the human KP protein. Hybridization conditions include low stringent conditions. Low stringent conditions may be, for example, 42° C. in 2x SSC and 0.1% SDS, preferably 50° C. in 2x SSC and 0.1% SDS for washing after hybridization. More preferably, high stringent conditions such as 65° C. in 0.1x SSC and 0.1% SDS may be chosen. DNA with higher homology may be efficiently obtained at higher temperature under these conditions. However, several factors are thought to influence the stringency of hybridization, such as temperatures and salt concentrations, and one skilled in the art can suitably select these factors to accomplish a similar stringency. More guidelines for the hybridization condition are available in the art, for example, in a reference by Sambrook et al. (1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.) and in unit 2.10 of the reference by Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.).

[0054] Also, in lieu of hybridization, it is also possible to isolate functionally equivalent proteins by a gene amplification method, such as PCR, by synthesizing sequences based on the sequence information of the DNA encoding the human KP protein (SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23) and using them as primers.

[0055] The proteins functionally equivalent to the human KP proteins encoded by the DNA isolated by the hybridization or gene amplification techniques, usually are highly homologous to the human KP proteins (SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 25) at the amino acid sequence level. The proteins of the invention include proteins functionally equivalent to the human KP protein and are highly homologous to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 25. “Highly homologous” means typically 65% or higher, preferably 75% or higher, more preferably 85% or higher, and even more preferably 95% or higher identity at the amino acid level. Homology between proteins can be determined according to the algorithm described in the literature (Wilbur et al., Proc. Natl. Acad. Sci. USA 80:726-730, 1983).

[0056] The term “substantially pure” as used herein in reference to a given polypeptide means that the polypeptide is substantially free from other biological macromolecules. For example, the substantially pure polypeptide is at least 75%, 80, 85, 95, or 99% pure by dry weight. Purity can be measured by any appropriate standard method known in the art, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

[0057] Accordingly, the invention includes a polypeptide having a sequence shown as SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 25. The invention also includes a polypeptide, or fragment thereof, that differs from the corresponding sequence shown as SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 25. The differences are, preferably, differences or changes at a non-essential residue or a conservative substitution. In one embodiment, the polypeptide includes an amino acid sequence at least about 60% identical to a sequence shown as SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 25, or a fragment thereof. Preferably, the polypeptide is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 25 and has at least one protein kinase or protein phosphatase activity. Preferred polypeptide fragments of the invention are at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, or more, of the length of the sequence shown as SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 25 and have at least one protein kinase or protein phosphatase activity described herein. Or alternatively, the fragment can be merely an immunogenic fragment.

[0058] The proteins of the present invention may have variations in the amino acid sequence, molecular weight, isoelectric point, presence or absence of sugar chains, or form, depending on the cell or host used to produce them or the purification method utilized as described below. Nevertheless, so long as the protein obtained has a function equivalent to the human KP protein, it is within the scope of the present invention. For example, when the inventive protein is expressed in prokaryotic cells, e.g., E. coli, a methionine residue is added at the N-terminus of the original protein. The present invention also includes such proteins.

[0059] The proteins of the present invention can be prepared as recombinant proteins or as naturally occurring proteins, using methods commonly known in the art. The recombinant protein can be, for example, prepared as follows. The DNA encoding the protein of this invention (e.g., DNA having the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23) is inserted into an appropriate expression vector, and introduced into suitable host cells. Subsequently, the resulting transformants, the host cell inserted with the expression vector, are recovered, extracted and then purified by chromatography utilizing ion exchange, reverse phase, or gel filtration, or by affinity chromatography with a column in which the antibodies against the protein of the present invention are fixed, or by a combination of these columns.

[0060] Alternatively, the protein of the invention can be prepared by expressing the protein in host cells (e.g., animal cells or E. coli) as a fusion protein with glutathione S transferase protein, or as a recombinant protein with multiple histidine residues. The expressed protein can be purified using a glutathione column or nickel column. Subsequently, if necessary, regions of the fusion protein (apart from the desired protein) can be digested and removed with thrombin, factor Xa, etc.

[0061] The natural protein corresponding to the protein of the invention can be isolated by methods well known in the art, for example, by purifying tissue or cell extracts containing a protein of the invention with an affinity column to which the antibody that binds to the protein of the present invention described below is bound. The antibody may be a polyclonal antibody or monoclonal antibody.

[0062] The present invention also includes partial peptides of the proteins of the present invention. The partial peptides of the present invention comprise at least 7 or more amino acids, preferably 8 or more amino acids, more preferably 9 or more amino acids. The partial peptides can be used, for example, for generating antibodies against the protein of the present invention, screening of compounds binding to the protein of the present invention, or screening of promoters or inhibitors for the protein of the present invention. The partial peptides can be used as antagonists or competitive inhibitors for the protein of this invention. The partial peptides of the invention can be produced by genetic engineering, known methods of peptide synthesis, or by digesting the protein of the invention with an appropriate peptidase. For peptide synthesis, for example, solid phase synthesis or liquid phase synthesis may be used.

[0063] DNA encoding an inventive protein can be used for the production of the inventive protein in vivo and in vitro as described above; it is also applicable to, for example, gene therapy for diseases caused by the abnormality in the gene encoding the inventive protein and for diseases that can be treated by the inventive protein. Any type of DNA, such as cDNA synthesized from MRNA, genomic DNA or synthetic DNA, can be used so long as the DNA encodes a protein of the present invention. Also so long as they can encode a protein of the present invention, DNAs comprising arbitrary sequences based on the degeneracy of the genetic code are also included.

[0064] The DNA of the present invention can be prepared using methods known in the art. For example, a cDNA library can be constructed from the cells expressing the protein of the present invention, and hybridization can be conducted using a part of the DNA sequence of the present invention (for example, SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23) as a probe. cDNA libraries may be prepared by, for example, the method described in the literature (Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, 1989), and also, commercially available ones can be used. Alternatively, the DNA of the present invention can be obtained by preparing the RNA from the cells expressing the protein of the present invention, synthesizing cDNA by reverse transcriptase, synthesizing the oligo-DNAs based on the DNA sequence of the present invention (for example, SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23), and amplifying the cDNA encoding the protein of the present invention by PCR using the oligonucleotides as primers.

[0065] The nucleotide sequence of the obtained cDNA is determined to find an open reading frame, and thereby the amino acid sequence of the protein of the invention can be obtained. The cDNA obtained may also be used as a probe for screening a genomic library to isolate a genomic DNA.

[0066] More specifically, mRNAs may first be prepared from a cell, tissue, or organ in which the protein of the invention is expressed. Known methods can be used to isolate mRNAs; for instance, total RNA can be prepared by guanidine ultracentrifugation (Chirgwin et al., Biochemistry 18:5294-5299, 1979) or the AGPC method (Chomczynski et al., Anal. Biochem. 162:156-159, 1987). mRNA may then be purified from total RNA using mRNA Purification Kit (Pharmacia) and such; alternatively, mRNA may be directly purified by QuickPrep mRNA Purification Kit (Pharmacia).

[0067] The obtained mRNA is used to synthesize cDNA using reverse transcriptase. cDNA may be synthesized by using a kit such as the AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Kogyo). Alternatively, cDNA may be synthesized and amplified following the 5′-RACE method (Frohman et al., Proc. Natl. Acad. Sci. USA 85:8998-9002, 1988; Belyavsky et al., Nucleic Acids Res. 17:2919-2932, 1989) which uses primers described herein, the 5′-Ampli FINDER RACE Kit (Clontech), and polymerase chain reaction (PCR).

[0068] A desired DNA fragment is prepared from the PCR products and ligated with a vector DNA. The recombinant vectors are used to transform E. coli and such, and a desired recombinant vector is prepared from a selected colony. The nucleotide sequence of the desired DNA is verified by conventional methods, such as dideoxynucleotide chain termination.

[0069] A DNA of the invention may be designed to have a sequence that is expressed more efficiently by taking into account the frequency of codon usage in the host to be used for expression (Grantham et al., Nucleic Acids Res. 9:43-74, 1981). The DNA of the present invention may be altered by a commercially available kit or a conventional method. For instance, the DNA may be altered by digestion with restriction enzymes, insertion of a synthetic oligonucleotide or an appropriate DNA fragment, addition of a linker, or insertion of the initiation codon (ATG) and/or the stop codon (TAA, TGA, or TAG).

[0070] The DNAs of the present invention specifically include the DNA which comprises a region containing the following nucleotide sequence.

[0071] nucleotides from A at nucleotide residue 109 to T at nucleotide residue 1713 in the nucleotide sequence of SEQ ID NO: 1.

[0072] nucleotides from A at nucleotide residue 170 to C at nucleotide residue 1135 in the nucleotide sequence of SEQ ID NO:3.

[0073] nucleotides from A at nucleotide residue 173 to A at nucleotide residue 1450 in the nucleotide sequence of SEQ ID NO:5.

[0074] nucleotides from A at nucleotide residue 3 to A at nucleotide residue 1916 in the nucleotide sequence of SEQ ID NO:7.

[0075] nucleotides from A at nucleotide residue 71 to G at nucleotide residue 2479 in the nucleotide sequence of SEQ ID NO:9.

[0076] nucleotides from A at nucleotide residue 215 to C at nucleotide residue 1576 in the nucleotide sequence of SEQ ID NO: 11.

[0077] nucleotides from A at nucleotide residue 773 to C at nucleotide residue 2179 in the nucleotide sequence of SEQ ID NO: 13.

[0078] nucleotides from A at nucleotide residue 23 to G at nucleotide residue 2290 in the nucleotide sequence of SEQ ID NO:15.

[0079] nucleotides from A at nucleotide residue 67 to G at nucleotide residue 690 in the nucleotide sequence of SEQ ID NO:17.

[0080] nucleotides from A at nucleotide residue 1357 to A at nucleotide residue 1929 in the nucleotide sequence of SEQ ID NO: 19.

[0081] nucleotides from A at nucleotide residue 40 to C at nucleotide residue 2415 in the nucleotide sequence of SEQ ID NO:21.

[0082] nucleotides from A at nucleotide residue 1371 to A at nucleotide residue 1494 in the nucleotide sequence of SEQ ID NO:23.

[0083] The DNA of the present invention also include a DNA hybridizing to a DNA consisting of the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and encoding a protein functionally equivalent to the above-mentioned protein of the present invention. Those skilled in the art can properly select the appropriate hybridization conditions, and specifically the above-mentioned conditions can be used. Under these conditions, the higher the temperature, the higher the homology of the obtained DNA will be. The above-mentioned hybridizing DNA is preferably a naturally occurring DNA, for example, cDNA or chromosomal DNA.

[0084] As used herein, an “isolated nucleic acid” is a nucleic acid, the structure of which is not identical to that of any naturally occurring nucleic acid or to that of any fragment of a naturally occurring genomic nucleic acid spanning more than three genes. The term therefore covers, for example, (a) a DNA which has the sequence of part of a naturally occurring genomic DNA molecule but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Specifically excluded from this definition are nucleic acids present in random, uncharacterized mixtures of different DNA molecules, transfected cells, or cell clones, e.g., as these occur in a DNA library such as a cDNA or genomic DNA library.

[0085] Accordingly, in one aspect, the invention provides an isolated or purified nucleic acid molecule that encodes a polypeptide described herein or a fragment thereof. Preferably, the isolated nucleic acid molecule includes a nucleotide sequence that is at least 60% identical to the nucleotide sequence shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 or 24. More preferably, the isolated nucleic acid molecule is at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identical to the nucleotide sequence shown in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 or 24. In the case of an isolated nucleic acid molecule which is longer than or equivalent in length to the reference sequence, e.g., SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 or 24, the comparison is made with the full length of the reference sequence. Where the isolated nucleic acid molecule is shorter that the reference sequence, e.g., shorter than SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 or 24, the comparison is made to a segment of the reference sequence of the same length (excluding any loop required by the homology calculation).

[0086] As used herein, “% identity” of two amino acid sequences, or of two nucleic acid sequences, is determined using the algorithm of Karlin and Altschul (PNAS USA 87:2264-2268, 1990), modified as in Karlin and Altschul, PNAS USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches are performed with the NBLAST program, score =100, wordlength =12. BLAST protein searches are performed with the XBLAST program, score =50, wordlength =3. To obtain gapped alignment for comparison purposes GappedBLAST is utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST and GappedBLAST programs the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention.

[0087] The present invention also provides a vector into which a DNA of the present invention is inserted. The vectors of the present invention are useful for maintaining the DNA of the present invention within host cells or expressing the protein of the invention.

[0088] When the E. coli is used as a host cell, there is no limitation other than that the vector should have an “ori” to amplify and mass-produce the vector in E. Coli (e.g., JM109, DH5α, HB101, or XL1Blue), and a marker gene for selecting the transformed E. coli (e.g., a drug-resistance gene selected by a drug such as ampicillin, tetracycline, kanamycin, or chloramphenicol). For example, M13-series vectors, pUC-series vectors, pBR322, pBluescript, pCR-Script, and such can be used. pGEM-T, pDIRECT, pT7, and so on can also be used for subcloning and excision of the cDNA as well as the vectors described above. When a vector is used to produce a protein of the present invention, an expression vector is especially useful. The expression vector, for example, to be expressed in E. coli should have the above characteristics to be amplified in E. coli. When E. coli, such as JM109, DH5α, HB101, or XL1 Blue, is used as the host cell, the vector should have a promoter such as lacZ promoter (Ward et al., Nature 341:544-546, 1989; FASEB J. 6:2422-2427, 1992), araB promoter (Better et al., Science 240:1041-1043, 1988), or T7 promoter that can efficiently promote the expression of the desired gene in E. coli. Other examples of the vectors are pGEX-5X-1 (Pharmacia), “QlAexpress system” (Qiagen), pEGFP, and pET (for this vector, BL2 1, a strain expressing T7 RNA polymerase, is preferably used as the host).

[0089] Further, the vector may contain a signal sequence for the secretion of polypeptides. The pelB signal sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169, 4379) can be used as a signal sequence for secretion of proteins, when the proteins are intended to be produced in the periplasm of E. coli. Introduction of the vector into a host cell can be performed, for example, by the calcium chloride method or electroporation.

[0090] In addition to the vectors for E. coli, for example, the vector for producing the proteins of this invention may be a mammal-derived expression vector (e.g., pcDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. 1990, 18(17), p5322), pEF, and pCDM8), an insect cell-derived expression vector (e.g., “Bac-to-BAC baculovairus expression system” (GibcoBRL) and pBacPAK8), a plant-derived expression vector (e.g., pMH1 and pMH2), an animal virus-derived expression vector (e.g., pHSV, pMV, and pAdexLcw), a retrovirus-derived expression vector (e.g., pZlPneo), an yeast-derived expression vector (e.g., “Pichia Expression Kit” (Invitrogen), pNV11, and SP-QO1), a Bacillus subtilis-derived expression vector (e.g., pPL608 and pKTH50).

[0091] In order to express proteins in animal cells, such as CHO, COS, and NIH3T3 cells, the vector should have a promoter necessary for expression in such cells, e.g., SV40 promoter (Mulligan et al., Nature 277:108, 1979), MMLV-LTR promoter, EFl α promoter (Mizushima et al., Nucleic Acids Res. 18:5322, 1990), CMV promoter, etc., and more preferably it has a marker gene for selecting transformants (for example, a drug resistance gene selected by a drug (e.g., neomycin, G418, etc.)). Examples of vectors with these characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, pOP13, and so on.

[0092] The method using CHO cells deficient in nucleic acid synthetic pathways as the host, and incorporating a vector (such as pCHOI) with a DHFR gene that compensates for the deficiency and amplifying the vector with methotrexate (MTX) can be mentioned as an example method for stably expressing a gene and amplifying the copy number in cells. And as a method for transient expression, a method transforming the COS cells, which have the gene for SV40 T antigen on the chromosome, with a vector (such as pcD) having the SV40 replication origin can be mentioned. The origin used for replication may be those of polyomavirus, adenovirus, bovine papilloma virus (BPV), and the like. In addition, the expression vector may include a selection marker gene for amplification of the gene copies in host cells. Examples of such markers include, but are not limited to, the aminoglycoside transferase (APH) gene, the thymidine kinase (TK) gene, the E. coli xanthine-guanine phosphoribosyl transferase (Ecogpt) gene, and the dihydrofolate reductase (dhfr) gene.

[0093] The DNA of the present invention can be expressed in animals by, for example, inserting a DNA of the invention into an appropriate vector and introducing the vector into a living body by the retrovirus method, liposome method, cationic liposome method, adenovirus method, and so on. Thus, gene therapy can be conducted for diseases caused by mutations in the KP gene of this invention. The vectors used include, but are not limited to, adenoviral vectors (e.g., pAdexlcw) and retroviral vectors (e.g., pZlPneo). General techniques for gene manipulation, such as insertion of the DNA of the invention into a vector, can be performed according to conventional methods (Molecular Cloning, 5.61-5.63). The DNA of this invention can be administered to the living body by an ex vivo method or in vivo method.

[0094] The present invention also provides a host cell into which the vector of the present invention has been introduced. The host cell into which the vector of the invention is introduced is not particularly limited. E. coli and various animal cells can be used. The host cell of this invention can be used as, for example, a production system for producing or expressing the protein of the invention. The production system for producing a protein of the invention may be both in vitro or in vivo production system. For in vitro production, eukaryotic cells or prokaryotic cells can be used.

[0095] Useful eukaryotic host cells may be animal, plant, or fungi cells. As animal cells, mammalian cells such as CHO (J. Exp. Med. 108:945, 1995), COS, 3T3, myeloma, baby hamster kidney (BHK), HeLa, or Vero cells, amphibian cells such as Xenopus oocytes (Valle et al. Nature 291:340-358, 1981), or insect cells such as Sf9, Sf21, or Tn5 cells can be used. CHO cells lacking DHFR gene (dhfr-CHO) (Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980) or CHO K-1 (Proc. Natl. Acad. Sci. USA 60:1275, 1968) may also be used. Among the animal cells, CHO cells are particularly preferable for high-level expression. The vector can be introduced into the host cell by, for example, the calcium phosphate method, the DEAE-dextran method, cationic liposome DOTAP (Boehringer Mannheim) method, electroporation, lipofection, etc.

[0096] As plant cells, for example, plant cells originating from Nicotiana tabacum are known as protein production system and may be used as callus cultures. As fungi cells, yeast cells such as Saccharomyces, including Saccharomyces cerevisiae, or filamentous fungi such as Aspergillus, including Aspergillus niger, are known.

[0097] Useful prokaryotic cells include bacterial cells, such as E. coli, for example, JM 109, DH5α, and HB101, or Bacillus subtilis.

[0098] These cells are transformed by a desired DNA, and the resulting transformants are cultured in vitro to obtain the protein. Transformants can be cultured using known methods. Culture medium such as DMEM, MEM, RPMI1640, or IMDM may be used for animal cells. The culture medium can be used with or without serum supplement such as fetal calf serum (FCS). The pH of the culture medium is preferably between about 6 and 8. Cells are typically cultured at about 30 to 40° C. for about 15 to 200 hr, and the culture medium may be replaced, aerated, or stirred if necessary.

[0099] Animal and plant hosts may be used for in vivo production. For example, a desired DNA can be introduced into an animal or plant host. Encoded proteins are produced in vivo, and then are recovered. These animal and plant hosts are included in host cells of the present invention.

[0100] Animals to be used for the production system described above include mammals and insects. Mammals such as goat, porcine, sheep, mouse, and bovine may be used (Vicki Glaser, SPECTRUM Biotechnology Applications (1993)). Alternatively, the mammals may be transgenic animals.

[0101] For instance, a desired DNA may be prepared as a fusion gene, fused with a gene such as goat β casein gene which encodes a protein specifically produced into milk. DNA fragments comprising the fusion gene are injected into goat embryos, which are then transplanted back to female goats. Proteins of interest can be recovered from milk produced by the transgenic goats (i.e., those born from the goats that had received the embryos) or from their offspring. To increase the amount of milk containing the proteins produced by transgenic goats, hormones may be appropriately administered to them (Ebert et al., Bio/Technology 12:699-702, 1994).

[0102] Alternatively, insects, such as the silkworm, may be used. Baculoviruses into which the DNA encoding the protein of interest is inserted can be used to infect silkworms, and the desired protein can be recovered from their body fluid (Susumu et al., Nature 315:592-594, 1985).

[0103] As plants, for example, tobacco can be used. In use of tobacco, DNA encoding the protein of interest may be inserted into a plant expression vector, such as pMON530, which is introduced into bacteria, such as Agrobacterium tumefaciens. Then the bacteria is used to infect tobacco, such as Nicotiana tabacum, and a desired polypeptide can be recovered from their leaves (Julian et al., Eur. J. Immunol. 24:131-138, 1994).

[0104] A protein of the present invention obtained as above may be isolated from inside or outside of the host cells (e.g., culture media), and purified as a substantially pure homogeneous protein. The method for protein isolation and purification is not limited to any specific method; in fact, any standard method may be used. For instance, column chromatography, filter, ultrafiltration, salt precipitation, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric point electrophoresis, dialysis, recrystallization, and so on may be appropriately selected and combined to isolate and purify the protein.

[0105] For example, affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, adsorption chromatography, and such may be used for chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed. Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press (1996)). These chromatographies may be performed by liquid chromatography such as HPLC and FPLC. Thus, the present invention includes highly purified proteins, purified by the above methods.

[0106] A protein of the present invention may be optionally modified or partially deleted by treating it with an appropriate protein modification enzyme before or after purification. Useful protein modification enzymes include, but are not limited to, trypsin, chymotrypsin, lysylendopeptidase, protein kinase, glucosidase, and so on.

[0107] The present invention also provides antibodies that bind to the protein of the invention. The antibody of the invention may take any form, including monoclonal antibody, as well as polyclonal antibodies. Furthermore, antiserum obtained by immunizing an animal such as rabbit with the protein of the invention, all classes of polyclonal and monoclonal antibodies, human antibodies, and humanized antibodies produced by genetic recombination are included.

[0108] A protein of the invention used as the antigen to obtain antibodies may be derived from any animal species, but preferably it is derived from a mammal, such as a human, mouse, or rat, and more preferably from human. A human-derived protein may be obtained from the nucleotide or amino acid sequences disclosed herein.

[0109] Herein, a protein used as an antigen may be a complete protein or partial peptides thereof. A partial peptide may be, for example, an amino (N)-terminal or carboxy (C)-terminal fragment of the protein. Herein, an antibody is defined as an antibody that reacts with either the full-length or a fragment of the protein.

[0110] A gene encoding a protein of the invention or its fragment may be inserted into a known expression vector, which is used to transform a host cell as described herein. The desired protein or its fragment may be recovered from the outside or inside of the host cell by any standard method, and may be used as an antigen. Alternatively, cells expressing the protein or their lysates, or a chemically synthesized protein may be used as an antigen. Short peptides are preferably used as antigens by appropriately combining them with carrier proteins such as keyhole limpet hemocyanin, bovine serum albumin, and ovalbumin.

[0111] Any mammalian animal may be immunized with the antigen, but preferably the compatibility with parental cells used for cell fusion is taken into account. In general, animals of Rodentia, Lagomorpha, or Primates are used.

[0112] Animals of Rodentia include, for example, mouse, rat, and hamster. Animals of Lagomorpha include, for example, rabbit. Animals of Primates include, for example, a monkey of Catarrhini (old world monkey) such as crab-eating monkey, rhesus monkey, sacred baboon, or chimpanzee.

[0113] Methods for immunizing animals with antigens are known in the art. For instance, intraperitoneal injection or subcutaneous injection of antigens is used as a standard method for immunization of mammals. More specifically, antigens may be diluted and suspended in an appropriate amount with phosphate buffered saline (PBS), physiological saline, etc. If desired, the antigen suspension may be mixed with an appropriate amount of a standard adjuvant, such as Freund's complete adjuvant, made into emulsion, and then administered to mammals. Preferably, it is followed by several administrations of antigen mixed with an appropriately amount of Freund's incomplete adjuvant every 4 to 21 days. An appropriate carrier may also be used for immunization. After immunization as above, serum is examined for increase of the amount of desired antibodies by a standard method.

[0114] Polyclonal antibodies against the proteins of the present invention may be prepared by collecting blood from the immunized mammal examined for the increase of desired antibodies in the serum, and by separating serum from the blood by any conventional method. Serum containing the polyclonal antibodies, or if necessary, a fraction containing the polyclonal antibodies may be isolated from the serum to be used as the polyclonal antibodies of the present invention. For example, immunoglobulin G or M can be prepared by using an affinity column coupled with the protein of the invention to obtain the fraction exclusively recognizing the protein of the invention, and then, purifying the fraction by using protein A or protein G column.

[0115] To prepare monoclonal antibodies, immune cells are collected from the mammal immunized with the antigen and checked for the increased level of desired antibodies in the serum as described above, and are subjected to cell fusion. The immune cells used for cell fusion are preferably obtained from spleen. The other parent cell which is fused with the above immune cell is preferably a mammalian myeloma cell, and more preferably a myeloma cell that has acquired a special feature that can be used for selection of fusion cells by drugs.

[0116] Cell fusion of the above immune cell and myeloma cell may be performed by any standard method, such as those described in the literature (Galfre et al., Methods Enzymol. 73:3-46, 1981).

[0117] Hybridomas obtained by the cell fusion may be selected by cultivating them in a standard selection medium, such as HAT medium (hypoxanthine, aminopterin, and thymidine containing medium). The cell culture is typically continued in the HAT medium for several days to several weeks, the time being sufficient to allow all the other cells, except desired hybridoma (non-fused cells), to die. Then, the standard limiting dilution is performed to screen and clone a hybridoma cell producing the desired antibody.

[0118] Besides the above method, in which a nonhuman animal is immunized with an antigen for preparing hybridoma, human lymphocytes such as that infected by EB virus may be immunized with a protein, protein expressing cells, or their lysates in vitro. Then, the immunized lymphocytes are fused with human-derived myeloma cells that is capable of indefinitely dividing, such as U266, to yield a hybridoma producing a desired human antibody, able to bind to the protein can be obtained (Unexamined Published Japanese Patent Application (JP-A) No. Sho 63-17688).

[0119] Subsequently, the hybridomas thus obtained are transplanted into the abdominal cavity of a mouse from which the ascites is collected. The monoclonal antibodies thus obtained can be purified by, for example, ammonium sulfate precipitation or by column chromatography using a protein A or protein G column, a DEAE ion exchange column, an affinity column to which the protein of the invention is coupled, and such. The antibody of the invention can be used not only for purifying and detecting the protein of the invention, but also as a candidate for an agonist or antagonist to the protein of the present invention. It is also expected to use the antibody for antibody therapy of diseases associated with the protein of this invention. When the antibody obtained is administered to the human body (antibody therapy), human antibodies or humanized antibodies are preferred to reduce immunogenicity.

[0120] For example, transgenic animals having a repertory of human antibody genes may be immunized with a protein, protein expressing cells, or their lysates as an antigen. Antibody producing cells are collected from the animals, and fused with myeloma cells to obtain hybridoma, from which human antibodies against the protein can be prepared (see W092-03918, W093-2227, W094-02602, W094-25585, W096-33735, and W096-34096).

[0121] Alternatively, an immune cell, such as an immunized lymphocyte, producing antibodies may be immortalized by an oncogene and used for preparing monoclonal antibodies.

[0122] Monoclonal antibodies thus obtained can also be recombinantly prepared using genetic engineering techniques (see, for example, Borrebaeck C. A. K. and Larrick J. W. Therapeutic Monoclonal Antibodies, published in the United Kingdom by MacMillan Publishers LTD (1990)). A DNA encoding an antibody may be cloned from an immune cell, such as hybridomas or immunized lymphocytes producing the antibody; inserted into an appropriate vector; and introduced into host cells to prepare a recombinant antibody. The present invention also includes recombinant antibodies prepared as described above.

[0123] The antibody of the present invention may be a fragment of an antibody or modified antibody, so long as it binds to the protein of the invention. For instance, the antibody fragment may be Fab, F(ab′)₂, Fv, or single chain Fv (scFv), in which Fv fragments from H and L chains are ligated by an appropriate linker (Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). More specifically, an antibody fragment may be generated by treating an antibody with an enzyme such as papain or pepsin. Alternatively, a gene encoding the antibody fragment may be constructed; inserted into an expression vector; and expressed in an appropriate host cell (see, for example, Co et al., J. Immunol. 152:2968-2976, 1994; Better et al., Methods Enzymol. 178:476-496, 1989; Pluckthun et al., Methods Enzymol. 178:497-515, 1989; Lamoyi, Methods Enzymol. 121:652-663, 1986; Rousseaux et al., Methods Enzymol. 121:663-669, 1986; Bird et al., Trends Biotechnol. 9:132-137, 1991).

[0124] An antibody may be modified by conjugation with a variety of molecules, such as polyethylene glycol (PEG). The antibody of the present invention includes such modified antibodies. A modified antibody can be obtained by chemically modifying an antibody. These modification methods have been already established in the field.

[0125] Alternatively, the antibody of the present invention may be obtained as a chimeric antibody, between a variable region derived from nonhuman antibody and the constant region derived from human antibody, or as a humanized antibody, comprising the complementarity determining region (CDR) derived from nonhuman antibody, the frame work region (FR) derived from human antibody, and the constant region. Such antibodies can be prepared by using known technology.

[0126] Obtained antibodies may be purified to homogeneity. The antibodies can be separated and purified by using standard methods for protein separation and purification. For instance, column chromatography such as affinity chromatography, filter, ultrafiltration, salt precipitation, dialysis, SDS-polyacrylamide gel electrophoresis, isoelectric point electrophoresis, and so on may be appropriately selected and combined to isolate and purify the antibody (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988), but methods are not limited to them. The concentration of the antibody obtained as described above can be determined by the measurement of absorbance, enzyme-linked immunosorbent assay (ELISA), or others.

[0127] Columns for affinity chromatography include protein A column and protein G column. For example, protein A column includes Hyper D, POROS, Sepharose F. F. (Pharmacia) and the like.

[0128] In addition to affinity chromatography, chromatographic methods include, for example, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, adsorption chromatography and others (“Strategies for Protein Purification and Characterization: A Laboratory Course Manual” Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographic methods can be conducted by using liquid chromatography such as HPLC and FPLC.

[0129] For example, absorbance measurement, enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), radioimmunoassay (RIA), or immunofluorescence may be used to measure the antigen binding activity of the antibody of the invention. In ELISA, the antibody of the present invention is immobilized on a plate; the protein of the invention is applied to the plate; and then a sample containing a desired antibody, such as culture supernatant of antibody producing cells or purified antibodies, is applied. Then, a secondary antibody that recognizes the primary antibody and which is labeled with an enzyme such as alkaline phosphatase is applied, and the plate is incubated. After washing, an enzyme substrate, such asp-nitrophenyl phosphate, is added to the plate, and the absorbance is measured to evaluate the antigen binding activity of the sample. A fragment of the protein, such as a C-terminal fragment, may be used as a protein. BlAcore (Pharmacia) may be used to evaluate the activity of the antibody according to the present invention.

[0130] The above methods allow for the detection or measurement of the protein of the invention, by exposing the antibody of the invention to a sample assumed to contain the protein of the invention, and detecting or measuring the immune complex formed by the antibody and the protein. Because the method of detection or measurement of the protein according to the invention can specifically detect or measure a protein, the method may be useful in a variety of experiments in which the protein is used.

[0131] The present invention also provides a polynucleotide containing at least 15 nucleotides complementary to the DNA (SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23) encoding the human KP protein or the complementary strand thereof.

[0132] Herein, the term “complementary strand” is defined as one strand of a double strand DNA composed of A:T and G:C base pair to the other strand. Also, “complementary” is defined as not only those completely matching within a continuous region of at least 15 nucleotides, but also having a homology of at least 70%, favorably 80% or higher, more favorably 90% or higher, and most favorably 95% or higher within that region. The homology may be determined using the algorithm described herein.

[0133] Such a nucleic acid includes probes and primers used for the detection and amplification of DNA encoding the inventive protein; probes and primers used for the detection of expression of the DNA; and nucleotide and nucleotide derivatives (e.g., antisense oligonucleotide and ribozyme, or DNAs encoding them, etc.) used for the regulation of expression of the inventive protein. In addition, such a nucleic acid can also be used for the preparation of DNA chip.

[0134] When used as primers, such nucleic acids are complementary at the 3′end, and restriction enzyme recognition sequences or tags can be added to the 5′end.

[0135] The antisense oligonucleotides include, for example, antisense oligonucleotides hybridizing to any region of the nucleotide sequence of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. The antisense oligonucleotide is preferably an antisense of a continuous sequence of a length of 15 nucleotides or longer within the nucleotide sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. More preferably, the above continuous sequence of a length of 15 nucleotides or longer contains the translation initiation codon.

[0136] A derivative or modified form of antisense oligonucleotide may also be used. The modified antisense oligonucleotides may be those modified with lower alkylphosphonate such as methylphosphonate and ethylphosphonate; phosphorothioate; phosphoroamidate; and so on.

[0137] Herein, an antisense oligonucleotide is not restricted to those in which all nucleotides are complementary to the corresponding nucleotides within a given region of a DNA or mRNA; so long as it can specifically hybridize with the nucleotide sequences of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, it may have one or more nucleotide mismatches.

[0138] A derivative of the antisense oligonucleotide of the present invention may act on cells producing the protein of the invention and may bind to a DNA or mRNA encoding the protein, whereby inhibiting the expression of the protein of the invention by inhibiting its transcription or translation, or by promoting the degradation of mRNA, and thereby inhibiting the function of the protein of the invention.

[0139] A derivative of the antisense oligonucleotide of the present invention may be mixed with appropriate carriers which are inactive against the derivative, and may be used as a medicine for externally application such as salve or poultice.

[0140] If necessary, it may be mixed with an excipient, isotonizing agent, solubilizing agent, stabilizer, preservative, pain-killer, or the like, and prepared as a tablet, powder, granule, capsule, liposome capsule, injectable solution, liquid formulation, nose drops, freeze-dried agent, etc. The above may be achieved according to standard methods.

[0141] For treating patients, a derivative of an antisense oligonucleotide of the present invention may be, for example, directly applied to the affected area of a patient, or administered into blood vessels so as to finally reach the affected area. Moreover, the derivative may be encapsulated in antisense-encapsulating materials such as liposome, poly-L-lysine, lipid, cholesterol, lipofectin, or their derivative in order to increase durability and/or membrane permeability.

[0142] Dose of the derivative of the antisense oligonucleotide of the present invention may be appropriately adjusted depending on the patient's conditions, and a favorable amount such as 0.1 to 100 mg/kg, or more preferably 0.1 to 50 mg/kg may be administered.

[0143] As the antisense oligonucleotides of the present invention inhibit expression of the protein of the invention, they find utility as inhibitors of the biological activity of the protein of the invention. An inhibitor of expression comprising the antisense oligonucleotide of the present invention is useful because it can inhibit the biological activity of the protein of the invention.

[0144] The protein of the invention may be used to screen for compounds that bind to the protein of the present invention. Specifically, the protein may be used in methods of screening for compounds, which method comprises the steps of exposing the protein of the present invention to a test sample in which a compound binding to the protein is expected to be contained; and selecting the compound having the activity of binding to the protein.

[0145] The proteins of the invention used for screening may be recombinant or natural proteins, or partial peptides. Alternatively, they may be expressed on the surface of cells or in the form of a membrane fraction. There is no particular restriction on the test sample as it includes, for example, cell extract, cell culture supernatant, product of fermentation microorganism, extract from marine organism, extract from plant, purified or crude protein, peptide, non-peptide compound, synthetic low-molecular-weight compound, natural compound, etc. The inventive protein to be contacted with a test sample can be contacted with the test sample, for example, as a purified protein, as a soluble protein, in a form of protein immobilized on carriers, as a fusion protein with other proteins, in a form of protein presented on cell membrane, as a membrane fraction.

[0146] Many methods known to those skilled in the art can be used to screen proteins capable of binding to the inventive protein. Such screening can be carried out, for example, by the immunoprecipitation method. Specifically, the method can be carried out as follows. The gene encoding a protein of this invention is expressed by inserting the gene into a vector for foreign gene expression in pSV2neo, pcDNA I, pCD8, and such, and expressing the gene in animal cells, etc. Any generally used promoters may be employed for the expression, including the SV40 early promoter (Rigby In Williamson (ed.), Genetic Engineering, Vol. 3. Academic Press, London, p.83-141 (1982)), EF-1 α promoter (Kim et al., Gene 91:217-223, 1990), CAG promoter (Niwa et al., Gene 108:193-200, 1991), RSV LTR promoter (Cullen, Methods in Enzymology 152:684-704, 1987), SR α promoter (Takebe et al., Mol. Cell. Biol. 8:466, 1988), CMV immediate early promoter (Seed et al., Proc. Natl. Acad. Sci. USA 84:3365-3369, 1987), SV40 late promoter (Gheysen et al., J. Mol. Appl. Genet. 1:385-394, 1982), Adenovirus late promoter (Kaufman et al., Mol. Cell. Biol. 9:946, 1989), HSV TK promoter, etc.

[0147] Transfer of a foreign gene into animal cells for its expression can be performed by any of the following methods, including the electroporation method (Chu et al., Nucl. Acid Res. 15:1311-1326, 1987), the calcium phosphate method (Chen et al., Mol. Cell. Biol. 7:2745-2752, 1987), the DEAE dextran method (Lopata et al., Nucl. Acids Res. 12:5707-5717, 1984; Sussman et al., Mol. Cell. Biol. 4:1642-1643, 1985), the lipofectin method (Derijard, Cell. 7:1025-1037, 1994; Lamb et al., Nature Genetics 5:22-30, 1993; Rabindran et al., Science 259:230-234, 1993), etc.

[0148] The protein of this invention can be expressed as a fusion protein having a recognition site for a monoclonal antibody by introducing the recognition site (epitope) for the monoclonal antibody, the specificity of which has been established, into the N- or C-terminus of the protein of this invention. For this purpose, commercial epitope-antibody systems can be utilized (Igaku, Experimental Medicine 13:85-90, 1995). Vectors which can express fusion proteins with the β-galactosidase, maltose-binding protein, glutathione S-transferase, green fluorescence protein (GFP), and such, via the multi-cloning site are commercially available.

[0149] There is also a report that a fusion protein may be prepared by introducing only small epitope portions consisting of several to a dozen amino acid residues so as not to change the property of the protein of the present invention by the fusion. For example, epitopes such as polyhistidine (His-tag), influenza hemagglutinin (HA), human c-myc, FLAG, Vesicular stomatitis virus glycoprotein (VSV-GP), T7 gene 10 protein (T7-tag), human herpes simplex virus glycoprotein (HSV-tag), E-tag (epitope on the monoclonal phage), and such, and monoclonal antibodies to recognize them can be utilized as the epitope-antibody system for screening proteins binding to the protein of this invention (Igaku, Experimental Medicine 13:85-90, 1995).

[0150] In immunoprecipitation, immune complexes are formed by adding these antibodies to the cell lysate prepared using suitable surfactants. The immune complex comprises a protein of this invention, a protein comprising the binding ability with the protein, and an antibody. Immunoprecipitation can be also performed by using antibodies against a protein of this invention, besides using antibodies against the above-described epitopes. An antibody to a protein of this invention can be prepared, for example, by inserting a gene encoding the protein of the invention into an appropriate expression vector of E. coli to express it in the bacterium, purifying the expressed protein, and immunizing rabbits, mice, rats, goats, chicken, and such against the purified protein. The antibody can be also prepared by immunizing the above-described animals against synthetic partial peptides of the protein of the present invention.

[0151] Immune complexes can be precipitated using, for example, Protein A Sepharose and Protein G Sepharose when the antibody is a murine IgG antibody. In addition, if a protein of this invention is prepared as a fusion protein with the epitope, such as GST, an immune complex can be formed by using a substance specifically binding to these epitopes, such as glutathione-Sepharose 4B, in the same manner as in the use of the antibody against the protein of the present invention.

[0152] Immune precipitation, in general, may be carried out according to, or following the method described in the literature (Harlow et al.: Antibodies, pp.511-552, Cold Spring Harbor Laboratory publications, New York (1988)).

[0153] SDS-PAGE is generally used for the analysis of immunoprecipitated proteins. Bound proteins can be analyzed based on the molecular weights of proteins using a gel of an appropriate concentration. In this case, although proteins bound to a protein of this invention, in general, are hardly detectable by the usual protein staining method, such as Coomassie staining and silver staining, the detection sensitivity can be improved by culturing cells in a medium containing radioisotopes, such as ³⁵S-methionine and ³⁵S-cysteine, to label proteins inside the cells, and detecting the labeled proteins. Once the molecular weight of the protein is determined, the desired protein can be purified directly from the SDS-polyacrylamide gel and can be sequenced.

[0154] In addition, proteins binding to a protein of this invention can be isolated using the West-western blotting method (Skolnik et al., Cell 65:83-90, 1991) with the protein of this invention. Namely, cDNA is isolated from cells, tissues, and organs, in which the protein binding to a protein of this invention is expected to be expressed (e.g., liver and kidney), and transferred into a phage vector (for example, λgt11, ZAP, and such) to prepare a cDNA library, which is then expressed on LB-agarose plates. The protein thus expressed is fixed on a filter; reacted with the labeled, purified protein of this invention; and plaques expressing a protein bound to a protein of this invention can be detected by the label. Methods for labeling the proteins of this invention include methods using the binding activity of biotin and avidin; methods using antibodies specifically binding to the proteins of this invention, or peptides or polypeptides fused with the protein of this invention (e.g., GST); methods using the radioisotopes; methods using fluorescence; etc.

[0155] Alternatively, in another embodiment of the method for screening of the present invention, the two-hybrid system utilizing cells may be used (Fields et al., Trends Genet. 10:286-292, 1994; Dalton et al., Cell 68:597-612, 1992; “MATCHMAKER Two-Hybrid System”, “Mammalian MATCHMAKER Two-Hybrid Assay Kit”, “MATCHMAKER One-Hybrid System” (all from Clontech), “HybriZAP Two-Hybrid Vector System” (Stratagene)). In the two-hybrid system, an inventive protein or a partial peptide thereof is fused with the SRF DNA-binding region or GAL4 DNA-binding region, and then is expressed in yeast cells; a cDNA library, which express proteins in the form of fusion protein with the VP16 or GAL4 transcription activation region, is prepared from cells that are predicted to express a protein binding to an inventive protein; the resulting cDNA library is introduced into the above-mentioned yeast cells; and then a cDNA derived from the library is isolated from a detected positive clone (when a protein binding to the inventive protein is expressed in yeast cells, the reporter gene is activated by the binding of the two proteins, and thus positive clones are detectable). A protein encoded by the cDNA can be prepared after the isolated cDNA is introduced and expressed in E coli. Thus it is possible to prepare a protein binding to an inventive protein or the encoding gene. Reporter genes to be used in the two-hybrid system include, but are not limited to, for example, Ade2 gene, LacZ gene, CAT gene, luciferase gene, PAI-1 (Plasminogen activator inhibitor typel) gene in addition to HIS3 gene. The screening by the two-hybrid method can be conduced by using mammalian cells or others in addition to yeast.

[0156] Compounds binding to a protein of the present invention can be screened by affinity chromatography. For example, a protein of the invention is immobilized on a carrier of an affinity column, and a test sample, in which a protein binding to the protein of the invention is supposed to be expressed, is applied to the column. A test sample herein may be, for example, cell extracts, cell lysates, etc. After loading the test sample, the column is washed, and proteins bound to a protein of the invention can be prepared.

[0157] The amino acid sequence of the resulting protein is then analyzed. Based on the result, an oligo-DNA is synthesized and used as the probe to screen a cDNA library. This can provide a DNA encoding the protein.

[0158] In the present invention, a biosensor on the basis of surface plasmon resonance phenomenon can be used as a means to detect or assay the bound compounds. By utilizing the biosensor on the basis of surface plasmon resonance phenomenon, the interaction between the inventive protein and a test compound can be observed as a surface plasmon resonance signal in real time using a small amount of protein without labeling (e.g., BlAcore, Pharmacia). Thus the binding between the inventive protein and the test compound can be assessed by using biosensor of BlAcore, or the like.

[0159] In addition, methods are known in the art for isolating compounds binding to a protein of the invention, which are not limited only to proteins (including agonists and antagonists). Such methods include, for example, the method of screening for a molecule binding to a protein of the invention by contacting a synthetic compound or natural substance bank, or a random phage peptide display library with an immobilized protein of the invention, and the high-throughput screening method using a combinatorial chemistry technique (Wrighton et al., Science 273:458-64, 1996; Verdine, Nature 384:11-13, 1996; Hogan, J. C. Jr., Nature 384:17-9, 1996).

[0160] Compounds isolated by the screening of this invention are candidates for agents to regulate the activity of a protein of this invention, and thought to be applied to treatments for disorders caused by expressional and functional abnormalities, and such of the protein, and diseases which can be treated by controlling the activity of the protein. Compounds which can be obtained by the screening method of this invention, the partial structure of which is modified by addition, deletion and/or substitution, are also included in the compounds binding to the protein of this invention.

[0161] When a protein of this invention or compounds isolated by the screening of this invention are used as drugs for humans and other animals, for example, mice, rats, guinea pigs, rabbits, chickens, cats, dogs, sheep, pigs, cattle, monkeys, baboons, and chimpanzees, they can be administered by directly administering the protein or isolated compound itself to a patient or by administering it after formulated according to known pharmaceutical methods. They can be administered, as the occasion demands, for example, orally, as sugar-coated tablets, capsules, elixirs and microcapsules, or parenterally, in the form of sterile solutions in water or other pharmaceutically acceptable liquids, or suspensions for injections. For example, they may be formulated by appropriately mixing with pharmaceutically acceptable carriers or media, specifically sterile water, physiological saline, plant oil, emulsifying agents, suspending agents, surfactants, stabilizers, seasonings, excipients, vehicles, anticeptics, binders, and such, in the unit dosage form required in a generally accepted pharmaceutical procedure. Amounts of effective ingredients in these pharmaceutical preparations are adjusted so as to obtain the appropriate dose in the specified range.

[0162] Additives which can be mixed in tablets and capsules include, for example, binders such as gelatin, corn starch, tragacanth gum and arabic gum; excipients such as crystalline cellulose; bulking agents such as corn starch, gelatin and alginic acid; lubricants such as magnesium stearate; sweetening agents such as sucrose, lactose or saccharine; and flavors such as peppermint, Gaultheria adenothrix oil or cherry. When the dispensing unit form is a capsule, liquid carriers, such as oil, can be further added to the above-described materials. Sterile compositions for injection can be prescribed using vehicles such as distilled water for injection according to standard pharmaceutical procedure.

[0163] Aqueous solutions for injections include, for example, physiological saline, and isotonic solutions containing: glucose and other supplements such as D-sorbitol, D-mannose, D-mannitol, sodium chloride, and such; and suitable solubilizers, for example, alcohols, more specifically, ethanol, polyalcohols such as propylene glycol, polyethylene glycol, non-ionic surfactants such as polysorbate 80 (TM) and HCO-50 may be used together.

[0164] Oily solutions, including sesame oil and soybean oil, and benzyl benzoate and benzyl alcohol may be used together as the solubilizer. Injections may be combined with buffers such as phosphate buffer and sodium acetate buffer; soothing agents such as procaine hydrochloride; stabilizers such as benzyl alcohol, phenols and antioxidants. Injections thus prepared are typically filled in suitable ampules.

[0165] The administration to patients is done by methods commonly known to those skilled in the art, such as intraarterial, intravenous, or subcutaneous injections, as well as intranasal, bronchial, intramuscular, percutaneous, or oral administrations. One skilled in the art can suitably select the dosage according to the body-weight or age of a patient, or the method of administration. If the compound can be encoded by DNA, the DNA may be used for gene therapy by incorporating the DNA into a vector for gene therapy. Dosages and administration methods vary depending on the body-weight, age, symptoms, and such of patients, but those skilled in the art can appropriately select them.

[0166] Although the specific dosage of the protein of the invention changes according to the subject to be treated, the target organs, symptoms, and administration methods, it is generally considered to be, for example, about 100 μg to 20 mg one day for an adult (as body-weight 60 kg) in the form of injections.

[0167] Though they vary depending on the symptoms, doses of compounds binding to a protein of this invention or compounds regulating the activity of such a protein may be generally in the range of about 0.1 to 100 mg, preferably about 1.0 to 50 mg, and more preferably about 1.0 to 20 mg per day for adults (based on the body weight 60 kg) in the case of oral administration.

[0168] Though it varies depending on the subject to be administered, target organ, symptom and method of administration, a single dose of the compounds for the parenteral administration is thought to be preferably administered, for example, when it is in the form of injection, intravenously to normal adults (based on the body weight 60 kg) in the range of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg or thereabout per day. Doses converted on the 60 kg body weight basis or the body surface area can be similarly administered to other animals.

[0169] All publications and patents cited herein are incorporated by reference in their entirety.

DETAILED DESCRIPTION

[0170] The invention is illustrated more specifically with reference to the following examples, but is not to be construed as being limited thereto.

EXAMPLE 1

[0171] Construction of a CDNA library by the oligo-capping method

[0172] The NT-2 neuron progenitor cells (Stratagene), teratocarcinoma cells from human fetal testis, which can be differentiated into neurons by the treatment with retinoic acid were treated as follows according to the manufacturer's instructions.

[0173] (1) NT-2 cells were cultured without the induction by retinoic acid (NT2RM4).

[0174] (2) After NT-2 cells were cultured, retinoic acid was added thereto, and the cells were cultured for 2 weeks (NT2RP2).

[0175] After the culture, the respective cells were collected, and mRNA was extracted according to the method described in the literature (Sambrook et al., Molecular Cloning Second edition, Cold Spring harbor Laboratory Press 1989). Then, poly(A)⁺RNA was purified by using oligo dT cellulose.

[0176] Similarly, human placenta (PLACE1, PLACE2), human ovary cancer tissue (OVARC1), and tissue from human embryo at 10 weeks, which is enriched with head (HEMBA1) were used to extract mRNA by the method described in the literature (Molecular Cloning 2nd edition. (1989) Sambrook et al., Cold Spring Harbor Laboratory Press). Furthermore, poly(A)⁺RNA was purified from the mRNA using oligo-dT cellulose.

[0177] This poly(A)⁺RNA was used to construct a cDNA library by the oligo-capping method (Maruyama et al., Gene 138:171-174, 1994). Using the Oligo-cap linker (agcaucgagu cggccuuguu ggccuacugg/ SEQ ID NO:26) and the Oligo-dT primer (gcggctgaag acggcctatg tggccttttt tttttttt tt/ SEQ ID NO:27), bacterial alkaline phosphatase (BAP) treatment, tobacco acid phosphatase (TAP) treatment, RNA ligation, the first strand cDNA synthesis, and removal of RNA were performed according to the references (Suzuki et al., Protein, Nucleic acid and Enzyme, 41:197-201, 1996; Suzuki et al., Gene 200:149-156, 1997). Then, 5′- and 3′-PCR primers (agcatcgagt cggccttgtt g/ SEQ ID NO:28, and gcggctgaag acggcctatg t/ SEQ ID NO:29, respectively) were used for performing PCR to convert the cDNA into double stranded cDNA, which was then digested with SfiI. Then, the DraIII-cleaved vector pUC19FL3 or pME18SFL3 (GenBank AB009864, expression vector) (NT2RM4, NT2RP2, NT2RP3, PLACE1, PLACE2, OVARC 1, HEMBA 1) was used for cloning the CDNA in a unidirectional manner, and cDNA libraries were obtained. The nucleotide sequence of the 5′- and 3′- ends of the cDNA clones was analyzed with a DNA sequencer (ABI PRISM 377, PE Biosystems) after sequencing reactions performed with the DNA sequencing reagents (Dye Terminator Cycle Sequencing FS Ready Reaction Kit, dRhodamine Terminator Cycle Sequencing FS Ready Reaction Kit, or BigDye Terminator Cycle Sequencing FS Ready Reaction Kit, PE Biosystems), according to the instructions. The obtained data were used for a database.

[0178] Oligo-cap high full-length ratio cDNA libraries for samples except NT2RM1 and NT2RP1 were prepared by using an expression vector, pME18SFL3, which can be expressed in eukaryotic cells. pME18SFL3 vector contains the SRα. promoter and SV40 small t intron in the upstream, as well as the SV40 polyA addition signal sequence downstream of the cloning site, respectively. As the cloning site of pME18SFL3 has asymmetrical DraIII sites, and the ends of cDNA fragments contain SfiI sites complementary to the DraIII sites, the cloned cDNA fragments can be unidirectionally inserted downstream of the SRα promoter. Therefore, clones containing full-length cDNA can be expressed transiently by introducing the obtained plasmid directly into COS cells. Thus, the clones can be analyzed very easily in terms of the proteins that are the gene products of the clones, or in terms of the biological activities of the proteins.

EXAMPLE 2

[0179] Estimation of the completeness at the 5′-ends of the clones contained in the cDNA libraries constructed by the oligo-capping method

[0180] The full-length ratio at the 5′-end sequence of respective clones in the human cDNA libraries constructed by the oligo-capping method was determined as follows. The clones whose 5′-end sequences were consistent with those of known human mRNA in the public database were judged to be “full-length” if they had a longer 5′-end sequence than that of the known human mRNA; or even though the 5′-end sequence was shorter, if it contained the translation initiation codon it was judged to have the “full-length” sequence. Clones which did not contain the translation initiation codon were judged to be “not-full-length”. The full-length ratio ((the number of full-length clones)/(the number of full-length and not-full-length clones)) at the 5′-end of the cDNA clones from each library was determined by comparing with known human mRNA. As a result, the full-length ratio of the 5′-ends was 63.5%. The result indicates that the full-length ratio at the 5′-end sequence was extremely high in the human cDNA clones obtained by the oligo-capping method.

EXAMPLE 3

[0181] Assessment of the full-length ratio of the 5′-end of the cDNA by the ATGpr and the ESTiMateFL

[0182] The ATGpr, developed by Salamov A. A., Nishikawa T., and Swindells M. B. in the Helix Research Institute, is a program for prediction of the translation initiation codon based on the characteristics of the sequences in the vicinity of the ATG codon (Salamov et al., Bioinformatics 14:384-390, 1998; http://www.hri.cojp/atgpr/). The results are shown with expectations (also mentioned as ATGprl below) whether the ATG is a true initiation codon (0.05-0.94). When it was not considered that the sequence was the 5′-end of the cDNA or not, both of the sensitivity and specificity of analytical results by this program were estimated as 66%. When the program was applied to the 5′-end sequences of the clones from the cDNA library that was obtained by the oligo-capping method having 65% full-length ratio, the sensitivity and specificity of the estimation of the full-length clone (clone containing the N-terminus of the ORF) were improved to 82 to 83% by selecting only clones having an ATGprl score 0.6 or higher. The maximum ATGpr1 scores for 5′-end sequences were shown in Table 1. TABLE 1 Clone name Sequence name Maximum ATGpr1 score HEMBA1002212 F-HEMBA1002212 0.39 HEMBA1006173 F-HEMBA1006173 0.42 NT2RM4001411 F-NT2RM4001411 0.47 NT2RM4001758 F-NT2RM4001758 0.59 NT2RP2000668 F-NT2RP2000668 0.81 NT2RP2001839 F-NT2RP2001839 0.83 NT2RP2002710 F-NT2RP2002710 0.94 NT2RP2004933 F-NT2RP2004933 0.94 PLACE1011923 F-PLACE1011923 0.74 PLACE2000034 F-PLACE2000034 0.88 OVARC1000556 F-OVARC1000556 0.94 HEMBA1001019 F-HEMBA1001019 0.08

[0183] Next, the ESTiMateFL was used for the assessment of the clones. The ESTiMateFL, developed by Nishikawa and Ota in the Helix Research Institute, is a method for selecting clones expected to have a full-length cDNA by comparing with the 5′-end or 3′-end sequences of ESTs in the public database.

[0184] By this method, a cDNA clone is judged to be most likely not to be full-length if there exist any ESTs which have longer 5′-end or 3′-end sequences than the clone. The method is systematized for high throughput analysis. A clone is judged to be full-length if the clone has a longer 5′-end sequence than the ESTs in the public database corresponding thereto. Even if a clone has a shorter 5′-end, the clone is judged to be full-length if the difference in length is within 50 bases, and otherwise judged not to be full-length, for convenience. Those clones whose 5′-end sequence is matching with the known MRNA, about 80% of the clones judged to be full-length by the comparison with ESTs were also judged to be full-length by the assessment of the 5′-end sequence by comparing with known mRNA. Also, about 80% of the clones judged to be not full-length in the 5′-end sequence by comparing with ESTs were also judged to be not full-length in the 5′-end sequence by comparison with known mRNA. The precision of the estimation by comparing with ESTs is improved with increasing numbers of ESTs to be compared. However, in case with limited numbers of ESTs, the reliability becomes low. Thus, the method is effective in excluding clones with high probability of being not-full-length from the cDNA clones that is synthesized by the oligo-capping method having a 5′-end sequence full-length ratio of about 60%. In particular, the ESTiMateFL is efficiently used in estimating the full-length ratio at the 3′-end sequence of cDNA of a human unknown mRNA, a significant number of which are deposited in the public database as EST deposits.

[0185] Results of the above assessment for the full-length ratio showed that the clones “C-HEMBA1006173”, “C-PLACE2000034”, and “OVARC1000556” were novel clones with a high probability of being full-length and also which share no sequence identity with any of human EST sequences at least either at the 5′-end sequence or 3′-end sequence, or both ends.

[0186] Whereas the “C-HEMBA1002212” is a full-length sequence and is a novel clone; the number of human EST sequences that shared a common sequence to this clone at both 5′-and 3′-end was 1 or more and 5 or less.

[0187] Furthermore, “C-NT2RM4001411 ”, “C-NT2RM4001758”, “C-NT2RP2000668”, “C-NT2RP2001839”, “C-NT2RP2002710”, “C-NT2RP2004933”, and “C-PLACE1011923” are also full-length clones; the number of human EST sequences that shared a common sequence to each of these clones at the 5′-end was 20 or less (clones which do not share sequences with certain human EST sequences at least either at the 5′-end or at 3′-end, or at both ends of the clone; excluding clones in which the number of human EST sequences that shared a common sequence to each of the clones at both of the 5′- and 3-end was 1 or more and 5 or less). Accordingly, they were concluded to be novel clones.

[0188] Although the clone “C-HEMBAl001019” has a low ATGpr1 value and a low ATGpr2 value, still it was a full-length clone based on the full-length ratio, and furthermore, it is a novel clone which shares no sequence identity at least at the 5′-end with any human EST sequences.

EXAMPLE 4

[0189] Selection of clones having a kinase/phosphatase-like sequence

[0190] Clones having a kinase/phosphatase-like sequence were selected from the helix clones. All the helix clones were searched for homology by NCBI TBLASTN2.0 by using the following 31 amino acid sequences of known kinases and phosphatases (also including phospholipid kinases) as queries. Clones with a expectation value (Expect) 1.0e-05 or lower were selected.

[0191] The query sequences used in the homology search as well as their SEQ ID NOs and GenBank accession numbers are as follows. Query sequence No. SEQ ID NO: GenBank accession No. hLKB1 30 gi|3024670 hVRK1 31 gi|4507903 hCDC2 32 gi|4502709 hAuroraK1 33 gb|AAC1278.1 hAuroraK2 34 gi|4759178 hIKKA 35 gb|AAC51662.1 hMKK3 36 gb|AAB40653.1 hERK1 37 pir|A48082 hRAF1 38 gi|4506401 hAKT 39 gi|4885061 hPIKP85 40 sp|P27986 hATM 41 gi|4502267 hc-src 42 gi|4758078 hJAK1 43 ref|NP_002218.1 hFLT1 44 gb|AAC16449.1 hPP2A 45 gi|4506017 hMKP2 46 gb|AAC50452.1 hVHR 47 gi|4758208 hPTP-SL 48 gi|4506325 hSTEP 49 sp|P54829 hPTEN 50 gi|4506249 Cdc14B1 51 gb|AAD15415.1 DUSP12 52 gi|6005956 AK000449 53 gi|8923413 DUS7 54 sp|Q16829 calcineurin A alpha 55 gi|6715568 PNP1 56 emb|CAA56124.1 TPTE 57 gi|7019559 PPP1CC 58 gi|4506007 PP-1 gamma 59 gb|AAA19823.1 PP2A 60 gi|4506017

[0192] The results of homology search were shown in Tables 2 and 3. TABLE 2 Search score Expectation Query Helix clone (score) value (expect) hLKB1 C-NT2RP2004933 126 1e-29 hLKB1 C-PLACE1011923 89 2e-28 hLKB1 C-NT2RM4001758 118 3e-27 hLKB1 C-OVARC1000556 64 1e-10 hCDC2 C-NT2RP2004933 109 1e-24 hCDC2 C-HEMBA1001019 72 3e-13 hCDC2 C-NT2RM4001758 68 5e-12 hCDC2 C-OVARC1000556 53 1e-07 hCDC2 C-PLACE1011923 47 6e-06 hAuroraK1 C-PLACE1011923 115 3e-37 hAuroraK1 C-NT2RP2004933 145 2e-35 hAuroraK1 C-NT2RM4001758 121 3e-28 hAuroraK1 C-NT2RP2000668 66 2e-11 hAuroraK1 C-NT2RP2001839 53 2e-07 hAuroraK1 C-OVARC1000556 51 6e-07 hAuroraK2 C-PLACE1011923 105 4e-37 hAuroraK2 C-NT2RP2004933 138 2e-33 hAuroraK2 C-NT2RM4001758 112 1e-25 hAuroraK2 C-OVARC1000556 57 9e-09 hIKKA C-NT2RP2004933 103 2e-22 hIKKA C-NT2RM4001758 82 5e-16 hIKKA C-PLACE1011923 48 8e-06 hMKK3 C-PLACE1011923 75 4e-14 hNKK3 C-NT2RP2004933 63 1e-10 hNKK3 C-NT2R144001758 60 9e-10 hMKK3 C-HEMBA1002212 60 1e-09 hERK1 C-NT2RP2004933 89 2e-18 hERK1 C-PLACE1011923 70 1e-12 hERK1 C-NT2RM4001758 60 1e-09 hERK1 C-OVARC1000556 48 4e-06

[0193] (TABLE 3) Search score Expectation Query Helix clone (score) value (expect) hRAF1 C-NT2RP2004933 73 2e-13 hRAF1 C-PLACE1011923 72 6e-13 hRAF1 C-NT2RM4001758 65 8e-11 hAXT C-NT2RM4001758 129 1e-30 hAKT C-NT2RP2004933 129 1e-30 hART C-PLACE1011923 97 9e-28 hART C-OVARC1000556 60 2e-09 hPIKP85 C-N72RP2002710 65 7e-11 hc-src C-NT2RM4001758 69 2e-12 hc-src C-NT2RP2004933 65 5e-11 hc-src C-NT2RM4001411 58 7e-09 hc-src C-HEMBA1002212 57 1e-08 hJAK1 C-NT2RP2004933 82 7e-16 hJAK1 C-REMBA1002212 60 5e-09 hJAK1 C-NT2RM4001758 55 2e-07 hFLT1 C-HEMBA1002212 64 2e-10 hFLT1 C-NT2RP2004933 59 7e-09 hFLT1 C-PLACE1011923 55 1e-07 hFLT1 C-PLACE2000034 54 2e-07 hFLT1 C-NT2RM4001758 51 2e-06 hSTEP C-HEMBA1006173 51 1e-06

[0194] Based on the result, non-overlapping 12 clones were selected as clones having kinase/phosphatase-like structure (KP clones), which are “C-NT2RP2000668”, “C-HEMBA002212”, “C-NT2RM4001411”, “C-NT2RM4001758”, “C-NT2RP2002710”, “C-NT2RP2004933”, “C-PLACE 1011923”, “C-NT2RP2001839”, “C-HEMBA1006173”, “C-OVARC1000556”, “C-PLACE2000034”, and “C-HEMBA1001019”. The clones encode novel human proteins, and each of the proteins was deduced to function as a protein kinase and/or a protein phosphatase.

EXAMPLE 5

[0195] Gene expression analysis by hybridization using high density DNA filter

[0196] DNA for spotting onto the nylon membranes was prepared according to the following procedure. E. coli was cultured in each well of a 96-well plate (in a LB medium at 37° C. for 16 hours). A part of each culture was suspended in 10 μl of sterile water in the well of a 96-well plate. The plate was heated at 100° C. for 10 minutes. Then the samples were analyzed by PCR. PCR was performed in a 20 μl solution per one reaction by using TaKaRa PCR Amplification Kit (Takara) according to the supplier's protocol. A pair of sequencing primers, ME761 FW (5′tacggaagtgttacttctgc 3′/ SEQ ID NO:61) and ME1250RV (5′tgtgggaggttttttctcta 3′/SEQ ID NO:62), or a pair of primers, M13M4 (5′gttttcccagtcacgac 3′/SEQ ID NO:63) and M13RV (5′caggaaacagctatgac 3′/SEQ ID NO:64) were used for the amplification of the insert cDNA in the plasmid. PCR was performed in a thermal cycler, GeneAmp System 9600 (PE Biosystems). The cycling profile consisted of pre-heating at 95° C. for 5 minutes; 10 cycles of denaturation at 95° C. for 10 seconds, and annealing/extension at 68° C. for 1 minute; 20 cycles of denaturation at 98° C. for 20 seconds and annealing/extension at 60° C. for 3 minutes; and final extension at 72° C. for 10 minutes. After the PCR, 2 μl of the reaction solution was electrophoresed on a 1% agarose gel. DNA on the gel was stained with ethidium bromide to confirm the amplification of cDNA. When cDNAs were not amplified by PCR, plasmids containing the corresponding insert cDNAs were prepared by the alkali-extraction method (Sambrook et al., Molecular Cloning, A laboratory manual/ 2nd edition, Cold Spring Harbor Laboratory Press, 1989).

[0197] DNA array was prepared by the following procedure. An Aliquot of the DNA solution was added to each well of a 384-well plate. DNA was spotted onto a nylon membrane (Boehringer) by using a 384-pin tool of Biomek 2000 Laboratory Automation System (Beckman-Coulter). More specifically, the 384-well plate containing the DNA was placed under the 384-pin tool. The independent 384 needles of the pin tool were simultaneously dipped into the DNA solution to fix the DNA on the needles. The needles were gently pressed onto a nylon membrane, and the DNA fixed on the needles was spotted onto the membrane. Denaturation of the spotted DNA and immobilization of the DNA on the nylon membrane were carried out according to conventional methods (Sambrook et al., Molecular Cloning, A laboratory manual/2nd edition, Cold Spring Harbor Laboratory Press, 1989).

[0198] 1st strand cDNA labeled with radioisotope was used as the hybridization probe. The 1st strand cDNA was synthesized by using Thermoscript(^(M)) RT-PCR System (GIBCO). More specifically, the 1st strand cDNA was synthesized by using 1.5 μg mRNAs from various human tissues (Clontech), 1 μl 50 μM Oligo(dT)20, and 50 μCi [α³³P]dATP according to the attached protocol. Purification of the probe was carried out by using ProbeQuant(™) G-50 micro column (Amersham-Pharmacia Biotech) according to the attached protocol. In the next step, 2 units of E. coli RNaseH were added to the reaction mixture. The mixture was incubated at room temperature for 10 minutes, and then 100 μg of human COT-1 DNA (GIBCO) was added thereto. The mixture was incubated at 97° C. for 10 minutes, and then was allowed to stand on ice to give the hybridization probe.

[0199] Hybridization of the radioisotope-labeled probe to the DNA array was performed in a usual manner (Sambrook et al., Molecular Cloning, A laboratory manual/ 2nd edition, Cold Spring Harbor Laboratory Press, 1989). The membrane was washed as follows: the nylon membrane was washed three times by incubating in the Washing solution 1 (2X SSC, 1% SDS) at room temperature (about 26° C.) for 20 minutes; then the membrane was washed 3 times by incubating it in the Washing solution 2 (0.1X SSC, 1% SDS) at 65° C. for 20 minutes. Autoradiography was performed by using an image plate for BAS2000 (Fuji Photo Film Co., Ltd.). Specifically, the nylon membrane used for the hybridization was wrapped with a piece of Saran Wrap, and was contacted with the light-sensitive surface of the image plate. The membrane with the image plate was placed in an imaging cassette for radioisotope and was allowed to stand in dark for 4 hours. The radioactivity recorded on the image plate was analyzed by BAS2000 (Fuji Photo Film Co., Ltd.) and was recorded as an image file of the autoradiogram by electronic conversion. The signal intensity of each DNA spot was analyzed by using Visage High Density Grid Analysis Systems (Genomic Solutions Inc.). The signal intensity was converted into numerical data. The data were taken by duplicated measurements. The reproducibility was assessed by comparing the signal intensities of the corresponding spots on the duplicated DNA filters that were hybridized to a single DNA probe. The ratio between the corresponding spots falls within a range of 2-folds or less in 95% of entire spots, and the correlation coefficient was r=0.97. Thus, the reproducibility was assumed to be satisfactory.

[0200] The detection sensitivity in gene expression analysis was estimated by examining increases in the signal intensity of the probe concentration-dependent spot of the hybridization using a probe complementary to the DNA spotted on the nylon membrane. PLACE1008092 (the same DNA as that deposited in GenBank Accession No. AF107253) was used as the DNA. The DNA array with the DNA of PLACE1008092 was prepared according to the above-mentioned method. The probe was prepared as follows: mRNA was synthesized in vitro from the clone, PLACE1008092; using this mRNA as the template, radioisotope-labeled 1st strand cDNA was synthesized in the same manner as the probe preparation method described above; and the cDNA was used as the probe. The cDNA PLACE1008092 was inserted into pBluescript SK(-), so that the 5′-end of the PLACE1008092 is ligated to the T7 promoter of the pBluescript SK(-) to give a recombinant plasmid for in vitro synthesis of the mRNA from PLACE1008092. Specifically, the PLACE1008092 inserted at the DraIII site of the pME18SFL3 was cut out by XhoI digestion. The resulting PLACE1008092 fragment was ligated to XhoI-predigested pBluescript SK(-) by using the DNA ligation kit ver.2 (Takara). The in-vitro mRNA synthesis from PLACE1008092 inserted in pBluescript SK(-) was carried out by using the Ampliscribe(™) T7 high yield transcription kit (Epicentre technologies). The hybridization and analysis of signal intensity of each DNA spot were conducted using the same methods described above. When the probe concentration was 1×10⁷ μg/ml or less, there was no increase of signal intensity proportional to the probe concentration. Therefore it was assumed to be difficult to compare the signals with one another in this concentration range. Thus, spots with a intensity of 40 or less were indiscriminately taken as low-level signals. Within a concentration of the probe ranging from 1×10⁷ μg/ml to 0.1 μg/ml, signals were found to increase in a probe concentration-dependent manner. The detection sensitivity is 1:100,000 in a ratio of mRNA expression level in a sample.

[0201] Table 4 shows the expression of each cDNA in human normal tissues (heart, lung, pituitary gland, thymus, brain, kidney, liver and spleen). The expression levels are indicated by numerical values of 0 to 10,000. Each of the “C-HEMBA1006173”, “C-NT2RP2000668”, “C-NT2RP2001839”, “C-NT2RP2002710”, “C-NT2RP2004933”, “C-OVARC 1000556”, “C-PLACE1101923”, and “C-PLACE2000034” was expressed in at least one tissue.

[0202] The expression of “C-NT2RP2002710” was detectable in all the tissues. The clones “C-HEMBA1001019”, “C-HEMBA1002212”, “C-NT2RM4001411”, and “C-NT2RM4001758” were expressed at only low levels in all the tissues.

[0203] Further, genes expressed in a characteristic way were selected by statistical analysis of the data. Genes which expression level greatly varies among tissues as compared with the expression level of β-actin commonly used as a control, were identified as follows. Specifically, the sum of squared deviation of signal intensity in each tissue was determined for β-actin, and then, the value was divided by the degree of freedom 7 to determine variance S_(a) ^(2.) Next, the sum of squared deviation of signal intensity in each tissue was determined for the gene to be compared, and the value was divided by the degree of freedom 7 to determine variance S_(b) ² Genes with significance levels 5% or higher in the F-distribution were selected taking the variance ratio as F=S_(b) ^(2/)S_(a) ^(2.) Thus, “C-NT2RP2002710” was selected as a gene exhibiting a characteristic feature in the expression.

[0204] Additionally, “C-NT2RP2002710” was selected as a gene which expression level greatly varied among tissues. Specifically, the sum of squared deviation of signal intensity in each tissue was determined for OVARC1000037, and the value was divided by the degree of freedom 7 to determine variance S_(a) ^(2.) Next, the sum of squared deviation of signal intensity in each tissue was determined for the gene to be compared, and the value was divided by the degree of freedom 7 to determine variance S_(b) ². Genes with a significance levels 5% or higher in the F-distribution, were selected taking the variance ratio as F=S_(b) ²/S_(a) ² . TABLE 4 Pituitary Clone name Heart Lung gland Thymus Brain Kidney Liver Spleen GAPDH 38.210 32.670 23.820 13.580 11.230 21.120 24.910 22.440 β-actin 279.280 368.870 111.100 117.500 92.880 114.650 82.990 256.790 HEMBA1001019 7.327 7.582 14.865 6.154 10.598 5.643 3.920 7.188 HEMBA1002212 8.709 6.241 10.946 9.855 2.602 5.864 5.366 4.214 HEMBA1006173 63.939 35.393 52.598 22.894 32.403 35.413 40.872 67.870 NT2RM4001411 8.505 7.030 30.358 2.388 3.324 0.962 1.969 1.931 NT2RM4001758 24.391 23.518 27.924 5.579 12.781 14.153 7.027 6.943 NT2RP2000668 41.209 35.434 46.568 16.251 14.705 25.339 29.016 11.020 NT2RP2001839 68.237 44.006 65.237 21.186 23.824 37.874 35.524 54.235 NT2RP2002710 876.030 389.806 785.892 246.642 312.053 990.051 876.290 401.334 NT2RP2004933 18.660 21.000 61.644 10.893 8.184 31.855 24.143 11.593 OVARC1000556 84.636 47.645 29.302 13.010 36.300 34.811 56.871 26.716 PLACE1011923 32.608 43.041 19.701 8.083 15.625 16.742 22.157 29.615 PLACE2000034 42.847 21.194 15.709 12.449 11.089 18.174 25.238 21.354

EXAMPLE 6

[0205] Analysis of disease-associated genes

[0206] Non-enzymic protein glycation reaction is believed to be a cause of a variety of chronic diabetic complications. Accordingly, genes of which expression is elevated or decreased in a glycated protein-specific manner are associated with diabetic complications caused by glycated proteins. Vascular endothelial cells are affected with glycated proteins present in blood. Reaction products of non-enzymic protein glycation include amadori compound (glycated protein) as a mildly glycated protein and advanced glycation endproduct as a heavily glycated protein. Hence, whether or not the expression of the KP genes of this invention was varied depending on the presence of these proteins in endothelial cells was examined.

[0207] The mRNAs were extracted from endothelial cells that were cultured in the presence or absence of glycated protein. The mRNAs were converted into radiolabeled first strand cDNAs for preparing probes. The probes were hybridized to the above-mentioned DNA array. Signal of each DNA spot was detected by BAS2000 and analyzed by ArrayGauge (Fuji Photo Film Co., Ltd.).

[0208] Advanced glycation endproduct of bovine serum albumin was prepared as follows: bovine serum albumin (BSA; Sigma) was incubated in a phosphate buffer solution containing 50 mM glucose at 37° C. for 8 weeks; and the resulting brownish BSA was dialyzed against a phosphate buffer solution.

[0209] Human normal pulmonary arterial endothelial cells (Cell Applications) were cultured in an Endothelial Cell Growth Medium (Cell Applications). The culture dish (Falcon) with the cells was incubated in a CO₂ incubator (37° C., 5% CO₂, in a humid atmosphere). When the cells were grown to be confluent in the dish, 250 μg/ml of bovine serum albumin (sigma), glycated bovine serum albumin (Sigma) or advanced glycation endproduct of serum albumin was added thereto and the cells were incubated for 33 hours. The mRNA was extracted from the cells by using a FastTrack(™) 2.0 kit (Invitrogen). The labeling of hybridization probe was carried out by using the mRNA according to the same procedure as described above.

[0210] Table 5 shows the expression level of each CDNA in human pulmonary arterial endothelial cells cultured in a medium containing bovine serum albumin, glycated bovine serum albumin or advanced glycation endproduct of bovine serum albumin. Genes of which expression was detected in the endothelial cell are “C-HEMBA1006173”, “C-NT2RP2000668”, “C-NT2RP2002710”, “C-NT2RP2001839”, “C-OVARC1000556”, “C-PLACE1011923”, and “C-PLACE2000034”. TABLE 5 Advanced glycation Glycated bovine Advanced glycation Bovine Glycated endproduct of albumin addition/ endproduct of bovine serum bovine bovine serum Bovine serum serum albumin/Bovine Clone name albumin albumin albumin albumin ratio serum albumin ratio GAPDH(Cr1) 100.81 134.21 115.16 1.33 1.14 β-actin(Cr2) 1101.9 1092.57 997.36 0.99 0.91 HEMBA1006173 769.5 879.52 703.94 1.14 0.91 NT2RP2000668 100.83 114.72 104.66 1.14 1.04 NT2RP2001839 1191.8 1454.46 831.23 1.22 0.7 NT2RP2002710 305.22 324.01 248.69 1.06 0.81 OVARC1000556 68.77 93.52 73.85 1.36 1.07 PLACE1011923 318.75 346.7 273.3 1.09 0.86 PLACE2000034 57.78 58.66 54.29 1.02 0.94

EXAMPLE 7

[0211] Analysis of ultraviolet radiation damage-associated genes

[0212] It is known that ultraviolet rays give considerably adverse influence on health. In recent years, the risks of tissue damage by ultraviolet rays has been increased due to the destruction of the ozone layer, and ultraviolet radiation has been recognized as a risk factor for diseases such as skin cancers (United States Environmental Protection Agency: Ozone Depletion Home Page, http://www.epa.gov/ozone/). Genes whose expression levels change with exposure of the skin epidermal cells to ultraviolet rays are considered to be associated with skin damage caused by ultraviolet radiation. Culturing primary cultured skin fibroblast cells irradiated with ultraviolet ray, it was examined whether the expression of KP genes of this invention varies depending on the irradiation of ultraviolet ray.

[0213] First, after culturing to confluence in a culture dish, the primary cultured skin fibroblast cells (Cell Applications) were exposed to 10,000 μJ/cm² of 254-nm ultraviolet light. Thereafter, messenger RNAs were extracted by using a FastTrack™2.0 mRNA Isolation kit (Invitrogen) from the unexposed cells and from the cells that were exposed to the ultraviolet light and then cultured for 4 or 24 hours. The labeling of the hybridization probe was carried out by using 1.5 μg of each mRNA in the same manner as described above. The data were obtained in triplicate (n=3). The hybridization signals were compared between the cells exposed to the ultraviolet light and the unexposed cells. The comparison was preformed by statistical treatment with two-sample t-test. Clones with significant differences in the signal distribution were selected under the condition of p<0.05. According to the analysis, the difference in the signal values can be also detected statistically even when the signal values are low. Accordingly, clones with signal value of 40 or lower were also assessed.

[0214] Table 6 shows the expression of each cDNA in skin-derived fibroblast cells exposed and unexposed to ultraviolet light.

[0215] Averaged signal values (M₁, M₂) and sample variances (s₁ ², S₂ ²) were calculated for each gene in each of the cells, and then, pooled sample variances s² were obtained from the sample variances of the two types of cells to be compared. The t values were determined according to the following formula: t=(M₁-M₂)/s/(⅓+⅓)^(½). When the determined t-value was greater than a t-value at P, probability of significance level, of 0.05 or 0.01 in the t-distribution table with 4 degrees of freedom, it was judged that a difference exists in the expression level of the gene between the two types of cells at P<0.05 or P<0.01, respectively. The table also includes the information of an increase (+) or decrease (−) in the average expression level of a signal in the clones compared with that of undifferentiated cells.

[0216] The results showed that the expression level of “C-NT2RP2002710”, “C-NT2RP2004933”, “C-OVARC1000556”, and “C-PLACE1011923” was reduced 4 hours or 24 hours after ultraviolet ray irradiation, suggesting that they are clones associated with ultraviolet ray disorders. TABLE 6 UV_0 h UV_4 h UV_24 h t test 4 h 24 h Clone Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 3 Exp. 1 Exp. 2 Exp. 3 0/4 0/24 +/− +/− GAPDH(Cr1) 0 1.29 0.1 0.9 0.06 1.18 1.49 0.47 0 β actin(Cr2) 256.82 283.53 414.29 388.38 117.29 329.8 189.18 190.26 157.87 * − NT2RP2002710 30.61 29.84 37.75 21.5 19.35 13.67 11.45 15.23 13.68 * ** − − NT2RP2004933 6.78 7.42 14.62 6.21 3.1 2.23 3.41 1.97 1.54 * − OVARC1000556 22.37 23.81 26.15 14.72 11.54 9.38 19.99 16.63 22.58 ** − PLACE1011923 166.86 139.43 146.9 104.2 117.42 86.95 136.93 140 124.61 * −

INDUSTRIAL APPLICABILITY

[0217] The present invention provides novel human protein kinase and protein phosphatase proteins, as well as genes encoding the proteins. The regulation of the phosphorylation state of proteins by kinase and/or phosphatase plays central roles in normal differentiation and/or proliferation of cells, as well as in physiological functions at the cellular level. The novel kinases and phosphatases of the present invention can be assumed to be closely associated with intracellular physiological functions, and thus, the inventive proteins are useful as target molecules of agents in the development of pharmaceuticals. Furthermore, agents acting on the inventive proteins are expected to be effective pharmaceuticals which can control intracellular physiological functions more precisely than agents represented by previous receptor agonists and antagonists.

1 64 1 2159 DNA Homo sapiens CDS (109)...(1713) 1 cgctgtgagg gagtcgctgt gatccggggc cccggaaccc gagctggagc tgaagcgcag 60 gctgcggggc gcggagtcgg gagtgcaggc ctgagtgttc cttccagc atg tcg gag 117 Met Ser Glu 1 ggg gag tcc cag aca gta ctt agc agt ggc tca gac cca aag gta gaa 165 Gly Glu Ser Gln Thr Val Leu Ser Ser Gly Ser Asp Pro Lys Val Glu 5 10 15 tcc tca tct tca gct cct ggc ctg aca tca gtg tca cct cct gtg acc 213 Ser Ser Ser Ser Ala Pro Gly Leu Thr Ser Val Ser Pro Pro Val Thr 20 25 30 35 tcc aca acc tca gct gct tcc cca gag gaa gaa gaa gaa agt gaa gat 261 Ser Thr Thr Ser Ala Ala Ser Pro Glu Glu Glu Glu Glu Ser Glu Asp 40 45 50 gag tct gag att ttg gaa gag tcg ccc tgt ggg cgc tgg cag aag agg 309 Glu Ser Glu Ile Leu Glu Glu Ser Pro Cys Gly Arg Trp Gln Lys Arg 55 60 65 cga gaa gag gtg aat caa cgg aat gta cca ggt att gac agt gca tac 357 Arg Glu Glu Val Asn Gln Arg Asn Val Pro Gly Ile Asp Ser Ala Tyr 70 75 80 ctg gcc atg gat aca gag gaa ggt gta gag gtt atg tgg aat gag gta 405 Leu Ala Met Asp Thr Glu Glu Gly Val Glu Val Met Trp Asn Glu Val 85 90 95 cag ttc tct gaa cgc aag aac tac aag ctg cag gag gaa aag gtt cgt 453 Gln Phe Ser Glu Arg Lys Asn Tyr Lys Leu Gln Glu Glu Lys Val Arg 100 105 110 115 gct gtg ttt gat aat ctg att caa ttg gag cat ctt aac att gtt aag 501 Ala Val Phe Asp Asn Leu Ile Gln Leu Glu His Leu Asn Ile Val Lys 120 125 130 ttt cac aaa tat tgg gct gac att aaa gag aac aag gcc agg gtc att 549 Phe His Lys Tyr Trp Ala Asp Ile Lys Glu Asn Lys Ala Arg Val Ile 135 140 145 ttt atc aca gaa tac atg tca tct ggg agt ctg aag caa ttt ctg aag 597 Phe Ile Thr Glu Tyr Met Ser Ser Gly Ser Leu Lys Gln Phe Leu Lys 150 155 160 aag acc aaa aag aac cac aag acg atg aat gaa aag gca tgg aag cgt 645 Lys Thr Lys Lys Asn His Lys Thr Met Asn Glu Lys Ala Trp Lys Arg 165 170 175 tgg tgc aca caa atc ctc tct gcc cta agc tac ctg cac tcc tgt gac 693 Trp Cys Thr Gln Ile Leu Ser Ala Leu Ser Tyr Leu His Ser Cys Asp 180 185 190 195 ccc ccc atc atc cat ggg aac ctg acc tgt gac acc atc ttc atc cag 741 Pro Pro Ile Ile His Gly Asn Leu Thr Cys Asp Thr Ile Phe Ile Gln 200 205 210 cac aac gga ctc atc aag att ggc tct gtg gct cct gac act atc aac 789 His Asn Gly Leu Ile Lys Ile Gly Ser Val Ala Pro Asp Thr Ile Asn 215 220 225 aat cat gtg aag act tgt cga gaa gag cag aag aat cta cac ttc ttt 837 Asn His Val Lys Thr Cys Arg Glu Glu Gln Lys Asn Leu His Phe Phe 230 235 240 gca cca gag tat gga gaa gtc act aat gtg aca aca gca gtg gac atc 885 Ala Pro Glu Tyr Gly Glu Val Thr Asn Val Thr Thr Ala Val Asp Ile 245 250 255 tac tcc ttt ggc atg tgt gca ctg gag atg gca gtg ctg gag att cag 933 Tyr Ser Phe Gly Met Cys Ala Leu Glu Met Ala Val Leu Glu Ile Gln 260 265 270 275 ggc aat gga gag tcc tca tat gtg cca cag gaa gcc atc agc agt gcc 981 Gly Asn Gly Glu Ser Ser Tyr Val Pro Gln Glu Ala Ile Ser Ser Ala 280 285 290 atc cag ctt cta gaa gac cca tta cag agg gag ttc att caa aag tgc 1029 Ile Gln Leu Leu Glu Asp Pro Leu Gln Arg Glu Phe Ile Gln Lys Cys 295 300 305 ctg cag tct gag cct gct cgc aga cca aca gcc aga gaa ctt ctg ttc 1077 Leu Gln Ser Glu Pro Ala Arg Arg Pro Thr Ala Arg Glu Leu Leu Phe 310 315 320 cac cca gca ttg ttt gaa gtg ccc tcg ctc aaa ctc ctt gcg gcc cac 1125 His Pro Ala Leu Phe Glu Val Pro Ser Leu Lys Leu Leu Ala Ala His 325 330 335 tgc att gtg gga cac caa cac atg atc cca gag aac gct cta gag gag 1173 Cys Ile Val Gly His Gln His Met Ile Pro Glu Asn Ala Leu Glu Glu 340 345 350 355 atc acc aaa aac atg gat act agt gcc gta ctg gct gaa atc cct gca 1221 Ile Thr Lys Asn Met Asp Thr Ser Ala Val Leu Ala Glu Ile Pro Ala 360 365 370 gga cca gga aga gaa cca gtt cag act ttg tac tct cag tca cca gct 1269 Gly Pro Gly Arg Glu Pro Val Gln Thr Leu Tyr Ser Gln Ser Pro Ala 375 380 385 ctg gaa tta gat aaa ttc ctt gaa gat gtc agg aat ggg atc tat cct 1317 Leu Glu Leu Asp Lys Phe Leu Glu Asp Val Arg Asn Gly Ile Tyr Pro 390 395 400 ctg aca gcc ttt ggg ctg cct cgg ccc cag cag cca cag cag gag gag 1365 Leu Thr Ala Phe Gly Leu Pro Arg Pro Gln Gln Pro Gln Gln Glu Glu 405 410 415 gtg aca tca cct gtc gtg ccc ccc tct gtc aag act ccg aca cct gaa 1413 Val Thr Ser Pro Val Val Pro Pro Ser Val Lys Thr Pro Thr Pro Glu 420 425 430 435 cca gct gag gtg gag act cgc aag gtg gtg ctg atg cag tgc aac att 1461 Pro Ala Glu Val Glu Thr Arg Lys Val Val Leu Met Gln Cys Asn Ile 440 445 450 gag tcg gtg gag gag gga gtc aaa cac cac ctg aca ctt ctg ctg aag 1509 Glu Ser Val Glu Glu Gly Val Lys His His Leu Thr Leu Leu Leu Lys 455 460 465 ttg gag gac aaa ctg agc cgg cac ctg agc tgt gac ctg atg cca aat 1557 Leu Glu Asp Lys Leu Ser Arg His Leu Ser Cys Asp Leu Met Pro Asn 470 475 480 gag aat atc ccc gag ttg gcg gct gag ctg gtg cag ctg ggc ttc att 1605 Glu Asn Ile Pro Glu Leu Ala Ala Glu Leu Val Gln Leu Gly Phe Ile 485 490 495 agt gag gct gac cag agc cgg ttg act tct ctg cta gaa gag acc ttg 1653 Ser Glu Ala Asp Gln Ser Arg Leu Thr Ser Leu Leu Glu Glu Thr Leu 500 505 510 515 aac aag ttc aat ttt gcc agg aac agt acc ctc aac tca gcc gct gtc 1701 Asn Lys Phe Asn Phe Ala Arg Asn Ser Thr Leu Asn Ser Ala Ala Val 520 525 530 acc gtc tcc tct tagagctcac tcgggccagg ccctgatctg cgctgtggct 1753 Thr Val Ser Ser 535 gtccctggac gtgctgcagc cctcctgtcc cttcccccca gtcagtatta ccctgtgaag 1813 ccccttccct cctttattat tcaggagggc tgggggggct ccctggttct gagcatcatc 1873 ctttcccctc ccctctcttc ctcccctctg cactttgttt acttgttttg cacagacgtg 1933 ggcctgggcc ttctcagcag ccgccttcta gttgggggct agtcgctgat ctgccggctc 1993 ccgcccagcc tgtgtggaaa ggaggcccac gggcactagg ggagccgaat tctacaatcc 2053 cgctggggcg gccggggcgg gagagaaagg tggtgctgca gtggtggccc tggggggcca 2113 ttcgattcgc ctcagttgct gctgtaataa aagtctactt tttgct 2159 2 535 PRT Homo sapiens 2 Met Ser Glu Gly Glu Ser Gln Thr Val Leu Ser Ser Gly Ser Asp Pro 1 5 10 15 Lys Val Glu Ser Ser Ser Ser Ala Pro Gly Leu Thr Ser Val Ser Pro 20 25 30 Pro Val Thr Ser Thr Thr Ser Ala Ala Ser Pro Glu Glu Glu Glu Glu 35 40 45 Ser Glu Asp Glu Ser Glu Ile Leu Glu Glu Ser Pro Cys Gly Arg Trp 50 55 60 Gln Lys Arg Arg Glu Glu Val Asn Gln Arg Asn Val Pro Gly Ile Asp 65 70 75 80 Ser Ala Tyr Leu Ala Met Asp Thr Glu Glu Gly Val Glu Val Met Trp 85 90 95 Asn Glu Val Gln Phe Ser Glu Arg Lys Asn Tyr Lys Leu Gln Glu Glu 100 105 110 Lys Val Arg Ala Val Phe Asp Asn Leu Ile Gln Leu Glu His Leu Asn 115 120 125 Ile Val Lys Phe His Lys Tyr Trp Ala Asp Ile Lys Glu Asn Lys Ala 130 135 140 Arg Val Ile Phe Ile Thr Glu Tyr Met Ser Ser Gly Ser Leu Lys Gln 145 150 155 160 Phe Leu Lys Lys Thr Lys Lys Asn His Lys Thr Met Asn Glu Lys Ala 165 170 175 Trp Lys Arg Trp Cys Thr Gln Ile Leu Ser Ala Leu Ser Tyr Leu His 180 185 190 Ser Cys Asp Pro Pro Ile Ile His Gly Asn Leu Thr Cys Asp Thr Ile 195 200 205 Phe Ile Gln His Asn Gly Leu Ile Lys Ile Gly Ser Val Ala Pro Asp 210 215 220 Thr Ile Asn Asn His Val Lys Thr Cys Arg Glu Glu Gln Lys Asn Leu 225 230 235 240 His Phe Phe Ala Pro Glu Tyr Gly Glu Val Thr Asn Val Thr Thr Ala 245 250 255 Val Asp Ile Tyr Ser Phe Gly Met Cys Ala Leu Glu Met Ala Val Leu 260 265 270 Glu Ile Gln Gly Asn Gly Glu Ser Ser Tyr Val Pro Gln Glu Ala Ile 275 280 285 Ser Ser Ala Ile Gln Leu Leu Glu Asp Pro Leu Gln Arg Glu Phe Ile 290 295 300 Gln Lys Cys Leu Gln Ser Glu Pro Ala Arg Arg Pro Thr Ala Arg Glu 305 310 315 320 Leu Leu Phe His Pro Ala Leu Phe Glu Val Pro Ser Leu Lys Leu Leu 325 330 335 Ala Ala His Cys Ile Val Gly His Gln His Met Ile Pro Glu Asn Ala 340 345 350 Leu Glu Glu Ile Thr Lys Asn Met Asp Thr Ser Ala Val Leu Ala Glu 355 360 365 Ile Pro Ala Gly Pro Gly Arg Glu Pro Val Gln Thr Leu Tyr Ser Gln 370 375 380 Ser Pro Ala Leu Glu Leu Asp Lys Phe Leu Glu Asp Val Arg Asn Gly 385 390 395 400 Ile Tyr Pro Leu Thr Ala Phe Gly Leu Pro Arg Pro Gln Gln Pro Gln 405 410 415 Gln Glu Glu Val Thr Ser Pro Val Val Pro Pro Ser Val Lys Thr Pro 420 425 430 Thr Pro Glu Pro Ala Glu Val Glu Thr Arg Lys Val Val Leu Met Gln 435 440 445 Cys Asn Ile Glu Ser Val Glu Glu Gly Val Lys His His Leu Thr Leu 450 455 460 Leu Leu Lys Leu Glu Asp Lys Leu Ser Arg His Leu Ser Cys Asp Leu 465 470 475 480 Met Pro Asn Glu Asn Ile Pro Glu Leu Ala Ala Glu Leu Val Gln Leu 485 490 495 Gly Phe Ile Ser Glu Ala Asp Gln Ser Arg Leu Thr Ser Leu Leu Glu 500 505 510 Glu Thr Leu Asn Lys Phe Asn Phe Ala Arg Asn Ser Thr Leu Asn Ser 515 520 525 Ala Ala Val Thr Val Ser Ser 530 535 3 1818 DNA Homo sapiens CDS (170)...(1135) 3 gaattgcaac ggcagctgcc gggcgtatgt gttggtgcta gaggcagctg cagggtctcg 60 ctgggggcca atcgggacca attttgagga ggtacttggc cacgacttat tttcacctcc 120 gacctttcct tccaggcggt gagactctgg actgagagtg gctttcaca atg gaa ggg 178 Met Glu Gly 1 atc agt aat ttc aag aca cca agc aaa tta tca gaa aaa aag aaa tct 226 Ile Ser Asn Phe Lys Thr Pro Ser Lys Leu Ser Glu Lys Lys Lys Ser 5 10 15 gta tta tgt tca act cca act ata aat atc ccg gcc tct ccg ttt atg 274 Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro Ala Ser Pro Phe Met 20 25 30 35 cag aag ctt ggc ttt ggt act ggg gta aat gtg tac cta atg aaa aga 322 Gln Lys Leu Gly Phe Gly Thr Gly Val Asn Val Tyr Leu Met Lys Arg 40 45 50 tct cca aga ggt ttg tct cat tct cct tgg gct gta aaa aag att aat 370 Ser Pro Arg Gly Leu Ser His Ser Pro Trp Ala Val Lys Lys Ile Asn 55 60 65 cct ata tgt aat gat cat tat cga agt gtg tat caa aag aga cta atg 418 Pro Ile Cys Asn Asp His Tyr Arg Ser Val Tyr Gln Lys Arg Leu Met 70 75 80 gat gaa gct aag att ttg aaa agc ctt cat cat cca aac att gtt ggt 466 Asp Glu Ala Lys Ile Leu Lys Ser Leu His His Pro Asn Ile Val Gly 85 90 95 tat cgt gct ttt act gaa gcc agt gat ggc agt ctg tgt ctt gct atg 514 Tyr Arg Ala Phe Thr Glu Ala Ser Asp Gly Ser Leu Cys Leu Ala Met 100 105 110 115 gaa tat gga ggt gaa aag tct cta aat gac tta ata gaa gaa cga tat 562 Glu Tyr Gly Gly Glu Lys Ser Leu Asn Asp Leu Ile Glu Glu Arg Tyr 120 125 130 aaa gcc agc caa gat cct ttt cca gca gcc ata att tta aaa gtt gct 610 Lys Ala Ser Gln Asp Pro Phe Pro Ala Ala Ile Ile Leu Lys Val Ala 135 140 145 ttg aat atg gca aga ggg tta aag tat ctg cac caa gaa aag aaa ctg 658 Leu Asn Met Ala Arg Gly Leu Lys Tyr Leu His Gln Glu Lys Lys Leu 150 155 160 ctt cat gga gac ata gag tct tca aat gtt gta att aaa ggc gat ttt 706 Leu His Gly Asp Ile Glu Ser Ser Asn Val Val Ile Lys Gly Asp Phe 165 170 175 gaa aca att aaa atc tgt gat gta gga gtc tct cta cca ctg gat gaa 754 Glu Thr Ile Lys Ile Cys Asp Val Gly Val Ser Leu Pro Leu Asp Glu 180 185 190 195 aat atg act gtg act gac cct gag gct tgt tac att ggc aca gag cca 802 Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr Ile Gly Thr Glu Pro 200 205 210 tgg aaa ccc aaa gaa gct gtg gag gag aat ggt gtt att act gac aag 850 Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly Val Ile Thr Asp Lys 215 220 225 gca gac ata ttt gcc ttt ggc ctt act ttg tgg gaa atg atg act tta 898 Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp Glu Met Met Thr Leu 230 235 240 tcg att cca cac att aat ctt tca aat gat aat gat gat gaa gat aaa 946 Ser Ile Pro His Ile Asn Leu Ser Asn Asp Asn Asp Asp Glu Asp Lys 245 250 255 act ttt gat gaa agt gat ttt gat gat gaa gca tac tat gca gcc ttg 994 Thr Phe Asp Glu Ser Asp Phe Asp Asp Glu Ala Tyr Tyr Ala Ala Leu 260 265 270 275 gga act agg cca cct att aat atg gaa gaa ctg gat gaa tca tac cag 1042 Gly Thr Arg Pro Pro Ile Asn Met Glu Glu Leu Asp Glu Ser Tyr Gln 280 285 290 aaa gta att gaa ctc ttc tct gta tgc act aat gaa gac cct aaa gat 1090 Lys Val Ile Glu Leu Phe Ser Val Cys Thr Asn Glu Asp Pro Lys Asp 295 300 305 cgt cct tct gct gca cac att gtt gaa gct ctg gaa aca gat gtc 1135 Arg Pro Ser Ala Ala His Ile Val Glu Ala Leu Glu Thr Asp Val 310 315 320 tagtgatcat ctcagctgaa gtgtggcttg cgtaaataac tgtttattcc aaaatattta 1195 catagttact atcagtagtt attagactct aaaattggca tatttcagga ccatagtttc 1255 ttgttaacat atggataact atttctaata tgaaatatgc ttatattggc tataagcact 1315 tggaattgta ctgggttttc tgtaaagttt tagaaactag ctacataagt actttgatac 1375 tgctcatgct gacttaaaac actagcagta aaacgctgta aactgtaaca ttaaattgaa 1435 tgaccattac ttttattaat gatctttctt aaatattcta tattttaatg gatctactga 1495 cattagcact ttgtacagta caaaataaag tctacatttg tttaaaacac tgaacctttt 1555 gctgatgtgt ttatcaaatg ataactggaa gctgaggaga atatgcctca aaaagagtag 1615 ctccttggat acttcagact ctggttacag attgtcttga tctcttggat ctcctcagat 1675 cttctttggt ttttgcttta atttattaaa tgtattttcc atactgagtt taaaatttat 1735 taatttgtac cttaagcatt tcccagctgt gtaaaaacaa taaaactcaa ataggatgat 1795 aaagaataaa ggacactttg ggt 1818 4 322 PRT Homo sapiens 4 Met Glu Gly Ile Ser Asn Phe Lys Thr Pro Ser Lys Leu Ser Glu Lys 1 5 10 15 Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro Ala Ser 20 25 30 Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn Val Tyr Leu 35 40 45 Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro Trp Ala Val Lys 50 55 60 Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg Ser Val Tyr Gln Lys 65 70 75 80 Arg Leu Met Asp Glu Ala Lys Ile Leu Lys Ser Leu His His Pro Asn 85 90 95 Ile Val Gly Tyr Arg Ala Phe Thr Glu Ala Ser Asp Gly Ser Leu Cys 100 105 110 Leu Ala Met Glu Tyr Gly Gly Glu Lys Ser Leu Asn Asp Leu Ile Glu 115 120 125 Glu Arg Tyr Lys Ala Ser Gln Asp Pro Phe Pro Ala Ala Ile Ile Leu 130 135 140 Lys Val Ala Leu Asn Met Ala Arg Gly Leu Lys Tyr Leu His Gln Glu 145 150 155 160 Lys Lys Leu Leu His Gly Asp Ile Glu Ser Ser Asn Val Val Ile Lys 165 170 175 Gly Asp Phe Glu Thr Ile Lys Ile Cys Asp Val Gly Val Ser Leu Pro 180 185 190 Leu Asp Glu Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr Ile Gly 195 200 205 Thr Glu Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly Val Ile 210 215 220 Thr Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp Glu Met 225 230 235 240 Met Thr Leu Ser Ile Pro His Ile Asn Leu Ser Asn Asp Asn Asp Asp 245 250 255 Glu Asp Lys Thr Phe Asp Glu Ser Asp Phe Asp Asp Glu Ala Tyr Tyr 260 265 270 Ala Ala Leu Gly Thr Arg Pro Pro Ile Asn Met Glu Glu Leu Asp Glu 275 280 285 Ser Tyr Gln Lys Val Ile Glu Leu Phe Ser Val Cys Thr Asn Glu Asp 290 295 300 Pro Lys Asp Arg Pro Ser Ala Ala His Ile Val Glu Ala Leu Glu Thr 305 310 315 320 Asp Val 5 2200 DNA Homo sapiens CDS (173)...(1450) 5 gtcaggcccc ccagtcttag gtggaaacag caactccaac tcctctggcg gggctgggac 60 cgttggtagg ggactggtca gtgatggaac gtcccctggg gaaagatgga ctcaccgttt 120 tgagaggctg agactcagtc ggggaggggg cgccttgaag gatggagcag gg atg gtg 178 Met Val 1 cag agg gaa gag ctg ctg agt ttc atg ggg gct gag gag gca gcc cct 226 Gln Arg Glu Glu Leu Leu Ser Phe Met Gly Ala Glu Glu Ala Ala Pro 5 10 15 gac cca gcc gga gtg ggc cgg gga gga ggg gtg gct ggg cct cct tca 274 Asp Pro Ala Gly Val Gly Arg Gly Gly Gly Val Ala Gly Pro Pro Ser 20 25 30 ggg gga gga ggg cag cct cag tgg cag aag tgt cgc ctg ctg ctt cga 322 Gly Gly Gly Gly Gln Pro Gln Trp Gln Lys Cys Arg Leu Leu Leu Arg 35 40 45 50 agt gaa gga gaa gga gga gga gga agt cgc ctg gag ttc ttt gta cca 370 Ser Glu Gly Glu Gly Gly Gly Gly Ser Arg Leu Glu Phe Phe Val Pro 55 60 65 ccc aag gcc tct cgg ccc cga ctc agc atc ccc tgc tct tct atc aca 418 Pro Lys Ala Ser Arg Pro Arg Leu Ser Ile Pro Cys Ser Ser Ile Thr 70 75 80 gac gtc cgg aca acc aca gcc ctg gag atg cct gac cgg gag aac acg 466 Asp Val Arg Thr Thr Thr Ala Leu Glu Met Pro Asp Arg Glu Asn Thr 85 90 95 ttt gtg gtt aag gtg gaa ggt cca tcc gag tat atc atg gag aca gtg 514 Phe Val Val Lys Val Glu Gly Pro Ser Glu Tyr Ile Met Glu Thr Val 100 105 110 gat gcc cag cat gtg aag gcc tgg gtg tct gac atc caa gaa tgc ctg 562 Asp Ala Gln His Val Lys Ala Trp Val Ser Asp Ile Gln Glu Cys Leu 115 120 125 130 agc cca gga ccc tgc cct gct acc agt ccc cgc ccc atg acc ctc cct 610 Ser Pro Gly Pro Cys Pro Ala Thr Ser Pro Arg Pro Met Thr Leu Pro 135 140 145 ctg gcc cct ggg acc tca ttc ctt aca agg gag aac aca gac agc ctg 658 Leu Ala Pro Gly Thr Ser Phe Leu Thr Arg Glu Asn Thr Asp Ser Leu 150 155 160 gag ctg tcc tgc ctg aat cac tcg gag agt cta ccc agc cag gac ctg 706 Glu Leu Ser Cys Leu Asn His Ser Glu Ser Leu Pro Ser Gln Asp Leu 165 170 175 ctg ctt gga ccc agc gag agc aat gac cgc ctg tcg cag ggg gca tat 754 Leu Leu Gly Pro Ser Glu Ser Asn Asp Arg Leu Ser Gln Gly Ala Tyr 180 185 190 ggg ggc ctc tca gac cgc ccc tcg gca tcc atc tcc ccc agc tct gcc 802 Gly Gly Leu Ser Asp Arg Pro Ser Ala Ser Ile Ser Pro Ser Ser Ala 195 200 205 210 tcc att gcc gcc tcc cat ttt gac tcg atg gaa ctg ctt ccc cca gag 850 Ser Ile Ala Ala Ser His Phe Asp Ser Met Glu Leu Leu Pro Pro Glu 215 220 225 ttg ccc ccc cgc atc ccc att gaa gag gga ccc cca gca ggg aca gtt 898 Leu Pro Pro Arg Ile Pro Ile Glu Glu Gly Pro Pro Ala Gly Thr Val 230 235 240 cat ccc ctc tca gcc ccc tac cct ccc ttg gac act ccg gaa aca gcc 946 His Pro Leu Ser Ala Pro Tyr Pro Pro Leu Asp Thr Pro Glu Thr Ala 245 250 255 aca ggg tcc ttc ctg ttc cag ggg gag cca gag ggc ggt gag ggg gac 994 Thr Gly Ser Phe Leu Phe Gln Gly Glu Pro Glu Gly Gly Glu Gly Asp 260 265 270 cag ccc ctc tca ggg tat cct tgg ttc cac ggg atg ctc tct cgg ctc 1042 Gln Pro Leu Ser Gly Tyr Pro Trp Phe His Gly Met Leu Ser Arg Leu 275 280 285 290 aag gct gca cag ttg gtg ctg act ggc ggc act ggc tcc cac ggt gtc 1090 Lys Ala Ala Gln Leu Val Leu Thr Gly Gly Thr Gly Ser His Gly Val 295 300 305 ttc ctg gtg cgc cag agt gag aca agg cgg ggt gaa tac gtc ctc acc 1138 Phe Leu Val Arg Gln Ser Glu Thr Arg Arg Gly Glu Tyr Val Leu Thr 310 315 320 ttc aac ttc cag ggc aag gcc aag cac ctg cgt ttg tcg ctg aac gag 1186 Phe Asn Phe Gln Gly Lys Ala Lys His Leu Arg Leu Ser Leu Asn Glu 325 330 335 gag ggt cag tgc cgg gtc cag cac ctg tgg ttc cag tcc att ttc gat 1234 Glu Gly Gln Cys Arg Val Gln His Leu Trp Phe Gln Ser Ile Phe Asp 340 345 350 atg ctc gag cac ttc cgg gtg cac ccc atc cct ttg gag tcg gga ggc 1282 Met Leu Glu His Phe Arg Val His Pro Ile Pro Leu Glu Ser Gly Gly 355 360 365 370 tcc agt gat gtt gtc ctt gtc agc tat gtc cca tcc tcc cag cga cag 1330 Ser Ser Asp Val Val Leu Val Ser Tyr Val Pro Ser Ser Gln Arg Gln 375 380 385 cag ggc cgg gag cag gct ggg agc cat gcg ggg gtg tgc gag gga gat 1378 Gln Gly Arg Glu Gln Ala Gly Ser His Ala Gly Val Cys Glu Gly Asp 390 395 400 gga tgc cac ccc gat gcc tcc tgc acc ctc atg ccc ttc gga gcg agt 1426 Gly Cys His Pro Asp Ala Ser Cys Thr Leu Met Pro Phe Gly Ala Ser 405 410 415 gac tgt gta acc gac cac ctc cca tgacccaccc cagccccctg aacccccttc 1480 Asp Cys Val Thr Asp His Leu Pro 420 425 atggacagat cccccacagc ctggggcaga agaggcgtcg agggcgccag aagtggcggc 1540 agcagcagcc gcagcagcca aagagaggca agagaaagag aaagcgggcg gtggaggggt 1600 cccggaagag ctggtccccg tggttgagct ggtccccgtg gttgaattgg aagaggccat 1660 agccccaggc tcagaggccc agggcgctgg gtctggtggg gacgcggggg tgcccccaat 1720 ggtgcagctg cagcagtcac cactaggggg tgatggagag gaagggggcc accccagggc 1780 cattaacaac cagtactcct tcgtgtgagc caaccccacc cgctccaccc tttttaaacc 1840 ccccagccct gctcgtgaga ttgggctggg tagggacaga ggaggccgaa atccctcccc 1900 catgcttcct gacccttgtt ggccaagggc atctttgatg gtacaagcag aggctcggga 1960 gaggctcccg tcacacacta caggtcccct ccccagggca ggggatttgg gctccatgag 2020 ctccttgagg ggctcttctg gtcagcccca ccctgggggc catttcccca ttaactaccc 2080 ccagcccgag gcagggtgag ggggaagggc tgtcagttac attaaggtgg ttgttgttgt 2140 tgttttaaac aaaatggaga agcataaata aataaaaagg tttatctcgg ttctatcgtg 2200 6 426 PRT Homo sapiens 6 Met Val Gln Arg Glu Glu Leu Leu Ser Phe Met Gly Ala Glu Glu Ala 1 5 10 15 Ala Pro Asp Pro Ala Gly Val Gly Arg Gly Gly Gly Val Ala Gly Pro 20 25 30 Pro Ser Gly Gly Gly Gly Gln Pro Gln Trp Gln Lys Cys Arg Leu Leu 35 40 45 Leu Arg Ser Glu Gly Glu Gly Gly Gly Gly Ser Arg Leu Glu Phe Phe 50 55 60 Val Pro Pro Lys Ala Ser Arg Pro Arg Leu Ser Ile Pro Cys Ser Ser 65 70 75 80 Ile Thr Asp Val Arg Thr Thr Thr Ala Leu Glu Met Pro Asp Arg Glu 85 90 95 Asn Thr Phe Val Val Lys Val Glu Gly Pro Ser Glu Tyr Ile Met Glu 100 105 110 Thr Val Asp Ala Gln His Val Lys Ala Trp Val Ser Asp Ile Gln Glu 115 120 125 Cys Leu Ser Pro Gly Pro Cys Pro Ala Thr Ser Pro Arg Pro Met Thr 130 135 140 Leu Pro Leu Ala Pro Gly Thr Ser Phe Leu Thr Arg Glu Asn Thr Asp 145 150 155 160 Ser Leu Glu Leu Ser Cys Leu Asn His Ser Glu Ser Leu Pro Ser Gln 165 170 175 Asp Leu Leu Leu Gly Pro Ser Glu Ser Asn Asp Arg Leu Ser Gln Gly 180 185 190 Ala Tyr Gly Gly Leu Ser Asp Arg Pro Ser Ala Ser Ile Ser Pro Ser 195 200 205 Ser Ala Ser Ile Ala Ala Ser His Phe Asp Ser Met Glu Leu Leu Pro 210 215 220 Pro Glu Leu Pro Pro Arg Ile Pro Ile Glu Glu Gly Pro Pro Ala Gly 225 230 235 240 Thr Val His Pro Leu Ser Ala Pro Tyr Pro Pro Leu Asp Thr Pro Glu 245 250 255 Thr Ala Thr Gly Ser Phe Leu Phe Gln Gly Glu Pro Glu Gly Gly Glu 260 265 270 Gly Asp Gln Pro Leu Ser Gly Tyr Pro Trp Phe His Gly Met Leu Ser 275 280 285 Arg Leu Lys Ala Ala Gln Leu Val Leu Thr Gly Gly Thr Gly Ser His 290 295 300 Gly Val Phe Leu Val Arg Gln Ser Glu Thr Arg Arg Gly Glu Tyr Val 305 310 315 320 Leu Thr Phe Asn Phe Gln Gly Lys Ala Lys His Leu Arg Leu Ser Leu 325 330 335 Asn Glu Glu Gly Gln Cys Arg Val Gln His Leu Trp Phe Gln Ser Ile 340 345 350 Phe Asp Met Leu Glu His Phe Arg Val His Pro Ile Pro Leu Glu Ser 355 360 365 Gly Gly Ser Ser Asp Val Val Leu Val Ser Tyr Val Pro Ser Ser Gln 370 375 380 Arg Gln Gln Gly Arg Glu Gln Ala Gly Ser His Ala Gly Val Cys Glu 385 390 395 400 Gly Asp Gly Cys His Pro Asp Ala Ser Cys Thr Leu Met Pro Phe Gly 405 410 415 Ala Ser Asp Cys Val Thr Asp His Leu Pro 420 425 7 2720 DNA Homo sapiens CDS (3)...(1916) 7 tc atg gaa tac gcg agt ggg ggt gaa gta ttt gat tac tta gtt gcc 47 Met Glu Tyr Ala Ser Gly Gly Glu Val Phe Asp Tyr Leu Val Ala 1 5 10 15 cat gga aga atg aaa gag aaa gag gcc cgt gca aaa ttt agg cag att 95 His Gly Arg Met Lys Glu Lys Glu Ala Arg Ala Lys Phe Arg Gln Ile 20 25 30 gta tct gct gta cag tat tgt cat caa aag tac att gtt cac cgt gat 143 Val Ser Ala Val Gln Tyr Cys His Gln Lys Tyr Ile Val His Arg Asp 35 40 45 ctt aag gct gaa aac ctt ctc ctt gat ggt gat atg aat att aaa att 191 Leu Lys Ala Glu Asn Leu Leu Leu Asp Gly Asp Met Asn Ile Lys Ile 50 55 60 gct gac ttt ggt ttt agt aat gaa ttt aca gtt ggg aac aaa ttg gac 239 Ala Asp Phe Gly Phe Ser Asn Glu Phe Thr Val Gly Asn Lys Leu Asp 65 70 75 aca ttt tgt gga agc cca ccc tat gct gct ccc gag ctt ttc caa gga 287 Thr Phe Cys Gly Ser Pro Pro Tyr Ala Ala Pro Glu Leu Phe Gln Gly 80 85 90 95 aag aag tat gat ggt cct gaa gtg gat gtg tgg agt ctg ggc gtc att 335 Lys Lys Tyr Asp Gly Pro Glu Val Asp Val Trp Ser Leu Gly Val Ile 100 105 110 ctc tat aca tta gtc agt ggc tcc ttg cct ttc gat ggc cag aat tta 383 Leu Tyr Thr Leu Val Ser Gly Ser Leu Pro Phe Asp Gly Gln Asn Leu 115 120 125 aag gaa ctg cga gag cga gtt tta cga ggg aag tac cgt att ccc ttc 431 Lys Glu Leu Arg Glu Arg Val Leu Arg Gly Lys Tyr Arg Ile Pro Phe 130 135 140 tat atg tcc aca gac tgt gaa aat ctt ctg aag aaa tta tta gtc ctg 479 Tyr Met Ser Thr Asp Cys Glu Asn Leu Leu Lys Lys Leu Leu Val Leu 145 150 155 aat cca ata aag aga ggc agc ttg gaa caa ata atg aaa gat cga tgg 527 Asn Pro Ile Lys Arg Gly Ser Leu Glu Gln Ile Met Lys Asp Arg Trp 160 165 170 175 atg aat gtt ggt cat gaa gag gaa gaa cta aag cca tat act gag cct 575 Met Asn Val Gly His Glu Glu Glu Glu Leu Lys Pro Tyr Thr Glu Pro 180 185 190 gat ccg gat ttc aat gac aca aaa aga ata gac att atg gtc acc atg 623 Asp Pro Asp Phe Asn Asp Thr Lys Arg Ile Asp Ile Met Val Thr Met 195 200 205 ggc ttt gca cga gat gaa ata aat gat gcc tta ata aat cag aag tat 671 Gly Phe Ala Arg Asp Glu Ile Asn Asp Ala Leu Ile Asn Gln Lys Tyr 210 215 220 gat gaa gtt atg gct act tat att ctt cta ggt aga aaa cca cct gaa 719 Asp Glu Val Met Ala Thr Tyr Ile Leu Leu Gly Arg Lys Pro Pro Glu 225 230 235 ttt gaa ggt ggt gaa tcg tta tcc agt gga aac ttg tgt cag agg tcc 767 Phe Glu Gly Gly Glu Ser Leu Ser Ser Gly Asn Leu Cys Gln Arg Ser 240 245 250 255 cgg ccc agt agt gac tta aac aac agc act ctt cag tcc cct gct cac 815 Arg Pro Ser Ser Asp Leu Asn Asn Ser Thr Leu Gln Ser Pro Ala His 260 265 270 ctg aag gtc cag aga agt atc tca gca aat cag aag cag cgg cgt ttc 863 Leu Lys Val Gln Arg Ser Ile Ser Ala Asn Gln Lys Gln Arg Arg Phe 275 280 285 agt gat cat gct ggt cca tcc att cct cct gct gta tca tat acc aaa 911 Ser Asp His Ala Gly Pro Ser Ile Pro Pro Ala Val Ser Tyr Thr Lys 290 295 300 aga cct cag gct aac agt gtg gaa agt gaa cag aaa gag gag tgg gac 959 Arg Pro Gln Ala Asn Ser Val Glu Ser Glu Gln Lys Glu Glu Trp Asp 305 310 315 aaa gat gtg gct cga aaa ctt ggc agc aca aca gtt gga tca aaa agc 1007 Lys Asp Val Ala Arg Lys Leu Gly Ser Thr Thr Val Gly Ser Lys Ser 320 325 330 335 gag atg act gca agc cct ctt gta ggg cca gag agg aaa aaa tct tca 1055 Glu Met Thr Ala Ser Pro Leu Val Gly Pro Glu Arg Lys Lys Ser Ser 340 345 350 act att cca agt aac aat gtg tat tct gga ggt agc atg gca aga agg 1103 Thr Ile Pro Ser Asn Asn Val Tyr Ser Gly Gly Ser Met Ala Arg Arg 355 360 365 aat aca tat gtc tgt gaa agg acc aca gat cga tac gta gca ttg cag 1151 Asn Thr Tyr Val Cys Glu Arg Thr Thr Asp Arg Tyr Val Ala Leu Gln 370 375 380 aat gga aaa aac agc agc ctt acg gag atg tct gtg agt agc ata tct 1199 Asn Gly Lys Asn Ser Ser Leu Thr Glu Met Ser Val Ser Ser Ile Ser 385 390 395 tct gca ggc tct tct gtg gcc tct gct gcc ccc tca gca cga ccc cgc 1247 Ser Ala Gly Ser Ser Val Ala Ser Ala Ala Pro Ser Ala Arg Pro Arg 400 405 410 415 cac cag aag tcc atg tcc act tct ggt cat cct att aaa gtc aca ctg 1295 His Gln Lys Ser Met Ser Thr Ser Gly His Pro Ile Lys Val Thr Leu 420 425 430 cca acc att aaa gac ggc tct gaa gct tac cgg cct ggt aca acc cag 1343 Pro Thr Ile Lys Asp Gly Ser Glu Ala Tyr Arg Pro Gly Thr Thr Gln 435 440 445 aga gtg cct gct gct tcc cca tct gct cac agt att agt act gcg act 1391 Arg Val Pro Ala Ala Ser Pro Ser Ala His Ser Ile Ser Thr Ala Thr 450 455 460 cca gac cgg acc cgt ttt ccc cga ggg agc tca agc cga agc act ttc 1439 Pro Asp Arg Thr Arg Phe Pro Arg Gly Ser Ser Ser Arg Ser Thr Phe 465 470 475 cat ggt gaa cag ctc cgg gag cga cgc agc gtt gct tat aat ggg cca 1487 His Gly Glu Gln Leu Arg Glu Arg Arg Ser Val Ala Tyr Asn Gly Pro 480 485 490 495 cct gct tca cca tcc cat gaa acg ggt gca ttt gca cat gcc aga agg 1535 Pro Ala Ser Pro Ser His Glu Thr Gly Ala Phe Ala His Ala Arg Arg 500 505 510 gga acg tca act ggt ata ata agc aaa atc aca tcc aaa ttt gtt cgc 1583 Gly Thr Ser Thr Gly Ile Ile Ser Lys Ile Thr Ser Lys Phe Val Arg 515 520 525 aga agt aca tca ggg gaa cca aaa gaa aga gac aag gaa gag ggt aaa 1631 Arg Ser Thr Ser Gly Glu Pro Lys Glu Arg Asp Lys Glu Glu Gly Lys 530 535 540 gat tct aag ccg cgt tct ttg cgg ttc aca tgg agt atg aag acc act 1679 Asp Ser Lys Pro Arg Ser Leu Arg Phe Thr Trp Ser Met Lys Thr Thr 545 550 555 agt tca atg gac cct aat gac atg atg aga gaa atc cga aaa gtg tta 1727 Ser Ser Met Asp Pro Asn Asp Met Met Arg Glu Ile Arg Lys Val Leu 560 565 570 575 gat gca aat aac tgt gat tat gag caa aaa gag aga ttt ttg ctt ttc 1775 Asp Ala Asn Asn Cys Asp Tyr Glu Gln Lys Glu Arg Phe Leu Leu Phe 580 585 590 tgt gtc cat gga gac gct aga cag gat agc ctc gtg cag tgg gag atg 1823 Cys Val His Gly Asp Ala Arg Gln Asp Ser Leu Val Gln Trp Glu Met 595 600 605 gaa gtc tgc aag ttg cac gac tgt cac tta atg ggg ttc gct tca agc 1871 Glu Val Cys Lys Leu His Asp Cys His Leu Met Gly Phe Ala Ser Ser 610 615 620 gaa tat ctg gga cat cta ttg cct tta aga aca ttg cat caa aaa 1916 Glu Tyr Leu Gly His Leu Leu Pro Leu Arg Thr Leu His Gln Lys 625 630 635 tagcaaatga gcttaagctg taaagaagtc caaatttaca ggttcaggga agatacatac 1976 atatatgagg tacagttttt gaatgtactg gtaatgccta atgtggtctg cctgtgaatc 2036 tccccatgta gaatttgccc ttaatgcaat aaggttatac atagttatga actgtaaaat 2096 taaagtcagt atgaactata ataaatatct gtagcttaaa aagtaggttc acatgtacag 2156 gtaagtatat tgtgtatttc tgttcatttt ctgttcatag agttgtataa taaaacatga 2216 ttgcttaaaa acttgtatag ttgtctagat ttctgcacct gaatgtatgt ttgatgcttt 2276 gatttgaaaa tgttcttccc tgttatttac attccggtgg gtttttaaaa ttcttacctc 2336 catcatgcaa ttttgaaaat tgtgtccaga attaaaagtg catagaaata gcctttacaa 2396 ttgtagcatg gacctttaaa aattgtttta aaatcttatt taaatttaaa ccagaagctg 2456 aaaaatagat cagctttatt atacacaaaa ttattactgc ttatctttgc tcttttcctt 2516 gttatcccgc aaggtttagt tgagaagata caaaatgttt acagtgttgg cacttagagt 2576 ttttaaattc aagtacatga aattcagtaa tagcattgcc ttgagctaac taggaagtac 2636 cgggaaaaaa gttaaatcta catcaagttt cttttgaact ttgaagtgtt ttctgaccca 2696 ctgctaactg tagcaacaaa attt 2720 8 638 PRT Homo sapiens 8 Met Glu Tyr Ala Ser Gly Gly Glu Val Phe Asp Tyr Leu Val Ala His 1 5 10 15 Gly Arg Met Lys Glu Lys Glu Ala Arg Ala Lys Phe Arg Gln Ile Val 20 25 30 Ser Ala Val Gln Tyr Cys His Gln Lys Tyr Ile Val His Arg Asp Leu 35 40 45 Lys Ala Glu Asn Leu Leu Leu Asp Gly Asp Met Asn Ile Lys Ile Ala 50 55 60 Asp Phe Gly Phe Ser Asn Glu Phe Thr Val Gly Asn Lys Leu Asp Thr 65 70 75 80 Phe Cys Gly Ser Pro Pro Tyr Ala Ala Pro Glu Leu Phe Gln Gly Lys 85 90 95 Lys Tyr Asp Gly Pro Glu Val Asp Val Trp Ser Leu Gly Val Ile Leu 100 105 110 Tyr Thr Leu Val Ser Gly Ser Leu Pro Phe Asp Gly Gln Asn Leu Lys 115 120 125 Glu Leu Arg Glu Arg Val Leu Arg Gly Lys Tyr Arg Ile Pro Phe Tyr 130 135 140 Met Ser Thr Asp Cys Glu Asn Leu Leu Lys Lys Leu Leu Val Leu Asn 145 150 155 160 Pro Ile Lys Arg Gly Ser Leu Glu Gln Ile Met Lys Asp Arg Trp Met 165 170 175 Asn Val Gly His Glu Glu Glu Glu Leu Lys Pro Tyr Thr Glu Pro Asp 180 185 190 Pro Asp Phe Asn Asp Thr Lys Arg Ile Asp Ile Met Val Thr Met Gly 195 200 205 Phe Ala Arg Asp Glu Ile Asn Asp Ala Leu Ile Asn Gln Lys Tyr Asp 210 215 220 Glu Val Met Ala Thr Tyr Ile Leu Leu Gly Arg Lys Pro Pro Glu Phe 225 230 235 240 Glu Gly Gly Glu Ser Leu Ser Ser Gly Asn Leu Cys Gln Arg Ser Arg 245 250 255 Pro Ser Ser Asp Leu Asn Asn Ser Thr Leu Gln Ser Pro Ala His Leu 260 265 270 Lys Val Gln Arg Ser Ile Ser Ala Asn Gln Lys Gln Arg Arg Phe Ser 275 280 285 Asp His Ala Gly Pro Ser Ile Pro Pro Ala Val Ser Tyr Thr Lys Arg 290 295 300 Pro Gln Ala Asn Ser Val Glu Ser Glu Gln Lys Glu Glu Trp Asp Lys 305 310 315 320 Asp Val Ala Arg Lys Leu Gly Ser Thr Thr Val Gly Ser Lys Ser Glu 325 330 335 Met Thr Ala Ser Pro Leu Val Gly Pro Glu Arg Lys Lys Ser Ser Thr 340 345 350 Ile Pro Ser Asn Asn Val Tyr Ser Gly Gly Ser Met Ala Arg Arg Asn 355 360 365 Thr Tyr Val Cys Glu Arg Thr Thr Asp Arg Tyr Val Ala Leu Gln Asn 370 375 380 Gly Lys Asn Ser Ser Leu Thr Glu Met Ser Val Ser Ser Ile Ser Ser 385 390 395 400 Ala Gly Ser Ser Val Ala Ser Ala Ala Pro Ser Ala Arg Pro Arg His 405 410 415 Gln Lys Ser Met Ser Thr Ser Gly His Pro Ile Lys Val Thr Leu Pro 420 425 430 Thr Ile Lys Asp Gly Ser Glu Ala Tyr Arg Pro Gly Thr Thr Gln Arg 435 440 445 Val Pro Ala Ala Ser Pro Ser Ala His Ser Ile Ser Thr Ala Thr Pro 450 455 460 Asp Arg Thr Arg Phe Pro Arg Gly Ser Ser Ser Arg Ser Thr Phe His 465 470 475 480 Gly Glu Gln Leu Arg Glu Arg Arg Ser Val Ala Tyr Asn Gly Pro Pro 485 490 495 Ala Ser Pro Ser His Glu Thr Gly Ala Phe Ala His Ala Arg Arg Gly 500 505 510 Thr Ser Thr Gly Ile Ile Ser Lys Ile Thr Ser Lys Phe Val Arg Arg 515 520 525 Ser Thr Ser Gly Glu Pro Lys Glu Arg Asp Lys Glu Glu Gly Lys Asp 530 535 540 Ser Lys Pro Arg Ser Leu Arg Phe Thr Trp Ser Met Lys Thr Thr Ser 545 550 555 560 Ser Met Asp Pro Asn Asp Met Met Arg Glu Ile Arg Lys Val Leu Asp 565 570 575 Ala Asn Asn Cys Asp Tyr Glu Gln Lys Glu Arg Phe Leu Leu Phe Cys 580 585 590 Val His Gly Asp Ala Arg Gln Asp Ser Leu Val Gln Trp Glu Met Glu 595 600 605 Val Cys Lys Leu His Asp Cys His Leu Met Gly Phe Ala Ser Ser Glu 610 615 620 Tyr Leu Gly His Leu Leu Pro Leu Arg Thr Leu His Gln Lys 625 630 635 9 3219 DNA Homo sapiens CDS (71)...(2479) 9 gtagtagctg ccaggctgtc ccccgccctg cccggcccga gccccgcggg ccgccgccgc 60 caccgccgcc atg aag aag cag ttc aac cgc atg aag cag ctg gct aac 109 Met Lys Lys Gln Phe Asn Arg Met Lys Gln Leu Ala Asn 1 5 10 cag acc gtg ggc aga gct gag aaa aca gaa gtc ctt agt gaa gat cta 157 Gln Thr Val Gly Arg Ala Glu Lys Thr Glu Val Leu Ser Glu Asp Leu 15 20 25 tta cag att gag aga cgc ctg gac acg gtg cgg tca ata tgc cac cat 205 Leu Gln Ile Glu Arg Arg Leu Asp Thr Val Arg Ser Ile Cys His His 30 35 40 45 tcc cat aag cgc ttg gtg gca tgt ttc cag ggc cag cat ggc acc gat 253 Ser His Lys Arg Leu Val Ala Cys Phe Gln Gly Gln His Gly Thr Asp 50 55 60 gcc gag agg aga cac aaa aaa ctg cct ctg aca gct ctt gct caa aat 301 Ala Glu Arg Arg His Lys Lys Leu Pro Leu Thr Ala Leu Ala Gln Asn 65 70 75 atg caa gaa gca tcg act cag ctg gaa gac tct ctc ctg ggg aag atg 349 Met Gln Glu Ala Ser Thr Gln Leu Glu Asp Ser Leu Leu Gly Lys Met 80 85 90 ctg gag acg tgt gga gat gct gag aat cag ctg gct ctc gag ctc tcc 397 Leu Glu Thr Cys Gly Asp Ala Glu Asn Gln Leu Ala Leu Glu Leu Ser 95 100 105 cag cac gaa gtc ttt gtt gag aag gag atc gtg gac cct ctg tac ggc 445 Gln His Glu Val Phe Val Glu Lys Glu Ile Val Asp Pro Leu Tyr Gly 110 115 120 125 ata gct gag gtg gag att ccc aac atc cag aag cag agg gag cag ctt 493 Ile Ala Glu Val Glu Ile Pro Asn Ile Gln Lys Gln Arg Glu Gln Leu 130 135 140 gca aga ttg gtg tta gac tgg gat tca gtc aga gcc agg tgg aac caa 541 Ala Arg Leu Val Leu Asp Trp Asp Ser Val Arg Ala Arg Trp Asn Gln 145 150 155 gct cac aaa tcc tca gga acc aac ttt cag ggg ctt cca tca aaa ata 589 Ala His Lys Ser Ser Gly Thr Asn Phe Gln Gly Leu Pro Ser Lys Ile 160 165 170 gat act cta aag gaa gag atg gat gaa gct gga aat aaa gta gaa cag 637 Asp Thr Leu Lys Glu Glu Met Asp Glu Ala Gly Asn Lys Val Glu Gln 175 180 185 tgc aag gat caa ctt gca gca gac atg tac aac ttt atg gcc aaa gaa 685 Cys Lys Asp Gln Leu Ala Ala Asp Met Tyr Asn Phe Met Ala Lys Glu 190 195 200 205 ggg gag tat ggc aaa ttc ttt gtt acg tta tta gaa gcc caa gca gat 733 Gly Glu Tyr Gly Lys Phe Phe Val Thr Leu Leu Glu Ala Gln Ala Asp 210 215 220 tac cat aga aaa gca tta gca gtc tta gaa aag acc ctc ccc gaa atg 781 Tyr His Arg Lys Ala Leu Ala Val Leu Glu Lys Thr Leu Pro Glu Met 225 230 235 cga gcc cat caa gat aag tgg gcg gaa aaa cca gcc ttt ggg act ccc 829 Arg Ala His Gln Asp Lys Trp Ala Glu Lys Pro Ala Phe Gly Thr Pro 240 245 250 cta gaa gaa cac ctg aag agg agc ggg cgc gag att gcg ctg ccc att 877 Leu Glu Glu His Leu Lys Arg Ser Gly Arg Glu Ile Ala Leu Pro Ile 255 260 265 gaa gcc tgt gtc atg ctg ctt ctg gag aca ggc atg aag gag gag ggc 925 Glu Ala Cys Val Met Leu Leu Leu Glu Thr Gly Met Lys Glu Glu Gly 270 275 280 285 ctt ttc cga att ggg gct ggg gcc tcc aag tta aag aag ctg aaa gct 973 Leu Phe Arg Ile Gly Ala Gly Ala Ser Lys Leu Lys Lys Leu Lys Ala 290 295 300 gct ttg gac tgt tct act tct cac ctg gat gag ttc tat tca gac ccc 1021 Ala Leu Asp Cys Ser Thr Ser His Leu Asp Glu Phe Tyr Ser Asp Pro 305 310 315 cat gct gta gca ggt gct tta aaa tcc tat tta cgg gaa ttg cct gaa 1069 His Ala Val Ala Gly Ala Leu Lys Ser Tyr Leu Arg Glu Leu Pro Glu 320 325 330 cct ttg atg act ttt aat ctg tat gaa gaa tgg aca caa gtt gca agt 1117 Pro Leu Met Thr Phe Asn Leu Tyr Glu Glu Trp Thr Gln Val Ala Ser 335 340 345 gtg cag gat caa gac aaa aaa ctt caa gac ttg tgg aga aca tgt cag 1165 Val Gln Asp Gln Asp Lys Lys Leu Gln Asp Leu Trp Arg Thr Cys Gln 350 355 360 365 aag ttg cca cca caa aat ttt gtt aac ttt aga tat ttg atc aag ttc 1213 Lys Leu Pro Pro Gln Asn Phe Val Asn Phe Arg Tyr Leu Ile Lys Phe 370 375 380 ctt gca aag ctt gct cag acc agc gat gtg aat aaa atg act ccc agc 1261 Leu Ala Lys Leu Ala Gln Thr Ser Asp Val Asn Lys Met Thr Pro Ser 385 390 395 aac att gcg att gtg tta gcc cct aac ttg tta tgg gcc aga aac gaa 1309 Asn Ile Ala Ile Val Leu Ala Pro Asn Leu Leu Trp Ala Arg Asn Glu 400 405 410 gga aca ctt gct gaa atg gca gca gcc aca tcc gtc cat gtg gtt gca 1357 Gly Thr Leu Ala Glu Met Ala Ala Ala Thr Ser Val His Val Val Ala 415 420 425 gtg att gaa ccc atc att cag cat gcc gac tgg ttc ttc cct gaa gag 1405 Val Ile Glu Pro Ile Ile Gln His Ala Asp Trp Phe Phe Pro Glu Glu 430 435 440 445 gtg gaa ttt aat gta tca gaa gca ttt gta cct ctc acc acc ccg agt 1453 Val Glu Phe Asn Val Ser Glu Ala Phe Val Pro Leu Thr Thr Pro Ser 450 455 460 tct aat cac tca ttc cac act gga aac gac tct gac tcg ggg acc ctg 1501 Ser Asn His Ser Phe His Thr Gly Asn Asp Ser Asp Ser Gly Thr Leu 465 470 475 gag agg aag cgg cct gct agc atg gcg gtg atg gaa gga gac ttg gtg 1549 Glu Arg Lys Arg Pro Ala Ser Met Ala Val Met Glu Gly Asp Leu Val 480 485 490 aag aag gaa agt cct ccc aaa ccg aag gac cct gta tct gca gct gtg 1597 Lys Lys Glu Ser Pro Pro Lys Pro Lys Asp Pro Val Ser Ala Ala Val 495 500 505 cca gca cca ggg aga aac aac agt cag ata gca tct ggc caa aat cag 1645 Pro Ala Pro Gly Arg Asn Asn Ser Gln Ile Ala Ser Gly Gln Asn Gln 510 515 520 525 ccc cag gca gct gct ggc tcc cac cag ctc tcc atg ggc caa cct cac 1693 Pro Gln Ala Ala Ala Gly Ser His Gln Leu Ser Met Gly Gln Pro His 530 535 540 aat gct gca ggg ccc agc ccg cat aca ctg cgc cga gct gtt aaa aaa 1741 Asn Ala Ala Gly Pro Ser Pro His Thr Leu Arg Arg Ala Val Lys Lys 545 550 555 ccc gct cca gca ccc ccg aaa ccg ggc aac cca cct cct ggc cac ccc 1789 Pro Ala Pro Ala Pro Pro Lys Pro Gly Asn Pro Pro Pro Gly His Pro 560 565 570 ggg ggc cag agt tct tca gga aca tct cag cat cca ccc agt ctg tca 1837 Gly Gly Gln Ser Ser Ser Gly Thr Ser Gln His Pro Pro Ser Leu Ser 575 580 585 cca aag cca ccc acc cga agc ccc tct cct ccc acc cag cac acg ggc 1885 Pro Lys Pro Pro Thr Arg Ser Pro Ser Pro Pro Thr Gln His Thr Gly 590 595 600 605 cag cct cca ggc cag ccc tcc gcc ccc tcc cag ctc tca gca ccc cgg 1933 Gln Pro Pro Gly Gln Pro Ser Ala Pro Ser Gln Leu Ser Ala Pro Arg 610 615 620 agg tac tcc agc agc ttg tct cca atc caa gct ccc aat cac cca ccg 1981 Arg Tyr Ser Ser Ser Leu Ser Pro Ile Gln Ala Pro Asn His Pro Pro 625 630 635 ccg cag ccc cct acg cag gcc acg cca ctg atg cac acc aaa ccc aat 2029 Pro Gln Pro Pro Thr Gln Ala Thr Pro Leu Met His Thr Lys Pro Asn 640 645 650 agc cag ggc cct ccc aac ccc atg gca ttg ccc agt gag cat gga ctt 2077 Ser Gln Gly Pro Pro Asn Pro Met Ala Leu Pro Ser Glu His Gly Leu 655 660 665 gag cag cca tct cac acc cct ccc cag act cca acg ccc ccc agt act 2125 Glu Gln Pro Ser His Thr Pro Pro Gln Thr Pro Thr Pro Pro Ser Thr 670 675 680 685 ccg ccc cta gga aaa cag aac ccc agt ctg cca gct cct cag acc ctg 2173 Pro Pro Leu Gly Lys Gln Asn Pro Ser Leu Pro Ala Pro Gln Thr Leu 690 695 700 gca ggg ggt aac cct gaa act gca cag cca cat gct gga acc tta ccg 2221 Ala Gly Gly Asn Pro Glu Thr Ala Gln Pro His Ala Gly Thr Leu Pro 705 710 715 aga ccg aga cca gta cca aag cca agg aac cgg ccc agc gtg ccc cca 2269 Arg Pro Arg Pro Val Pro Lys Pro Arg Asn Arg Pro Ser Val Pro Pro 720 725 730 ccc ccc caa cct cct ggt gtc cac tca gct ggg gac agc agc ctc acc 2317 Pro Pro Gln Pro Pro Gly Val His Ser Ala Gly Asp Ser Ser Leu Thr 735 740 745 aac aca gca cca aca gct tcc aag ata gta aca gac tcc aat tcc agg 2365 Asn Thr Ala Pro Thr Ala Ser Lys Ile Val Thr Asp Ser Asn Ser Arg 750 755 760 765 gtc tca gaa ccg cat cgc agc atc ttt cct gaa gtg cac tca gac tca 2413 Val Ser Glu Pro His Arg Ser Ile Phe Pro Glu Val His Ser Asp Ser 770 775 780 gcc agc aaa gac gtg cct ggc cgc atc ctg ctg gat ata gac aat gat 2461 Ala Ser Lys Asp Val Pro Gly Arg Ile Leu Leu Asp Ile Asp Asn Asp 785 790 795 acc gag agc act gcc ctg tgaagaaagc cctttcccag ccctccacca 2509 Thr Glu Ser Thr Ala Leu 800 cttccaccct ggcgagtgga gcaggggcag gcgaacctct ttctttgcag accgaacagt 2569 gaaaagcttt cagtggagga caaaggaggg cctcactgtg tgggacctgg ccttctgcac 2629 ggcccaagga gaacctggag gccaccacta aagctgaatg acctgtgtct tgaagaagtt 2689 ggctttcttt acatgggaag gaaatcatgc caaaaaaatc caaaacaaag aagtacctgg 2749 agtggagaga gtattcctgc tgaaacgcgc ataggaagct tttgtccctg ctgttaatgc 2809 gggcagcacc tacagcaact tggaatgagt aagaagcagt gcgttaacta tctatttaat 2869 aaaatgcgct cattatgcaa gtcgcctact ctctgctacc tggacgttca ttcttatgta 2929 ttaggaggga ggctgcgctc cttcagactt gctgcagaat cattttgtat catgtatggt 2989 ctgtgtctcc ccagtcccct cagaaccatg cccatggatg gtgactgctg gctctgtcac 3049 ctcatcaaac tggatgtgac ccatgccgcc tcgttggatt gtcggaatgt agacagaaat 3109 gtactgttct tttttttttt tttaaacaat gtaattgcta cttgataagg accgaacatt 3169 attctagttt catgtttaat ttgaattaaa tatattctgt ggtttatatg 3219 10 803 PRT Homo sapiens 10 Met Lys Lys Gln Phe Asn Arg Met Lys Gln Leu Ala Asn Gln Thr Val 1 5 10 15 Gly Arg Ala Glu Lys Thr Glu Val Leu Ser Glu Asp Leu Leu Gln Ile 20 25 30 Glu Arg Arg Leu Asp Thr Val Arg Ser Ile Cys His His Ser His Lys 35 40 45 Arg Leu Val Ala Cys Phe Gln Gly Gln His Gly Thr Asp Ala Glu Arg 50 55 60 Arg His Lys Lys Leu Pro Leu Thr Ala Leu Ala Gln Asn Met Gln Glu 65 70 75 80 Ala Ser Thr Gln Leu Glu Asp Ser Leu Leu Gly Lys Met Leu Glu Thr 85 90 95 Cys Gly Asp Ala Glu Asn Gln Leu Ala Leu Glu Leu Ser Gln His Glu 100 105 110 Val Phe Val Glu Lys Glu Ile Val Asp Pro Leu Tyr Gly Ile Ala Glu 115 120 125 Val Glu Ile Pro Asn Ile Gln Lys Gln Arg Glu Gln Leu Ala Arg Leu 130 135 140 Val Leu Asp Trp Asp Ser Val Arg Ala Arg Trp Asn Gln Ala His Lys 145 150 155 160 Ser Ser Gly Thr Asn Phe Gln Gly Leu Pro Ser Lys Ile Asp Thr Leu 165 170 175 Lys Glu Glu Met Asp Glu Ala Gly Asn Lys Val Glu Gln Cys Lys Asp 180 185 190 Gln Leu Ala Ala Asp Met Tyr Asn Phe Met Ala Lys Glu Gly Glu Tyr 195 200 205 Gly Lys Phe Phe Val Thr Leu Leu Glu Ala Gln Ala Asp Tyr His Arg 210 215 220 Lys Ala Leu Ala Val Leu Glu Lys Thr Leu Pro Glu Met Arg Ala His 225 230 235 240 Gln Asp Lys Trp Ala Glu Lys Pro Ala Phe Gly Thr Pro Leu Glu Glu 245 250 255 His Leu Lys Arg Ser Gly Arg Glu Ile Ala Leu Pro Ile Glu Ala Cys 260 265 270 Val Met Leu Leu Leu Glu Thr Gly Met Lys Glu Glu Gly Leu Phe Arg 275 280 285 Ile Gly Ala Gly Ala Ser Lys Leu Lys Lys Leu Lys Ala Ala Leu Asp 290 295 300 Cys Ser Thr Ser His Leu Asp Glu Phe Tyr Ser Asp Pro His Ala Val 305 310 315 320 Ala Gly Ala Leu Lys Ser Tyr Leu Arg Glu Leu Pro Glu Pro Leu Met 325 330 335 Thr Phe Asn Leu Tyr Glu Glu Trp Thr Gln Val Ala Ser Val Gln Asp 340 345 350 Gln Asp Lys Lys Leu Gln Asp Leu Trp Arg Thr Cys Gln Lys Leu Pro 355 360 365 Pro Gln Asn Phe Val Asn Phe Arg Tyr Leu Ile Lys Phe Leu Ala Lys 370 375 380 Leu Ala Gln Thr Ser Asp Val Asn Lys Met Thr Pro Ser Asn Ile Ala 385 390 395 400 Ile Val Leu Ala Pro Asn Leu Leu Trp Ala Arg Asn Glu Gly Thr Leu 405 410 415 Ala Glu Met Ala Ala Ala Thr Ser Val His Val Val Ala Val Ile Glu 420 425 430 Pro Ile Ile Gln His Ala Asp Trp Phe Phe Pro Glu Glu Val Glu Phe 435 440 445 Asn Val Ser Glu Ala Phe Val Pro Leu Thr Thr Pro Ser Ser Asn His 450 455 460 Ser Phe His Thr Gly Asn Asp Ser Asp Ser Gly Thr Leu Glu Arg Lys 465 470 475 480 Arg Pro Ala Ser Met Ala Val Met Glu Gly Asp Leu Val Lys Lys Glu 485 490 495 Ser Pro Pro Lys Pro Lys Asp Pro Val Ser Ala Ala Val Pro Ala Pro 500 505 510 Gly Arg Asn Asn Ser Gln Ile Ala Ser Gly Gln Asn Gln Pro Gln Ala 515 520 525 Ala Ala Gly Ser His Gln Leu Ser Met Gly Gln Pro His Asn Ala Ala 530 535 540 Gly Pro Ser Pro His Thr Leu Arg Arg Ala Val Lys Lys Pro Ala Pro 545 550 555 560 Ala Pro Pro Lys Pro Gly Asn Pro Pro Pro Gly His Pro Gly Gly Gln 565 570 575 Ser Ser Ser Gly Thr Ser Gln His Pro Pro Ser Leu Ser Pro Lys Pro 580 585 590 Pro Thr Arg Ser Pro Ser Pro Pro Thr Gln His Thr Gly Gln Pro Pro 595 600 605 Gly Gln Pro Ser Ala Pro Ser Gln Leu Ser Ala Pro Arg Arg Tyr Ser 610 615 620 Ser Ser Leu Ser Pro Ile Gln Ala Pro Asn His Pro Pro Pro Gln Pro 625 630 635 640 Pro Thr Gln Ala Thr Pro Leu Met His Thr Lys Pro Asn Ser Gln Gly 645 650 655 Pro Pro Asn Pro Met Ala Leu Pro Ser Glu His Gly Leu Glu Gln Pro 660 665 670 Ser His Thr Pro Pro Gln Thr Pro Thr Pro Pro Ser Thr Pro Pro Leu 675 680 685 Gly Lys Gln Asn Pro Ser Leu Pro Ala Pro Gln Thr Leu Ala Gly Gly 690 695 700 Asn Pro Glu Thr Ala Gln Pro His Ala Gly Thr Leu Pro Arg Pro Arg 705 710 715 720 Pro Val Pro Lys Pro Arg Asn Arg Pro Ser Val Pro Pro Pro Pro Gln 725 730 735 Pro Pro Gly Val His Ser Ala Gly Asp Ser Ser Leu Thr Asn Thr Ala 740 745 750 Pro Thr Ala Ser Lys Ile Val Thr Asp Ser Asn Ser Arg Val Ser Glu 755 760 765 Pro His Arg Ser Ile Phe Pro Glu Val His Ser Asp Ser Ala Ser Lys 770 775 780 Asp Val Pro Gly Arg Ile Leu Leu Asp Ile Asp Asn Asp Thr Glu Ser 785 790 795 800 Thr Ala Leu 11 2224 DNA Homo sapiens CDS (215)...(1576) 11 attctccggg ctgcggaggg taaagagcgg gctcgggccg aggctggagg gctgggtggg 60 gccagagcgg cgcttcgggg gcccgcggag gacgagggag ggagagaatc tgaggagctg 120 ggttgccatt aggggactcc tgaggtccta tctccaggct gcggtgactg cactttccct 180 ggagtggaag ctgctggaag gcggaccggc cgcc atg tcc acg ttc agg cag gag 235 Met Ser Thr Phe Arg Gln Glu 1 5 gac gtg gag gac cat tat gag atg ggg gag gag ctg ggc agc ggc cag 283 Asp Val Glu Asp His Tyr Glu Met Gly Glu Glu Leu Gly Ser Gly Gln 10 15 20 ttt gcg atc gtg cgg aag tgc cgg cag aag ggc acg ggc aag gag tac 331 Phe Ala Ile Val Arg Lys Cys Arg Gln Lys Gly Thr Gly Lys Glu Tyr 25 30 35 gca gcc aag ttc atc aag aag cgc cgc ctg tca tcc agc cgg cgt ggg 379 Ala Ala Lys Phe Ile Lys Lys Arg Arg Leu Ser Ser Ser Arg Arg Gly 40 45 50 55 gtg agc cgg gag gag atc gag cgg gag gtg aac atc ctg cgg gag atc 427 Val Ser Arg Glu Glu Ile Glu Arg Glu Val Asn Ile Leu Arg Glu Ile 60 65 70 cgg cac ccc aac atc atc acc ctg cac gac atc ttc gag aac aag acg 475 Arg His Pro Asn Ile Ile Thr Leu His Asp Ile Phe Glu Asn Lys Thr 75 80 85 gac gtg gtc ctc atc ctg gag ctg gtc tct ggc ggg gag ctc ttt gac 523 Asp Val Val Leu Ile Leu Glu Leu Val Ser Gly Gly Glu Leu Phe Asp 90 95 100 ttc ctg gcg gag aag gag tcg ctg acg gag gac gag gcc acc cag ttc 571 Phe Leu Ala Glu Lys Glu Ser Leu Thr Glu Asp Glu Ala Thr Gln Phe 105 110 115 ctc aag cag atc ctg gac ggc gtt cac tac ctg cac tct aag cgc atc 619 Leu Lys Gln Ile Leu Asp Gly Val His Tyr Leu His Ser Lys Arg Ile 120 125 130 135 gca cac ttt gac ctg aag ccg gaa aac atc atg ctg ctg gac aag aac 667 Ala His Phe Asp Leu Lys Pro Glu Asn Ile Met Leu Leu Asp Lys Asn 140 145 150 gtg ccc aac cca cga atc aag ctc atc gac ttc ggc atc gcg cac aag 715 Val Pro Asn Pro Arg Ile Lys Leu Ile Asp Phe Gly Ile Ala His Lys 155 160 165 atc gag gcg ggg aac gag ttc aag aac atc ttc ggc acc ccg gag ttt 763 Ile Glu Ala Gly Asn Glu Phe Lys Asn Ile Phe Gly Thr Pro Glu Phe 170 175 180 gtg gcc cca gag att gtg aac tat gag ccg ctg ggc ctg gag gcg gac 811 Val Ala Pro Glu Ile Val Asn Tyr Glu Pro Leu Gly Leu Glu Ala Asp 185 190 195 atg tgg agc atc ggt gtc atc acc tat atc ctc ctg agc ggt gca tcc 859 Met Trp Ser Ile Gly Val Ile Thr Tyr Ile Leu Leu Ser Gly Ala Ser 200 205 210 215 ccg ttc ctg ggc gag acc aag cag gag acg ctc acc aac atc tca gcc 907 Pro Phe Leu Gly Glu Thr Lys Gln Glu Thr Leu Thr Asn Ile Ser Ala 220 225 230 gtg aac tac gac ttc gac gag gag tac ttc agc aac acc ggc gag ctg 955 Val Asn Tyr Asp Phe Asp Glu Glu Tyr Phe Ser Asn Thr Gly Glu Leu 235 240 245 gcc aag gac ttc att cgc cgg ctg ctc gtc aaa gat ccc aag cgg aga 1003 Ala Lys Asp Phe Ile Arg Arg Leu Leu Val Lys Asp Pro Lys Arg Arg 250 255 260 atg acc att gcc cag agc ctg gaa cat tcc tgg att aag gcg atc cgg 1051 Met Thr Ile Ala Gln Ser Leu Glu His Ser Trp Ile Lys Ala Ile Arg 265 270 275 cgg cgg aac gtg cgt ggt gag gac agc ggc cgc aag ccc gag cgg cgg 1099 Arg Arg Asn Val Arg Gly Glu Asp Ser Gly Arg Lys Pro Glu Arg Arg 280 285 290 295 cgc ctg aag acc acg cgt ctg aag gag tac acc atc aag tcg cac tcc 1147 Arg Leu Lys Thr Thr Arg Leu Lys Glu Tyr Thr Ile Lys Ser His Ser 300 305 310 agc ctg ccg ccc aac aac agc tac gcc gac ttc gag cgc ttc tcc aag 1195 Ser Leu Pro Pro Asn Asn Ser Tyr Ala Asp Phe Glu Arg Phe Ser Lys 315 320 325 gtg ctg gag gag gcg gcg gcc gcc gag gag ggc ctg cgc gag ctg cag 1243 Val Leu Glu Glu Ala Ala Ala Ala Glu Glu Gly Leu Arg Glu Leu Gln 330 335 340 cgc agc cgg cgg ctc tgc cac gag gac gtg gag gcg ctg gcc gcc atc 1291 Arg Ser Arg Arg Leu Cys His Glu Asp Val Glu Ala Leu Ala Ala Ile 345 350 355 tac gag gag aag gag gcc tgg tac cgc gag gag agc gac agc ctg ggc 1339 Tyr Glu Glu Lys Glu Ala Trp Tyr Arg Glu Glu Ser Asp Ser Leu Gly 360 365 370 375 cag gac ctg cgg agg cta cgg cag gag ctg ctc aag acc gag gcg ctc 1387 Gln Asp Leu Arg Arg Leu Arg Gln Glu Leu Leu Lys Thr Glu Ala Leu 380 385 390 aag cgg cag gcg cag gag gag gcc aag ggc gcg ctg ctg ggg acc agc 1435 Lys Arg Gln Ala Gln Glu Glu Ala Lys Gly Ala Leu Leu Gly Thr Ser 395 400 405 ggc ctc aag cgc cgc ttc agc cgc ctg gag aac cgc tac gag gcg ctg 1483 Gly Leu Lys Arg Arg Phe Ser Arg Leu Glu Asn Arg Tyr Glu Ala Leu 410 415 420 gcc aag caa gta gcc tcc gag atg cgc ttc gtg cag gac ctc gtg cgc 1531 Ala Lys Gln Val Ala Ser Glu Met Arg Phe Val Gln Asp Leu Val Arg 425 430 435 gcc ctg gag cag gag aag ctg cag ggc gtg gag tgc ggg ctg cgc 1576 Ala Leu Glu Gln Glu Lys Leu Gln Gly Val Glu Cys Gly Leu Arg 440 445 450 taggcgcagt ggggtgggcc aggccccagg acagccggag ctcggcctgg ggtgggggcg 1636 cttcctgtgg acgctgcgcc tcccatcgcc cgggtgcctg tccttgccca gcgccaccag 1696 gctggaggcg gagtgggagg agctggagcc aggcccgtaa gttcgcaggc aggggtgggt 1756 gtgggacggg gctgcttctc tacacagcct ccacgctggc cttcaccttc acccctgcat 1816 cgtcggtgac cctgggaccc tccaggcagc gtggcctgtg gcaccgtgag ggttgggacc 1876 caccgaggcg cagaggcggc ccgaatgcag ccctggttca ggcccggagg agggtttgcg 1936 ggtagttgca cggacaattc ggcggggtgc tgcctgttgc tgccattagc ccaggaggag 1996 gtcgtgggac ggggagggtg ggatggacgg cggacaggca gtccccacgc tgctgggtgg 2056 cgccgggctt ggtggggtct tccactgtgt gcccttctcg ccgaggccgg tcccccgggt 2116 gtggggtgcc ctgctgcgga ctcctccgcg agccccatcg tcgcgcctgt ggacgcctag 2176 gcaagagcgg ccctctgcag ccaagagaaa taaaatactg gcttccag 2224 12 454 PRT Homo sapiens 12 Met Ser Thr Phe Arg Gln Glu Asp Val Glu Asp His Tyr Glu Met Gly 1 5 10 15 Glu Glu Leu Gly Ser Gly Gln Phe Ala Ile Val Arg Lys Cys Arg Gln 20 25 30 Lys Gly Thr Gly Lys Glu Tyr Ala Ala Lys Phe Ile Lys Lys Arg Arg 35 40 45 Leu Ser Ser Ser Arg Arg Gly Val Ser Arg Glu Glu Ile Glu Arg Glu 50 55 60 Val Asn Ile Leu Arg Glu Ile Arg His Pro Asn Ile Ile Thr Leu His 65 70 75 80 Asp Ile Phe Glu Asn Lys Thr Asp Val Val Leu Ile Leu Glu Leu Val 85 90 95 Ser Gly Gly Glu Leu Phe Asp Phe Leu Ala Glu Lys Glu Ser Leu Thr 100 105 110 Glu Asp Glu Ala Thr Gln Phe Leu Lys Gln Ile Leu Asp Gly Val His 115 120 125 Tyr Leu His Ser Lys Arg Ile Ala His Phe Asp Leu Lys Pro Glu Asn 130 135 140 Ile Met Leu Leu Asp Lys Asn Val Pro Asn Pro Arg Ile Lys Leu Ile 145 150 155 160 Asp Phe Gly Ile Ala His Lys Ile Glu Ala Gly Asn Glu Phe Lys Asn 165 170 175 Ile Phe Gly Thr Pro Glu Phe Val Ala Pro Glu Ile Val Asn Tyr Glu 180 185 190 Pro Leu Gly Leu Glu Ala Asp Met Trp Ser Ile Gly Val Ile Thr Tyr 195 200 205 Ile Leu Leu Ser Gly Ala Ser Pro Phe Leu Gly Glu Thr Lys Gln Glu 210 215 220 Thr Leu Thr Asn Ile Ser Ala Val Asn Tyr Asp Phe Asp Glu Glu Tyr 225 230 235 240 Phe Ser Asn Thr Gly Glu Leu Ala Lys Asp Phe Ile Arg Arg Leu Leu 245 250 255 Val Lys Asp Pro Lys Arg Arg Met Thr Ile Ala Gln Ser Leu Glu His 260 265 270 Ser Trp Ile Lys Ala Ile Arg Arg Arg Asn Val Arg Gly Glu Asp Ser 275 280 285 Gly Arg Lys Pro Glu Arg Arg Arg Leu Lys Thr Thr Arg Leu Lys Glu 290 295 300 Tyr Thr Ile Lys Ser His Ser Ser Leu Pro Pro Asn Asn Ser Tyr Ala 305 310 315 320 Asp Phe Glu Arg Phe Ser Lys Val Leu Glu Glu Ala Ala Ala Ala Glu 325 330 335 Glu Gly Leu Arg Glu Leu Gln Arg Ser Arg Arg Leu Cys His Glu Asp 340 345 350 Val Glu Ala Leu Ala Ala Ile Tyr Glu Glu Lys Glu Ala Trp Tyr Arg 355 360 365 Glu Glu Ser Asp Ser Leu Gly Gln Asp Leu Arg Arg Leu Arg Gln Glu 370 375 380 Leu Leu Lys Thr Glu Ala Leu Lys Arg Gln Ala Gln Glu Glu Ala Lys 385 390 395 400 Gly Ala Leu Leu Gly Thr Ser Gly Leu Lys Arg Arg Phe Ser Arg Leu 405 410 415 Glu Asn Arg Tyr Glu Ala Leu Ala Lys Gln Val Ala Ser Glu Met Arg 420 425 430 Phe Val Gln Asp Leu Val Arg Ala Leu Glu Gln Glu Lys Leu Gln Gly 435 440 445 Val Glu Cys Gly Leu Arg 450 13 2778 DNA Homo sapiens CDS (773)...(2179) 13 acaagtggac cggggtgttg ggtgctagtc ggcaccagag gcaagggtgc gaggaccacg 60 gccggctcgg acgtgtgacc gcgcctaggg ggtggcagcg ggcagtgcgg ggcggcaagg 120 cgaccatgga gcttttgcgg actatcacct accagccagc cgccagcacc aaaatgtgcg 180 agcaggcgct gggcaagggt tgcggagcgg actcgaagaa gaagcggccg ccgcagcccc 240 ccgaggaatc gcagccacct cagtcccagg cgcaagtgcc cccggcggcc cctcaccacc 300 atcaccacca ttcgcactcg gggccggaga tctcgcggat tatcgtcgac cccacgactg 360 ggaagcgcta ctaccggggc aaagtgctgg gaaagggtgg ctttgcaaaa tgttacgaga 420 tgacagattt gacaaataac aaagtctacg ccgcaaaaat tattcctcac agcagagtag 480 ctaaacctca tcaaagggaa aagattgaca aagaaataga gcttcacaga attcttcatc 540 ataagcatgt agtgcagttt taccactact tcgaggacaa agaaaacatt tacattctct 600 tggaatactg cagtagaagg tcaatggctc atattttgaa agcaagaaag gtgttgacag 660 agccagaagt tcgatactac ctcaggcaga ttgtgtctgg actgaatacc ttcatgaaca 720 agaaatcttg cacagagatc tcaaactagg gaactttttt attaatgaag cc atg gaa 778 Met Glu 1 cta aaa gtt ggg gac ttc ggt ctg gca gcc agg cta gaa ccc ttg gaa 826 Leu Lys Val Gly Asp Phe Gly Leu Ala Ala Arg Leu Glu Pro Leu Glu 5 10 15 cac aga agg aga acg ata tgt ggt acc cca aat tat ctc tct cct gaa 874 His Arg Arg Arg Thr Ile Cys Gly Thr Pro Asn Tyr Leu Ser Pro Glu 20 25 30 gtc ctc aac aaa caa gga cat ggc tgt gaa tca gac att tgg gcc ctg 922 Val Leu Asn Lys Gln Gly His Gly Cys Glu Ser Asp Ile Trp Ala Leu 35 40 45 50 ggc tgt gta atg tat aca atg tta cta ggg agg ccc cca ttt gaa act 970 Gly Cys Val Met Tyr Thr Met Leu Leu Gly Arg Pro Pro Phe Glu Thr 55 60 65 aca aat ctc aaa gaa act tat agg tgc ata agg gaa gca agg tat aca 1018 Thr Asn Leu Lys Glu Thr Tyr Arg Cys Ile Arg Glu Ala Arg Tyr Thr 70 75 80 atg ccg tcc tca ttg ctg gct cct gcc aag cac tta att gct agt atg 1066 Met Pro Ser Ser Leu Leu Ala Pro Ala Lys His Leu Ile Ala Ser Met 85 90 95 ttg tcc aaa aac cca gag gat cgt ccc agt ttg gat gac atc att cga 1114 Leu Ser Lys Asn Pro Glu Asp Arg Pro Ser Leu Asp Asp Ile Ile Arg 100 105 110 cat gac ttt ttt ttg cag ggc ttc act ccg gac aga ctg tct tct agc 1162 His Asp Phe Phe Leu Gln Gly Phe Thr Pro Asp Arg Leu Ser Ser Ser 115 120 125 130 tgt tgt cat aca gtt cca gat ttc cac tta tca agc cca gct aag aat 1210 Cys Cys His Thr Val Pro Asp Phe His Leu Ser Ser Pro Ala Lys Asn 135 140 145 ttc ttt aag aaa gca gct gct gct ctt ttt ggt ggc aaa aaa gac aaa 1258 Phe Phe Lys Lys Ala Ala Ala Ala Leu Phe Gly Gly Lys Lys Asp Lys 150 155 160 gca aga tat att gac aca cat aat aga gtg tct aaa gaa gat gaa gac 1306 Ala Arg Tyr Ile Asp Thr His Asn Arg Val Ser Lys Glu Asp Glu Asp 165 170 175 atc tac aag ctt agg cat gat ttg aaa aag act tca ata act cag caa 1354 Ile Tyr Lys Leu Arg His Asp Leu Lys Lys Thr Ser Ile Thr Gln Gln 180 185 190 ccc agc aaa cac agg aca gat gag gag ctc cag cca cct acc acc aca 1402 Pro Ser Lys His Arg Thr Asp Glu Glu Leu Gln Pro Pro Thr Thr Thr 195 200 205 210 gtt gcc agg tct gga aca ccc gca gta gaa aac aag cag cag att ggg 1450 Val Ala Arg Ser Gly Thr Pro Ala Val Glu Asn Lys Gln Gln Ile Gly 215 220 225 gat gct att cgg atg ata gtc aga ggg act ctt ggc agc tgt agc agc 1498 Asp Ala Ile Arg Met Ile Val Arg Gly Thr Leu Gly Ser Cys Ser Ser 230 235 240 agc agt gaa tgc ctt gaa gac agt acc atg gga agt gtt gca gac aca 1546 Ser Ser Glu Cys Leu Glu Asp Ser Thr Met Gly Ser Val Ala Asp Thr 245 250 255 gtg gca agg gtt ctt cgg gga tgt ctg gaa aac atg ccg gaa gct gat 1594 Val Ala Arg Val Leu Arg Gly Cys Leu Glu Asn Met Pro Glu Ala Asp 260 265 270 tgc att ccc aaa gag cag ctg agc aca tca ttt cag tgg gtc acc aaa 1642 Cys Ile Pro Lys Glu Gln Leu Ser Thr Ser Phe Gln Trp Val Thr Lys 275 280 285 290 tgg gtt gat tac tct aac aaa tat ggc ttt ggg tac cag ctc tca gac 1690 Trp Val Asp Tyr Ser Asn Lys Tyr Gly Phe Gly Tyr Gln Leu Ser Asp 295 300 305 cac acc gtc ggt gtc ctt ttc aac aat ggt gct cac atg agc ctc ctt 1738 His Thr Val Gly Val Leu Phe Asn Asn Gly Ala His Met Ser Leu Leu 310 315 320 cca gac aaa aaa aca gtt cac tat tac gca gag ctt ggc caa tgc tca 1786 Pro Asp Lys Lys Thr Val His Tyr Tyr Ala Glu Leu Gly Gln Cys Ser 325 330 335 gtt ttc cca gca aca gat gct cct gag caa ttt att agt caa gtg acg 1834 Val Phe Pro Ala Thr Asp Ala Pro Glu Gln Phe Ile Ser Gln Val Thr 340 345 350 gtg ctg aaa tac ttt tct cat tac atg gag gag aac ctc atg gat ggt 1882 Val Leu Lys Tyr Phe Ser His Tyr Met Glu Glu Asn Leu Met Asp Gly 355 360 365 370 gga gat ctg cct agt gtt act gat att cga aga cct cgg ctc tac ctc 1930 Gly Asp Leu Pro Ser Val Thr Asp Ile Arg Arg Pro Arg Leu Tyr Leu 375 380 385 ctt cag tgg cta aaa tct gat aag gcc cta atg atg ctc ttt aat gat 1978 Leu Gln Trp Leu Lys Ser Asp Lys Ala Leu Met Met Leu Phe Asn Asp 390 395 400 ggc acc ttt cag gtg aat ttc tac cat gat cat aca aaa atc atc atc 2026 Gly Thr Phe Gln Val Asn Phe Tyr His Asp His Thr Lys Ile Ile Ile 405 410 415 tgt agc caa aat gaa gaa tac ctt ctc acc tac atc aat gag gat agg 2074 Cys Ser Gln Asn Glu Glu Tyr Leu Leu Thr Tyr Ile Asn Glu Asp Arg 420 425 430 ata tct aca act ttc agg ctg aca act ctg ctg atg tct ggc tgt tca 2122 Ile Ser Thr Thr Phe Arg Leu Thr Thr Leu Leu Met Ser Gly Cys Ser 435 440 445 450 tca gaa tta aaa aat cga atg gaa tat gcc ctg aac atg ctc tta caa 2170 Ser Glu Leu Lys Asn Arg Met Glu Tyr Ala Leu Asn Met Leu Leu Gln 455 460 465 aga tgt aac tgaaagactt ttcgaatgga ccctatggga ctcctctttt 2219 Arg Cys Asn ccactgtgag atctacaggg aagccaaaag aatgatctag agtatgttga agaagatgga 2279 catgtggtgg tacgaaaaca attcccctgt ggcctgctgg actggttgga accagaacag 2339 gctaaggcat acagttcttg actttggaca atccaagagt gaaccagaat gcagttttcc 2399 ttgagatacc tgttttaaaa ggtttttcag acaattttgc agaaaggtgc attgattctt 2459 aaattctctc tgttgagagc atttcagcca gaggactttg gaactgtgaa tatacttcct 2519 gaaggggagg gagaagggag gaagctccca tgttgtttaa aggctgtaat tggagcagct 2579 tttggctgcg taactgtgaa ctatggccat atataatttt ttttcattaa tttttgaaga 2639 tacttgtggc tggaaaagtg cattccttgt taataaactt tttatttatt acagcccaaa 2699 gagcagtatt tattatcaaa atgtcttttt ttttatgttg accattttaa accgttggca 2759 ataaagagta tgaaaacgc 2778 14 469 PRT Homo sapiens 14 Met Glu Leu Lys Val Gly Asp Phe Gly Leu Ala Ala Arg Leu Glu Pro 1 5 10 15 Leu Glu His Arg Arg Arg Thr Ile Cys Gly Thr Pro Asn Tyr Leu Ser 20 25 30 Pro Glu Val Leu Asn Lys Gln Gly His Gly Cys Glu Ser Asp Ile Trp 35 40 45 Ala Leu Gly Cys Val Met Tyr Thr Met Leu Leu Gly Arg Pro Pro Phe 50 55 60 Glu Thr Thr Asn Leu Lys Glu Thr Tyr Arg Cys Ile Arg Glu Ala Arg 65 70 75 80 Tyr Thr Met Pro Ser Ser Leu Leu Ala Pro Ala Lys His Leu Ile Ala 85 90 95 Ser Met Leu Ser Lys Asn Pro Glu Asp Arg Pro Ser Leu Asp Asp Ile 100 105 110 Ile Arg His Asp Phe Phe Leu Gln Gly Phe Thr Pro Asp Arg Leu Ser 115 120 125 Ser Ser Cys Cys His Thr Val Pro Asp Phe His Leu Ser Ser Pro Ala 130 135 140 Lys Asn Phe Phe Lys Lys Ala Ala Ala Ala Leu Phe Gly Gly Lys Lys 145 150 155 160 Asp Lys Ala Arg Tyr Ile Asp Thr His Asn Arg Val Ser Lys Glu Asp 165 170 175 Glu Asp Ile Tyr Lys Leu Arg His Asp Leu Lys Lys Thr Ser Ile Thr 180 185 190 Gln Gln Pro Ser Lys His Arg Thr Asp Glu Glu Leu Gln Pro Pro Thr 195 200 205 Thr Thr Val Ala Arg Ser Gly Thr Pro Ala Val Glu Asn Lys Gln Gln 210 215 220 Ile Gly Asp Ala Ile Arg Met Ile Val Arg Gly Thr Leu Gly Ser Cys 225 230 235 240 Ser Ser Ser Ser Glu Cys Leu Glu Asp Ser Thr Met Gly Ser Val Ala 245 250 255 Asp Thr Val Ala Arg Val Leu Arg Gly Cys Leu Glu Asn Met Pro Glu 260 265 270 Ala Asp Cys Ile Pro Lys Glu Gln Leu Ser Thr Ser Phe Gln Trp Val 275 280 285 Thr Lys Trp Val Asp Tyr Ser Asn Lys Tyr Gly Phe Gly Tyr Gln Leu 290 295 300 Ser Asp His Thr Val Gly Val Leu Phe Asn Asn Gly Ala His Met Ser 305 310 315 320 Leu Leu Pro Asp Lys Lys Thr Val His Tyr Tyr Ala Glu Leu Gly Gln 325 330 335 Cys Ser Val Phe Pro Ala Thr Asp Ala Pro Glu Gln Phe Ile Ser Gln 340 345 350 Val Thr Val Leu Lys Tyr Phe Ser His Tyr Met Glu Glu Asn Leu Met 355 360 365 Asp Gly Gly Asp Leu Pro Ser Val Thr Asp Ile Arg Arg Pro Arg Leu 370 375 380 Tyr Leu Leu Gln Trp Leu Lys Ser Asp Lys Ala Leu Met Met Leu Phe 385 390 395 400 Asn Asp Gly Thr Phe Gln Val Asn Phe Tyr His Asp His Thr Lys Ile 405 410 415 Ile Ile Cys Ser Gln Asn Glu Glu Tyr Leu Leu Thr Tyr Ile Asn Glu 420 425 430 Asp Arg Ile Ser Thr Thr Phe Arg Leu Thr Thr Leu Leu Met Ser Gly 435 440 445 Cys Ser Ser Glu Leu Lys Asn Arg Met Glu Tyr Ala Leu Asn Met Leu 450 455 460 Leu Gln Arg Cys Asn 465 15 2574 DNA Homo sapiens CDS (23)...(2290) 15 attcttgcat agcagtgtga aa atg gtg cat gga aat atc act cct gaa aat 52 Met Val His Gly Asn Ile Thr Pro Glu Asn 1 5 10 ata att ttg aat aag agt gga gcc tgg aaa ata atg ggt ttt gat ttt 100 Ile Ile Leu Asn Lys Ser Gly Ala Trp Lys Ile Met Gly Phe Asp Phe 15 20 25 tgt gta tca tca acc aat cct tct gaa caa gag cct aaa ttt cct tgt 148 Cys Val Ser Ser Thr Asn Pro Ser Glu Gln Glu Pro Lys Phe Pro Cys 30 35 40 aaa gaa tgg gac cca aat tta cct tca ttg tgt ctt cca aat cct gaa 196 Lys Glu Trp Asp Pro Asn Leu Pro Ser Leu Cys Leu Pro Asn Pro Glu 45 50 55 tat ttg gct cct gaa tac ata ctt tct gtg agc tgt gaa aca gcc agt 244 Tyr Leu Ala Pro Glu Tyr Ile Leu Ser Val Ser Cys Glu Thr Ala Ser 60 65 70 gat atg tat tct tta gga act gtt atg tat gct gta ttt aat aaa ggg 292 Asp Met Tyr Ser Leu Gly Thr Val Met Tyr Ala Val Phe Asn Lys Gly 75 80 85 90 aaa cct ata ttt gaa gtc aac aag caa gat att tac aag agt ttc agt 340 Lys Pro Ile Phe Glu Val Asn Lys Gln Asp Ile Tyr Lys Ser Phe Ser 95 100 105 agg cag ttg gat cag ttg agt cgt tta gga tct agt tca ctt aca aat 388 Arg Gln Leu Asp Gln Leu Ser Arg Leu Gly Ser Ser Ser Leu Thr Asn 110 115 120 ata cct gag gaa gtt cgt gaa cat gta aag cta ctg tta aat gta act 436 Ile Pro Glu Glu Val Arg Glu His Val Lys Leu Leu Leu Asn Val Thr 125 130 135 ccg act gta aga cca gac gca gat caa atg aca aag att ccc ttc ttt 484 Pro Thr Val Arg Pro Asp Ala Asp Gln Met Thr Lys Ile Pro Phe Phe 140 145 150 gat gat gtt ggt gca gta aca ctg caa tat ttt gat acc tta ttc caa 532 Asp Asp Val Gly Ala Val Thr Leu Gln Tyr Phe Asp Thr Leu Phe Gln 155 160 165 170 aga gat aat ctt cag aaa tca cag ttt ttc aaa gga ctg cta aag gtt 580 Arg Asp Asn Leu Gln Lys Ser Gln Phe Phe Lys Gly Leu Leu Lys Val 175 180 185 cta cca aaa ctg ccc aag cgt gtc att gtg cag aga att ttg cct tgt 628 Leu Pro Lys Leu Pro Lys Arg Val Ile Val Gln Arg Ile Leu Pro Cys 190 195 200 ttg act tca gaa ttt gta aac cct gac atg gta cct ttt gtt ttg ccc 676 Leu Thr Ser Glu Phe Val Asn Pro Asp Met Val Pro Phe Val Leu Pro 205 210 215 aat gtt cta ctt att gct gag gaa tgc acc aaa gaa gaa tat gtc aaa 724 Asn Val Leu Leu Ile Ala Glu Glu Cys Thr Lys Glu Glu Tyr Val Lys 220 225 230 tta att ctt cct gaa ctt ggc cct gtg ttt aag cag cag gag cca atc 772 Leu Ile Leu Pro Glu Leu Gly Pro Val Phe Lys Gln Gln Glu Pro Ile 235 240 245 250 cag att ttg tta att ttc cta caa aaa atg gat ttg cta cta acc aaa 820 Gln Ile Leu Leu Ile Phe Leu Gln Lys Met Asp Leu Leu Leu Thr Lys 255 260 265 acc cct cct gat gag ata aag aac agt gtt cta ccc atg gtt tac aga 868 Thr Pro Pro Asp Glu Ile Lys Asn Ser Val Leu Pro Met Val Tyr Arg 270 275 280 gca cta gaa gct cct tcc att cag atc cag gag ctg tgt cta aac atc 916 Ala Leu Glu Ala Pro Ser Ile Gln Ile Gln Glu Leu Cys Leu Asn Ile 285 290 295 att cca acc ttt gca aat ctt ata gac tac cca tcc atg aaa aac gct 964 Ile Pro Thr Phe Ala Asn Leu Ile Asp Tyr Pro Ser Met Lys Asn Ala 300 305 310 ttg ata cca aga att aaa aat gct tgt cta caa aca tct tcc ctt gcg 1012 Leu Ile Pro Arg Ile Lys Asn Ala Cys Leu Gln Thr Ser Ser Leu Ala 315 320 325 330 gtt cgt gta aat tca tta gtg tgc tta gga aag att ttg gaa tac ttg 1060 Val Arg Val Asn Ser Leu Val Cys Leu Gly Lys Ile Leu Glu Tyr Leu 335 340 345 gat aag tgg ttt gta ctt gat gat atc cta ccc ttc tta caa caa att 1108 Asp Lys Trp Phe Val Leu Asp Asp Ile Leu Pro Phe Leu Gln Gln Ile 350 355 360 cca tcc aag gaa cct gcg gtc ctc atg gga att tta ggt att tac aaa 1156 Pro Ser Lys Glu Pro Ala Val Leu Met Gly Ile Leu Gly Ile Tyr Lys 365 370 375 tgt act ttt act cat aag aag ttg gga atc acc aaa gag cag ctg gcc 1204 Cys Thr Phe Thr His Lys Lys Leu Gly Ile Thr Lys Glu Gln Leu Ala 380 385 390 gga aaa gtg ttg cct cat ctt att ccc ctg agt att gaa aac aat ctt 1252 Gly Lys Val Leu Pro His Leu Ile Pro Leu Ser Ile Glu Asn Asn Leu 395 400 405 410 aat ctt aat cag ttc aat tct ttc att tcc gtc ata aaa gaa atg ctt 1300 Asn Leu Asn Gln Phe Asn Ser Phe Ile Ser Val Ile Lys Glu Met Leu 415 420 425 aat aga ttg gag tct gaa cat aag act aaa ctg gag caa ctt cat ata 1348 Asn Arg Leu Glu Ser Glu His Lys Thr Lys Leu Glu Gln Leu His Ile 430 435 440 atg caa gaa cag cag aaa tct ttg gat ata gga aat caa atg aat gtt 1396 Met Gln Glu Gln Gln Lys Ser Leu Asp Ile Gly Asn Gln Met Asn Val 445 450 455 tct gag gag atg aaa gtt aca aat att ggg aat cag caa att gac aaa 1444 Ser Glu Glu Met Lys Val Thr Asn Ile Gly Asn Gln Gln Ile Asp Lys 460 465 470 gtt ttt aac aac att gga gca gac ctt ctg act ggc agt gag tcc gaa 1492 Val Phe Asn Asn Ile Gly Ala Asp Leu Leu Thr Gly Ser Glu Ser Glu 475 480 485 490 aat aaa gag gac ggg tta cag aat aaa cat aaa aga gca tca ctt aca 1540 Asn Lys Glu Asp Gly Leu Gln Asn Lys His Lys Arg Ala Ser Leu Thr 495 500 505 ctt gaa gaa aaa caa aaa tta gca aaa gaa caa gag cag gca cag aag 1588 Leu Glu Glu Lys Gln Lys Leu Ala Lys Glu Gln Glu Gln Ala Gln Lys 510 515 520 ctg aaa agc cag cag cct ctt aaa ccc caa gtg cac aca cct gtt gct 1636 Leu Lys Ser Gln Gln Pro Leu Lys Pro Gln Val His Thr Pro Val Ala 525 530 535 act gtt aaa cag act aag gac ttg aca gac aca ctg atg gat aat atg 1684 Thr Val Lys Gln Thr Lys Asp Leu Thr Asp Thr Leu Met Asp Asn Met 540 545 550 tca tcc ttg acc agc ctt tct gtt agt acc cct aaa tct tct gct tca 1732 Ser Ser Leu Thr Ser Leu Ser Val Ser Thr Pro Lys Ser Ser Ala Ser 555 560 565 570 agt act ttc act tct gtt cct tcc atg ggc att ggt atg atg ttt tct 1780 Ser Thr Phe Thr Ser Val Pro Ser Met Gly Ile Gly Met Met Phe Ser 575 580 585 aca cca act gat aat aca aag aga aat ttg aca aat ggc cta aat gcc 1828 Thr Pro Thr Asp Asn Thr Lys Arg Asn Leu Thr Asn Gly Leu Asn Ala 590 595 600 aat atg ggc ttt cag act tca gga ttc aac atg ccc gtt aat aca aac 1876 Asn Met Gly Phe Gln Thr Ser Gly Phe Asn Met Pro Val Asn Thr Asn 605 610 615 cag aac ttc tac agt agt cca agc aca gtt gga gtg acc aag atg act 1924 Gln Asn Phe Tyr Ser Ser Pro Ser Thr Val Gly Val Thr Lys Met Thr 620 625 630 ctg gga aca cct ccc act ttg cca aac ttc aat gct ttg agt gtt cct 1972 Leu Gly Thr Pro Pro Thr Leu Pro Asn Phe Asn Ala Leu Ser Val Pro 635 640 645 650 cct gct ggt gca aag cag acc caa caa aga ccc aca gat atg tct gcc 2020 Pro Ala Gly Ala Lys Gln Thr Gln Gln Arg Pro Thr Asp Met Ser Ala 655 660 665 ctt aat aat ctc ttt ggc cct cag aaa ccc aaa gtt agc atg aac cag 2068 Leu Asn Asn Leu Phe Gly Pro Gln Lys Pro Lys Val Ser Met Asn Gln 670 675 680 tta tca caa cag aaa cca aat cag tgg ctt aat cag ttt gta cct cct 2116 Leu Ser Gln Gln Lys Pro Asn Gln Trp Leu Asn Gln Phe Val Pro Pro 685 690 695 caa ggt tct cca act atg ggc agt tca gta atg ggg aca cag atg aac 2164 Gln Gly Ser Pro Thr Met Gly Ser Ser Val Met Gly Thr Gln Met Asn 700 705 710 gtg ata gga caa tct gct ttt ggt atg cag ggt aat cct ttc ttt aac 2212 Val Ile Gly Gln Ser Ala Phe Gly Met Gln Gly Asn Pro Phe Phe Asn 715 720 725 730 cca cag aac ttt gca cag cca cca act act atg acc aat agc agt tca 2260 Pro Gln Asn Phe Ala Gln Pro Pro Thr Thr Met Thr Asn Ser Ser Ser 735 740 745 gct agc aat gat tta aaa gat ctt ttt ggg tgaggtgtct tacttctatt 2310 Ala Ser Asn Asp Leu Lys Asp Leu Phe Gly 750 755 ttgaaggatt atttcagttt caatcatggg tgagctgatt tacatcttta tatagttggc 2370 ttggaggaag tactcctatg ggaaagtgaa cagttctgtg acaggaaaca tctctgtcca 2430 tgccagcata gtagttgtat ggacttctaa ccagttgagt tttttaaagc attgaggatt 2490 ttttcctctt accaactcct cttcaggttt ttaaagcccc agcgcctata ttaaggcaca 2550 tttgaataaa ttctattacc agtt 2574 16 756 PRT Homo sapiens 16 Met Val His Gly Asn Ile Thr Pro Glu Asn Ile Ile Leu Asn Lys Ser 1 5 10 15 Gly Ala Trp Lys Ile Met Gly Phe Asp Phe Cys Val Ser Ser Thr Asn 20 25 30 Pro Ser Glu Gln Glu Pro Lys Phe Pro Cys Lys Glu Trp Asp Pro Asn 35 40 45 Leu Pro Ser Leu Cys Leu Pro Asn Pro Glu Tyr Leu Ala Pro Glu Tyr 50 55 60 Ile Leu Ser Val Ser Cys Glu Thr Ala Ser Asp Met Tyr Ser Leu Gly 65 70 75 80 Thr Val Met Tyr Ala Val Phe Asn Lys Gly Lys Pro Ile Phe Glu Val 85 90 95 Asn Lys Gln Asp Ile Tyr Lys Ser Phe Ser Arg Gln Leu Asp Gln Leu 100 105 110 Ser Arg Leu Gly Ser Ser Ser Leu Thr Asn Ile Pro Glu Glu Val Arg 115 120 125 Glu His Val Lys Leu Leu Leu Asn Val Thr Pro Thr Val Arg Pro Asp 130 135 140 Ala Asp Gln Met Thr Lys Ile Pro Phe Phe Asp Asp Val Gly Ala Val 145 150 155 160 Thr Leu Gln Tyr Phe Asp Thr Leu Phe Gln Arg Asp Asn Leu Gln Lys 165 170 175 Ser Gln Phe Phe Lys Gly Leu Leu Lys Val Leu Pro Lys Leu Pro Lys 180 185 190 Arg Val Ile Val Gln Arg Ile Leu Pro Cys Leu Thr Ser Glu Phe Val 195 200 205 Asn Pro Asp Met Val Pro Phe Val Leu Pro Asn Val Leu Leu Ile Ala 210 215 220 Glu Glu Cys Thr Lys Glu Glu Tyr Val Lys Leu Ile Leu Pro Glu Leu 225 230 235 240 Gly Pro Val Phe Lys Gln Gln Glu Pro Ile Gln Ile Leu Leu Ile Phe 245 250 255 Leu Gln Lys Met Asp Leu Leu Leu Thr Lys Thr Pro Pro Asp Glu Ile 260 265 270 Lys Asn Ser Val Leu Pro Met Val Tyr Arg Ala Leu Glu Ala Pro Ser 275 280 285 Ile Gln Ile Gln Glu Leu Cys Leu Asn Ile Ile Pro Thr Phe Ala Asn 290 295 300 Leu Ile Asp Tyr Pro Ser Met Lys Asn Ala Leu Ile Pro Arg Ile Lys 305 310 315 320 Asn Ala Cys Leu Gln Thr Ser Ser Leu Ala Val Arg Val Asn Ser Leu 325 330 335 Val Cys Leu Gly Lys Ile Leu Glu Tyr Leu Asp Lys Trp Phe Val Leu 340 345 350 Asp Asp Ile Leu Pro Phe Leu Gln Gln Ile Pro Ser Lys Glu Pro Ala 355 360 365 Val Leu Met Gly Ile Leu Gly Ile Tyr Lys Cys Thr Phe Thr His Lys 370 375 380 Lys Leu Gly Ile Thr Lys Glu Gln Leu Ala Gly Lys Val Leu Pro His 385 390 395 400 Leu Ile Pro Leu Ser Ile Glu Asn Asn Leu Asn Leu Asn Gln Phe Asn 405 410 415 Ser Phe Ile Ser Val Ile Lys Glu Met Leu Asn Arg Leu Glu Ser Glu 420 425 430 His Lys Thr Lys Leu Glu Gln Leu His Ile Met Gln Glu Gln Gln Lys 435 440 445 Ser Leu Asp Ile Gly Asn Gln Met Asn Val Ser Glu Glu Met Lys Val 450 455 460 Thr Asn Ile Gly Asn Gln Gln Ile Asp Lys Val Phe Asn Asn Ile Gly 465 470 475 480 Ala Asp Leu Leu Thr Gly Ser Glu Ser Glu Asn Lys Glu Asp Gly Leu 485 490 495 Gln Asn Lys His Lys Arg Ala Ser Leu Thr Leu Glu Glu Lys Gln Lys 500 505 510 Leu Ala Lys Glu Gln Glu Gln Ala Gln Lys Leu Lys Ser Gln Gln Pro 515 520 525 Leu Lys Pro Gln Val His Thr Pro Val Ala Thr Val Lys Gln Thr Lys 530 535 540 Asp Leu Thr Asp Thr Leu Met Asp Asn Met Ser Ser Leu Thr Ser Leu 545 550 555 560 Ser Val Ser Thr Pro Lys Ser Ser Ala Ser Ser Thr Phe Thr Ser Val 565 570 575 Pro Ser Met Gly Ile Gly Met Met Phe Ser Thr Pro Thr Asp Asn Thr 580 585 590 Lys Arg Asn Leu Thr Asn Gly Leu Asn Ala Asn Met Gly Phe Gln Thr 595 600 605 Ser Gly Phe Asn Met Pro Val Asn Thr Asn Gln Asn Phe Tyr Ser Ser 610 615 620 Pro Ser Thr Val Gly Val Thr Lys Met Thr Leu Gly Thr Pro Pro Thr 625 630 635 640 Leu Pro Asn Phe Asn Ala Leu Ser Val Pro Pro Ala Gly Ala Lys Gln 645 650 655 Thr Gln Gln Arg Pro Thr Asp Met Ser Ala Leu Asn Asn Leu Phe Gly 660 665 670 Pro Gln Lys Pro Lys Val Ser Met Asn Gln Leu Ser Gln Gln Lys Pro 675 680 685 Asn Gln Trp Leu Asn Gln Phe Val Pro Pro Gln Gly Ser Pro Thr Met 690 695 700 Gly Ser Ser Val Met Gly Thr Gln Met Asn Val Ile Gly Gln Ser Ala 705 710 715 720 Phe Gly Met Gln Gly Asn Pro Phe Phe Asn Pro Gln Asn Phe Ala Gln 725 730 735 Pro Pro Thr Thr Met Thr Asn Ser Ser Ser Ala Ser Asn Asp Leu Lys 740 745 750 Asp Leu Phe Gly 755 17 1074 DNA Homo sapiens CDS (67)...(690) 17 gcagtaccag tttgtgcacc acgtcatgag cctctacgaa aagcagctgt cccaccagtc 60 cccaga atg act gcg ctt ctc cta caa ggt tct ctg ggc act gcc cag 108 Met Thr Ala Leu Leu Leu Gln Gly Ser Leu Gly Thr Ala Gln 1 5 10 cct gag tct cgg ccc tca ccc agg gcc ctg cct cgg gtc ctg ggc ctg 156 Pro Glu Ser Arg Pro Ser Pro Arg Ala Leu Pro Arg Val Leu Gly Leu 15 20 25 30 ctc ccc gct tcc tcc cct tca gtc agc tcc ctc tgt cct ctg tca gcc 204 Leu Pro Ala Ser Ser Pro Ser Val Ser Ser Leu Cys Pro Leu Ser Ala 35 40 45 tgg cct gac ccc tac cct cca gca ttg ctc ttc cta ctg tac ata ttg 252 Trp Pro Asp Pro Tyr Pro Pro Ala Leu Leu Phe Leu Leu Tyr Ile Leu 50 55 60 ggg agt ggg ggg cag ggt cgg gaa ggg aca tgc cag gcc agg cct ggg 300 Gly Ser Gly Gly Gln Gly Arg Glu Gly Thr Cys Gln Ala Arg Pro Gly 65 70 75 gcc ccg ggg cct gac cca cac cac gca gac ccc ggg ctc cag ttt tta 348 Ala Pro Gly Pro Asp Pro His His Ala Asp Pro Gly Leu Gln Phe Leu 80 85 90 acg atg gtt cca tca ata cct gat cca gaa tgt ttc cgt gct aca ctt 396 Thr Met Val Pro Ser Ile Pro Asp Pro Glu Cys Phe Arg Ala Thr Leu 95 100 105 110 tgt gtc ctg ctg caa tgt gtt ctg tct gtc cat cca tct ctg ccc tct 444 Cys Val Leu Leu Gln Cys Val Leu Ser Val His Pro Ser Leu Pro Ser 115 120 125 gta ccg gac act gtg tct cct cag cca gga agg ggt aat gag ctc cag 492 Val Pro Asp Thr Val Ser Pro Gln Pro Gly Arg Gly Asn Glu Leu Gln 130 135 140 ccc cta agc aac cgg act tgc ctg cct cgg cct cac ccg cac ttc tcc 540 Pro Leu Ser Asn Arg Thr Cys Leu Pro Arg Pro His Pro His Phe Ser 145 150 155 caa aag gca gat gac ggg gag tta ggc atg ggg agc tcc aga agg tca 588 Gln Lys Ala Asp Asp Gly Glu Leu Gly Met Gly Ser Ser Arg Arg Ser 160 165 170 cca gag agc ttt cag ctg agg gag agt tct cta ggt tgg agt ggg cat 636 Pro Glu Ser Phe Gln Leu Arg Glu Ser Ser Leu Gly Trp Ser Gly His 175 180 185 190 cac agc cag ggt ggc ctc tgg gtg tca gat gct ctc agg agg gtg ccc 684 His Ser Gln Gly Gly Leu Trp Val Ser Asp Ala Leu Arg Arg Val Pro 195 200 205 agc ctg tgaggcactg gcaaggtagg gggcagatgg ggcatggaga acccagagga 740 Ser Leu tctaggccct gttggggagg ggaggggagc tcaaggtttg ggtggggact cagcccagat 800 ctacgtgaga catttttctg tgtcactgtg ggaaagcctt cccagaagtc tcactgcgtg 860 ttgctctgcg tgtgttccca tgtccgtgcg tgtgttgaga gcccatcagg agggcatgca 920 tgactctttg gcaacatgta ttatcttgga gccacgtgtt tttattgctg actttaaata 980 tttatcccac ggcagacaga gacatttggt gtctttttat aattcgctcg tggtcattga 1040 atagagcaat aaacggagca ttttgagcaa aact 1074 18 208 PRT Homo sapiens 18 Met Thr Ala Leu Leu Leu Gln Gly Ser Leu Gly Thr Ala Gln Pro Glu 1 5 10 15 Ser Arg Pro Ser Pro Arg Ala Leu Pro Arg Val Leu Gly Leu Leu Pro 20 25 30 Ala Ser Ser Pro Ser Val Ser Ser Leu Cys Pro Leu Ser Ala Trp Pro 35 40 45 Asp Pro Tyr Pro Pro Ala Leu Leu Phe Leu Leu Tyr Ile Leu Gly Ser 50 55 60 Gly Gly Gln Gly Arg Glu Gly Thr Cys Gln Ala Arg Pro Gly Ala Pro 65 70 75 80 Gly Pro Asp Pro His His Ala Asp Pro Gly Leu Gln Phe Leu Thr Met 85 90 95 Val Pro Ser Ile Pro Asp Pro Glu Cys Phe Arg Ala Thr Leu Cys Val 100 105 110 Leu Leu Gln Cys Val Leu Ser Val His Pro Ser Leu Pro Ser Val Pro 115 120 125 Asp Thr Val Ser Pro Gln Pro Gly Arg Gly Asn Glu Leu Gln Pro Leu 130 135 140 Ser Asn Arg Thr Cys Leu Pro Arg Pro His Pro His Phe Ser Gln Lys 145 150 155 160 Ala Asp Asp Gly Glu Leu Gly Met Gly Ser Ser Arg Arg Ser Pro Glu 165 170 175 Ser Phe Gln Leu Arg Glu Ser Ser Leu Gly Trp Ser Gly His His Ser 180 185 190 Gln Gly Gly Leu Trp Val Ser Asp Ala Leu Arg Arg Val Pro Ser Leu 195 200 205 19 1959 DNA Homo sapiens CDS (1357)...(1929) 19 agaaaaaatg tgctgcgttc tgaaaaataa ctccttagct tggtctgatt gttttcagac 60 cttaaaatat aaacttgttt cacaagcttt aatccatgtg gatttttttt tcttagagaa 120 ccacaaaaca taaaaggagc aagtcggact gaatacctgt ttccatagtg cccacagggt 180 attcctcaca ttttctccat agaagatgct ttttcccaag gctagaacga cctccaccat 240 gatgaatttg ctttttaggt cttaattatt tcacttcttt ttagaaactt aggaagaagt 300 ggataatcct gaggtcacac aatctgtcct cccagaaatg aacaaaagtc atcacctttt 360 ctgcttgcta cacaggcaac gattccccca tcagctgccc ggaccctttg gcctggcttg 420 gtgtgcaggc ctgtctgttt gcttaaagtc agtgggttct ggtgcaggga gtgagaagtg 480 ggggaagtga aagggaaagc atccgtgaga aagcggccac ggttttccct ccttgtgtgc 540 ccatggggca ccagctcatg gtctttttca gtcatcccag tttgtacaga cttagcttct 600 gaactctaag aatgccaaag ggaccgacga gactccccat cacagcgagc tctgtcctta 660 catgtatttg atgtgcatca gcggaggaga acactggctt ggccctgctc cgctgagtgt 720 ctgtgaaata cctctacttt ccctcccata tccagaacaa aatgatactt gacatccttc 780 cacaaaagtc agcctaaaga agttatggta tcatatgtta aactaagctt tcaaaaacct 840 tagtgaaata gcaagtgact gctttcaagc agcagtcgac atgtaaatga aggtgttctt 900 agaattcgca ttttgccagc tcagcgcacc tccacaacga atgaaatgct ccgtatgatt 960 tgcacaaatg acatagacct ccccaaaagt taactggctc tccttcctca cacagttcat 1020 cataacccaa ccccccaccc ccgggtcatg aaaatcacag aacttataaa cacattgaac 1080 cctagatctc aggcttcctg acctaccgcc agtggcccct tgctggccac cctatagggt 1140 cctccttccc tggcagcccc ccatgtggga gaaatacctg attctcccaa tctgcagtgg 1200 gagagctttg ctgaattcca tcccaaagtc aaacatgggc aagaggtgag gatttcactt 1260 ttaccctcaa gtccgatttg tctgtgattt taaactaact gtgtatgtat tgatgtttgg 1320 aagattgttt gaattttaaa gtgataatag tactta atg tta tcc agt att gtt 1374 Met Leu Ser Ser Ile Val 1 5 cat cga gac ctg aag ccg agt aac atc cac ttc acc gat ggc tac gag 1422 His Arg Asp Leu Lys Pro Ser Asn Ile His Phe Thr Asp Gly Tyr Glu 10 15 20 atc aag gag gac atc ggg gtg ggc tcc tac tca gtg tgc aag cga tgt 1470 Ile Lys Glu Asp Ile Gly Val Gly Ser Tyr Ser Val Cys Lys Arg Cys 25 30 35 gtg cat aaa gcc aca gac acc gag tat gcc gtg aag atc att gat aag 1518 Val His Lys Ala Thr Asp Thr Glu Tyr Ala Val Lys Ile Ile Asp Lys 40 45 50 agc aag aga gac ccc tcg gaa gag att gag atc ctc ctg cgg tac ggc 1566 Ser Lys Arg Asp Pro Ser Glu Glu Ile Glu Ile Leu Leu Arg Tyr Gly 55 60 65 70 cag cac ccg aac atc atc acc ctc aag gat gtc tat gat gat ggc aag 1614 Gln His Pro Asn Ile Ile Thr Leu Lys Asp Val Tyr Asp Asp Gly Lys 75 80 85 ttt gtg tac ctg gta atg gag ctg atg cgt ggt ggg gag ctc ctg gac 1662 Phe Val Tyr Leu Val Met Glu Leu Met Arg Gly Gly Glu Leu Leu Asp 90 95 100 cgc atc ctc cgg cag aga tac ttc tcg gag cgc gaa gcc agt gac gcc 1710 Arg Ile Leu Arg Gln Arg Tyr Phe Ser Glu Arg Glu Ala Ser Asp Ala 105 110 115 ctg tgc acc atc acc aag acc atg gac tac ctc cat tcc cag ggg gtt 1758 Leu Cys Thr Ile Thr Lys Thr Met Asp Tyr Leu His Ser Gln Gly Val 120 125 130 gtt cat cga gac ctg ttt aga gga ttc agc ttt gtg gcc tca agc ctg 1806 Val His Arg Asp Leu Phe Arg Gly Phe Ser Phe Val Ala Ser Ser Leu 135 140 145 150 atc cag gag ccc tca cag caa gat ctg cac aaa gtc cca gtt cac cca 1854 Ile Gln Glu Pro Ser Gln Gln Asp Leu His Lys Val Pro Val His Pro 155 160 165 atc ctg ctt tgt aat tca tgt ttg aga tgg gtg gcc act gta cag ata 1902 Ile Leu Leu Cys Asn Ser Cys Leu Arg Trp Val Ala Thr Val Gln Ile 170 175 180 ttt att acg ctt tcc aga ctt tct gaa tagatttttt tgaataaaca 1949 Phe Ile Thr Leu Ser Arg Leu Ser Glu 185 190 tggttttatg 1959 20 191 PRT Homo sapiens 20 Met Leu Ser Ser Ile Val His Arg Asp Leu Lys Pro Ser Asn Ile His 1 5 10 15 Phe Thr Asp Gly Tyr Glu Ile Lys Glu Asp Ile Gly Val Gly Ser Tyr 20 25 30 Ser Val Cys Lys Arg Cys Val His Lys Ala Thr Asp Thr Glu Tyr Ala 35 40 45 Val Lys Ile Ile Asp Lys Ser Lys Arg Asp Pro Ser Glu Glu Ile Glu 50 55 60 Ile Leu Leu Arg Tyr Gly Gln His Pro Asn Ile Ile Thr Leu Lys Asp 65 70 75 80 Val Tyr Asp Asp Gly Lys Phe Val Tyr Leu Val Met Glu Leu Met Arg 85 90 95 Gly Gly Glu Leu Leu Asp Arg Ile Leu Arg Gln Arg Tyr Phe Ser Glu 100 105 110 Arg Glu Ala Ser Asp Ala Leu Cys Thr Ile Thr Lys Thr Met Asp Tyr 115 120 125 Leu His Ser Gln Gly Val Val His Arg Asp Leu Phe Arg Gly Phe Ser 130 135 140 Phe Val Ala Ser Ser Leu Ile Gln Glu Pro Ser Gln Gln Asp Leu His 145 150 155 160 Lys Val Pro Val His Pro Ile Leu Leu Cys Asn Ser Cys Leu Arg Trp 165 170 175 Val Ala Thr Val Gln Ile Phe Ile Thr Leu Ser Arg Leu Ser Glu 180 185 190 21 4262 DNA Homo sapiens CDS (40)...(2415) 21 aaaagtgctc gggacaagga catagggctg agagtagcc atg ggc tct gga gga 54 Met Gly Ser Gly Gly 1 5 gac agc ctc ctg ggg ggc agg ggt tcc ctg cct ctg ctg ctc ctg ctc 102 Asp Ser Leu Leu Gly Gly Arg Gly Ser Leu Pro Leu Leu Leu Leu Leu 10 15 20 atc atg gga ggc atg gct cag gac tcc ccg ccc cag atc cta gtc cac 150 Ile Met Gly Gly Met Ala Gln Asp Ser Pro Pro Gln Ile Leu Val His 25 30 35 ccc cag gac cag ctg ttc cag ggc cct ggc cct gcc agg atg agc tgc 198 Pro Gln Asp Gln Leu Phe Gln Gly Pro Gly Pro Ala Arg Met Ser Cys 40 45 50 caa gcc tca ggc cag cca cct ccc acc atc cgc tgg ttg ctg aat ggg 246 Gln Ala Ser Gly Gln Pro Pro Pro Thr Ile Arg Trp Leu Leu Asn Gly 55 60 65 cag ccc ctg agc atg gtg ccc cca gac cca cac cac ctc ctg cct gat 294 Gln Pro Leu Ser Met Val Pro Pro Asp Pro His His Leu Leu Pro Asp 70 75 80 85 ggg acc ctt ctg ctg cta cag ccc cct gcc cgg gga cat gcc cac gat 342 Gly Thr Leu Leu Leu Leu Gln Pro Pro Ala Arg Gly His Ala His Asp 90 95 100 ggc cag gcc ctg tcc aca gac ctg ggt gtc tac aca tgt gag gcc agc 390 Gly Gln Ala Leu Ser Thr Asp Leu Gly Val Tyr Thr Cys Glu Ala Ser 105 110 115 aac cgg ctt ggc acg gca gtc agc aga ggc gct cgg ctg tct gtg gct 438 Asn Arg Leu Gly Thr Ala Val Ser Arg Gly Ala Arg Leu Ser Val Ala 120 125 130 gtc ctc cgg gag gat ttc cag atc cag cct cga gac atg gtg gct gtg 486 Val Leu Arg Glu Asp Phe Gln Ile Gln Pro Arg Asp Met Val Ala Val 135 140 145 gtg ggt gag cag ttt act ctg gaa tgt ggg ccg ccc tgg ggc cac cca 534 Val Gly Glu Gln Phe Thr Leu Glu Cys Gly Pro Pro Trp Gly His Pro 150 155 160 165 gag ccc aca gtc tca tgg tgg aaa gat gag aaa ccc ctg gcc ctc cag 582 Glu Pro Thr Val Ser Trp Trp Lys Asp Glu Lys Pro Leu Ala Leu Gln 170 175 180 ccc gga agg cac aca gtg tcc ggg ggg tcc ctg ctg atg gca aga gca 630 Pro Gly Arg His Thr Val Ser Gly Gly Ser Leu Leu Met Ala Arg Ala 185 190 195 gag aag agt gac gaa ggg acc tac atg tgt gtg gcc acc aac agc gca 678 Glu Lys Ser Asp Glu Gly Thr Tyr Met Cys Val Ala Thr Asn Ser Ala 200 205 210 gga cac agg gag agc cgc gca gcc cgg gtt tcc atc cag gag ccc cag 726 Gly His Arg Glu Ser Arg Ala Ala Arg Val Ser Ile Gln Glu Pro Gln 215 220 225 gac tac acg gag cct gtg gag ctt ctg gct gtg cga att cag ctg gaa 774 Asp Tyr Thr Glu Pro Val Glu Leu Leu Ala Val Arg Ile Gln Leu Glu 230 235 240 245 aat gtg aca ctg ctg aac ccg gat cct gca gag ggc ccc aag cct aga 822 Asn Val Thr Leu Leu Asn Pro Asp Pro Ala Glu Gly Pro Lys Pro Arg 250 255 260 ccg gcg gtg tgg ctc agc tgg aag gtc agt ggc cct gct gcg cct gcc 870 Pro Ala Val Trp Leu Ser Trp Lys Val Ser Gly Pro Ala Ala Pro Ala 265 270 275 caa tct tac acg gcc ttg ttc agg acc cag act gcc ccg gga ggc cag 918 Gln Ser Tyr Thr Ala Leu Phe Arg Thr Gln Thr Ala Pro Gly Gly Gln 280 285 290 gga gct ccg tgg gca gag gag ctg ctg gcc ggc tgg cag agc gca gag 966 Gly Ala Pro Trp Ala Glu Glu Leu Leu Ala Gly Trp Gln Ser Ala Glu 295 300 305 ctt gga ggc ctc cac tgg ggc caa gac tac gag ttc aaa gtg aga cca 1014 Leu Gly Gly Leu His Trp Gly Gln Asp Tyr Glu Phe Lys Val Arg Pro 310 315 320 325 tcc tct ggc cgg gct cga ggc cct gac agc aac gtg ctg ctc ctg agg 1062 Ser Ser Gly Arg Ala Arg Gly Pro Asp Ser Asn Val Leu Leu Leu Arg 330 335 340 ctg ccg gaa aaa gtg ccc agt gcc cca cct cag gaa gtg act cta aag 1110 Leu Pro Glu Lys Val Pro Ser Ala Pro Pro Gln Glu Val Thr Leu Lys 345 350 355 cct ggc aat ggc act gtc ttt gtg agc tgg gtc cca cca cct gct gaa 1158 Pro Gly Asn Gly Thr Val Phe Val Ser Trp Val Pro Pro Pro Ala Glu 360 365 370 aac cac aat ggc atc atc cgt ggc tac cag gtc tgg agc ctg ggc aac 1206 Asn His Asn Gly Ile Ile Arg Gly Tyr Gln Val Trp Ser Leu Gly Asn 375 380 385 aca tca ctg cca cca gcc aac tgg act gta gtt ggt gag cag acc cag 1254 Thr Ser Leu Pro Pro Ala Asn Trp Thr Val Val Gly Glu Gln Thr Gln 390 395 400 405 ctg gaa atc gcc acc cat atg cca ggc tcc tac tgc gtg caa gtg gct 1302 Leu Glu Ile Ala Thr His Met Pro Gly Ser Tyr Cys Val Gln Val Ala 410 415 420 gca gtc act ggt gct gga gct ggg gag ccc agt aga cct gtc tgc ctc 1350 Ala Val Thr Gly Ala Gly Ala Gly Glu Pro Ser Arg Pro Val Cys Leu 425 430 435 ctt tta gag cag gcc atg gag cga gcc acc caa gaa ccc agt gag cat 1398 Leu Leu Glu Gln Ala Met Glu Arg Ala Thr Gln Glu Pro Ser Glu His 440 445 450 ggt ccc tgg acc ctg gag cag ctg agg gct acc ttg aag cgg cct gag 1446 Gly Pro Trp Thr Leu Glu Gln Leu Arg Ala Thr Leu Lys Arg Pro Glu 455 460 465 gtc att gcc acc tgc ggt gtt gca ctc tgg ctg ctg ctt ctg ggc acc 1494 Val Ile Ala Thr Cys Gly Val Ala Leu Trp Leu Leu Leu Leu Gly Thr 470 475 480 485 gcc gtg tgt atc cac cgc cgg cgc cga gct agg gtg cac ctg ggc cca 1542 Ala Val Cys Ile His Arg Arg Arg Arg Ala Arg Val His Leu Gly Pro 490 495 500 ggt ctg tac aga tat acc agt gag gat gcc atc cta aaa cac agg atg 1590 Gly Leu Tyr Arg Tyr Thr Ser Glu Asp Ala Ile Leu Lys His Arg Met 505 510 515 gat cac agt gac tcc cag tgg ttg gca gac act tgg cgt tcc acc tct 1638 Asp His Ser Asp Ser Gln Trp Leu Ala Asp Thr Trp Arg Ser Thr Ser 520 525 530 ggc tct cgg gac ctg agc agc agc agc agc ctc agc agt cgg ctg ggg 1686 Gly Ser Arg Asp Leu Ser Ser Ser Ser Ser Leu Ser Ser Arg Leu Gly 535 540 545 gcg gat gcc cgg gac cca cta gac tgt cgt cgc tcc ttg ctc tcc tgg 1734 Ala Asp Ala Arg Asp Pro Leu Asp Cys Arg Arg Ser Leu Leu Ser Trp 550 555 560 565 gac tcc cga agc ccc ggc gtg ccc ctg ctt cca gac acc agc act ttt 1782 Asp Ser Arg Ser Pro Gly Val Pro Leu Leu Pro Asp Thr Ser Thr Phe 570 575 580 tat ggc tcc ctc atc gct gag ctg ccc tcc agt acc cca gcc agg cca 1830 Tyr Gly Ser Leu Ile Ala Glu Leu Pro Ser Ser Thr Pro Ala Arg Pro 585 590 595 agt ccc cag gtc cca gct gtc agg cgc ctc cca ccc cag ctg gcc cag 1878 Ser Pro Gln Val Pro Ala Val Arg Arg Leu Pro Pro Gln Leu Ala Gln 600 605 610 ctc tcc agc ccc tgt tcc agc tca gac agc ctc tgc agc cgc agg gga 1926 Leu Ser Ser Pro Cys Ser Ser Ser Asp Ser Leu Cys Ser Arg Arg Gly 615 620 625 ctc tct tct ccc cgc ttg tct ctg gcc cct gca gag gct tgg aag gcc 1974 Leu Ser Ser Pro Arg Leu Ser Leu Ala Pro Ala Glu Ala Trp Lys Ala 630 635 640 645 aaa aag aag cag gag ctg ccg cat gcc aac agt tcc cca ctg ctc cgg 2022 Lys Lys Lys Gln Glu Leu Pro His Ala Asn Ser Ser Pro Leu Leu Arg 650 655 660 ggc agc cac tcc ttg gag ctc cgg gcc tgt gag tta gga aat aga ggt 2070 Gly Ser His Ser Leu Glu Leu Arg Ala Cys Glu Leu Gly Asn Arg Gly 665 670 675 tcc aag aac ctt tcc caa agc cca gga gct gtg ccc caa gct ctg gtt 2118 Ser Lys Asn Leu Ser Gln Ser Pro Gly Ala Val Pro Gln Ala Leu Val 680 685 690 gcc tgg cgg gcc ctg gga ccg aaa ctc ctc agc tcc caa atg agc tgg 2166 Ala Trp Arg Ala Leu Gly Pro Lys Leu Leu Ser Ser Gln Met Ser Trp 695 700 705 tta ctc gtc atc tcc ctc cag cac ccc tct ttc ctc atg aaa ctc ccc 2214 Leu Leu Val Ile Ser Leu Gln His Pro Ser Phe Leu Met Lys Leu Pro 710 715 720 725 caa ctc aga gtc aac aga ccc agc ctc cgg tgg cac cac agg ctc cct 2262 Gln Leu Arg Val Asn Arg Pro Ser Leu Arg Trp His His Arg Leu Pro 730 735 740 cct cca tcc tgc tgc cag cag ccc cca tcc cca tcc tta gcc cct gca 2310 Pro Pro Ser Cys Cys Gln Gln Pro Pro Ser Pro Ser Leu Ala Pro Ala 745 750 755 gtc ccc cta gcc ccc agg cct ctt ccc tct ctg gcc cca gcc cag ctt 2358 Val Pro Leu Ala Pro Arg Pro Leu Pro Ser Leu Ala Pro Ala Gln Leu 760 765 770 cca gtc gcc tgt cca gct cct cac tgt cat ccc tgg ggg agg atc aag 2406 Pro Val Ala Cys Pro Ala Pro His Cys His Pro Trp Gly Arg Ile Lys 775 780 785 aca gcg tgc tgacacctga ggaggtagcc ctgtgcttgg aactcagtga 2455 Thr Ala Cys 790 gggtgaggag actcccagga acagcgtctc tcccatgcca agggctcctt caccccccac 2515 cacctatggg tacatcagcg tcccaacagc ctcagagttc acggacatgg gcaggactgg 2575 aggaggggtg gggcccaagg ggggagtctt gctgtgccca cctcggccct gcctcacccc 2635 cacccccagc gagggctcct tagccaatgg ttggggctca gcctctgagg acaatgccgc 2695 cagcgccaga gccagccttg tcagctcctc cgatggctcc ttcctcgctg atgctcactt 2755 tgcccgggcc ctggcagtgg ctgtggatag ttttggtttc ggtctagagc ccagggaggc 2815 agactgcgtc ttcatagatg cctcatcacc tccctcccca cgggatgaga tcttcctgac 2875 ccccaacctc tccctgcccc tgtgggagtg gaggccagac tggttggaag acatggaggt 2935 cagccacacc cagcggctgg gaagggggat gcctccctgg ccccctgact ctcagatctc 2995 ttcccagaga agtcagctcc actgtcgtat gcccaaggct ggtgcttctc ctgtagatta 3055 ctcctgaacc gtgtccctga gacttcccag acgggaatca gaaccacttc tcctgtccac 3115 ccacaagacc tgggctgtgg tgtgtgggtc ttggcctgtg tttctctgca gctggggtcc 3175 accttcccaa gcctccagag agttctccct ccacgattgt gaaaacaaat gaaaacaaaa 3235 ttagagcaaa gctgacctgg agccctcagg gagcaaaaca tcatctccac ctgactccta 3295 gccactgctt tctcctctgt gccatccact cccaccacca ggttgttttg gcctgaggag 3355 cagccctgcc tgctgctctt cccccaccat ttggatcaca ggaagtggag gagccagagg 3415 tgcctttgtg gaggacagca gtggctgctg ggagagggct gtggaggaag gagcttctcg 3475 gagccccctc tcagccttac ctgggcccct cctctagaga agagctcaac tctctcccaa 3535 cctcaccatg gaaagaaaat aattatgaat gccactgagg cactgaggcc ctacctcatg 3595 ccaaacaaag ggttcaaggc tgggtctagc gaggatgctg aaggaaggga ggtatgggac 3655 cgtaggtcaa aagcaccatc ctcgtactgt tgtcactatg agcttaagaa attcgatacc 3715 ataaaatggt aaagacttga gttctgtgag atcattcccc ggagcaccat ttttagggga 3775 gcacctggag agatggcaag aatttcctga gttaggcagg gatcaggcat tcattgacac 3835 tcagggagtg tcacacattt ctgttctgca attaaaggga gaatgaggtt catccaccaa 3895 attttaagca gaatatagga agggcagggg tggggagttt cagggtctgc tggtcctggc 3955 aacttatatt aaatccacct cctcaagata agccttaggg atatttatgg ctgagggaag 4015 tgggatggtc taaggcatgg ggaagggtga ttggctgtgg ggaaaatgaa gtaataggtt 4075 cattctgccc aagtgtactt ggggttcatg gcatttcata aggacatttg tgtagaaaat 4135 tgttttgctg gctgggcacg gtggctcacg cctgtaatcc cagcactttg ggaggcggag 4195 gtaggcagat catgaggtca ggagatcgag accatcctgg ctaacatggt gaaaccccgt 4255 ctctact 4262 22 792 PRT Homo sapiens 22 Met Gly Ser Gly Gly Asp Ser Leu Leu Gly Gly Arg Gly Ser Leu Pro 1 5 10 15 Leu Leu Leu Leu Leu Ile Met Gly Gly Met Ala Gln Asp Ser Pro Pro 20 25 30 Gln Ile Leu Val His Pro Gln Asp Gln Leu Phe Gln Gly Pro Gly Pro 35 40 45 Ala Arg Met Ser Cys Gln Ala Ser Gly Gln Pro Pro Pro Thr Ile Arg 50 55 60 Trp Leu Leu Asn Gly Gln Pro Leu Ser Met Val Pro Pro Asp Pro His 65 70 75 80 His Leu Leu Pro Asp Gly Thr Leu Leu Leu Leu Gln Pro Pro Ala Arg 85 90 95 Gly His Ala His Asp Gly Gln Ala Leu Ser Thr Asp Leu Gly Val Tyr 100 105 110 Thr Cys Glu Ala Ser Asn Arg Leu Gly Thr Ala Val Ser Arg Gly Ala 115 120 125 Arg Leu Ser Val Ala Val Leu Arg Glu Asp Phe Gln Ile Gln Pro Arg 130 135 140 Asp Met Val Ala Val Val Gly Glu Gln Phe Thr Leu Glu Cys Gly Pro 145 150 155 160 Pro Trp Gly His Pro Glu Pro Thr Val Ser Trp Trp Lys Asp Glu Lys 165 170 175 Pro Leu Ala Leu Gln Pro Gly Arg His Thr Val Ser Gly Gly Ser Leu 180 185 190 Leu Met Ala Arg Ala Glu Lys Ser Asp Glu Gly Thr Tyr Met Cys Val 195 200 205 Ala Thr Asn Ser Ala Gly His Arg Glu Ser Arg Ala Ala Arg Val Ser 210 215 220 Ile Gln Glu Pro Gln Asp Tyr Thr Glu Pro Val Glu Leu Leu Ala Val 225 230 235 240 Arg Ile Gln Leu Glu Asn Val Thr Leu Leu Asn Pro Asp Pro Ala Glu 245 250 255 Gly Pro Lys Pro Arg Pro Ala Val Trp Leu Ser Trp Lys Val Ser Gly 260 265 270 Pro Ala Ala Pro Ala Gln Ser Tyr Thr Ala Leu Phe Arg Thr Gln Thr 275 280 285 Ala Pro Gly Gly Gln Gly Ala Pro Trp Ala Glu Glu Leu Leu Ala Gly 290 295 300 Trp Gln Ser Ala Glu Leu Gly Gly Leu His Trp Gly Gln Asp Tyr Glu 305 310 315 320 Phe Lys Val Arg Pro Ser Ser Gly Arg Ala Arg Gly Pro Asp Ser Asn 325 330 335 Val Leu Leu Leu Arg Leu Pro Glu Lys Val Pro Ser Ala Pro Pro Gln 340 345 350 Glu Val Thr Leu Lys Pro Gly Asn Gly Thr Val Phe Val Ser Trp Val 355 360 365 Pro Pro Pro Ala Glu Asn His Asn Gly Ile Ile Arg Gly Tyr Gln Val 370 375 380 Trp Ser Leu Gly Asn Thr Ser Leu Pro Pro Ala Asn Trp Thr Val Val 385 390 395 400 Gly Glu Gln Thr Gln Leu Glu Ile Ala Thr His Met Pro Gly Ser Tyr 405 410 415 Cys Val Gln Val Ala Ala Val Thr Gly Ala Gly Ala Gly Glu Pro Ser 420 425 430 Arg Pro Val Cys Leu Leu Leu Glu Gln Ala Met Glu Arg Ala Thr Gln 435 440 445 Glu Pro Ser Glu His Gly Pro Trp Thr Leu Glu Gln Leu Arg Ala Thr 450 455 460 Leu Lys Arg Pro Glu Val Ile Ala Thr Cys Gly Val Ala Leu Trp Leu 465 470 475 480 Leu Leu Leu Gly Thr Ala Val Cys Ile His Arg Arg Arg Arg Ala Arg 485 490 495 Val His Leu Gly Pro Gly Leu Tyr Arg Tyr Thr Ser Glu Asp Ala Ile 500 505 510 Leu Lys His Arg Met Asp His Ser Asp Ser Gln Trp Leu Ala Asp Thr 515 520 525 Trp Arg Ser Thr Ser Gly Ser Arg Asp Leu Ser Ser Ser Ser Ser Leu 530 535 540 Ser Ser Arg Leu Gly Ala Asp Ala Arg Asp Pro Leu Asp Cys Arg Arg 545 550 555 560 Ser Leu Leu Ser Trp Asp Ser Arg Ser Pro Gly Val Pro Leu Leu Pro 565 570 575 Asp Thr Ser Thr Phe Tyr Gly Ser Leu Ile Ala Glu Leu Pro Ser Ser 580 585 590 Thr Pro Ala Arg Pro Ser Pro Gln Val Pro Ala Val Arg Arg Leu Pro 595 600 605 Pro Gln Leu Ala Gln Leu Ser Ser Pro Cys Ser Ser Ser Asp Ser Leu 610 615 620 Cys Ser Arg Arg Gly Leu Ser Ser Pro Arg Leu Ser Leu Ala Pro Ala 625 630 635 640 Glu Ala Trp Lys Ala Lys Lys Lys Gln Glu Leu Pro His Ala Asn Ser 645 650 655 Ser Pro Leu Leu Arg Gly Ser His Ser Leu Glu Leu Arg Ala Cys Glu 660 665 670 Leu Gly Asn Arg Gly Ser Lys Asn Leu Ser Gln Ser Pro Gly Ala Val 675 680 685 Pro Gln Ala Leu Val Ala Trp Arg Ala Leu Gly Pro Lys Leu Leu Ser 690 695 700 Ser Gln Met Ser Trp Leu Leu Val Ile Ser Leu Gln His Pro Ser Phe 705 710 715 720 Leu Met Lys Leu Pro Gln Leu Arg Val Asn Arg Pro Ser Leu Arg Trp 725 730 735 His His Arg Leu Pro Pro Pro Ser Cys Cys Gln Gln Pro Pro Ser Pro 740 745 750 Ser Leu Ala Pro Ala Val Pro Leu Ala Pro Arg Pro Leu Pro Ser Leu 755 760 765 Ala Pro Ala Gln Leu Pro Val Ala Cys Pro Ala Pro His Cys His Pro 770 775 780 Trp Gly Arg Ile Lys Thr Ala Cys 785 790 23 1605 DNA Homo sapiens 23 agcattagtt tttgtttttt atctgacagg tagctatgga tattctgagg gagaagccag 60 gattaataca catttttttt ttaagttgct gaattgtagt ggctctcctt tctagcattt 120 ttgtcactat tgagccctct tagtttatgc tagacgtgtt tttcttattg gttgatattt 180 taaattatta aagccatctt ctgaataagc tttattcgca ctttgtacct agtttctcca 240 tcagaaggat ctattgctat accattgtat acattttctc attggtcttc gggttacttt 300 cagagtgtaa agactcctta tgccacaaaa ttaagcttag atttccccca aatcaaatac 360 tataaatcag attccttagt ctagccacaa ttgacatatc ttggagtgga taaatctttg 420 ttgctggcat tgttctgtgc atcataactt gtttagtggc atgtcatcac tgtcttctac 480 tctctagatg ccattagtat actcttcaca gttaggacaa ccaaaagtgt ctccagatat 540 tgccaaatgt ctcctgatgg gcaaagtcta tcccagttgc gaaccattat tgtaaattaa 600 acttggtttc aaatttgagc tttattcctt agctctggga acttgggcaa gttacttccc 660 ttcgagcctc aatgtcctca tttgtaaaat gacattaata cctactttta gctgtgggaa 720 ttgagtacca tgatttatac aaagcagttt gtatggtgct ggttacatga gagttcagat 780 ggtaactagt tagtaaaaaa tctctagtgt gcttgttgat tttattttat tttagtattt 840 cttaaagatc aaatttaaca tcaatcctaa actttattta gctttttctg gcgtgtaaac 900 taacatacta agttgtgtga ctataattca tttagtgact catttttagc tatttttata 960 acacattgtg ctatgggggg ttttggaact tgctggaagc tacatcagaa actgccatag 1020 ttaattgcca tttcaagaat gttgtaaata actcaggtgg ccgtttaatt ctcaatgtaa 1080 atataattaa ctagacatct ttcctatatt tgtgtctcag ttttaaagct atttctggat 1140 gcttgagtct taccgtaatt gataacaaaa agaggttatt gagaatatct atgatttaca 1200 gagtaagtta ttctagacct caagagtgaa atgtagggga ggagacattt gtgtgttaaa 1260 ctaatggaaa tgctcattta atagatattc actgaaagta ttagttttgg tttattgtag 1320 aaaagttgag gttttatgga gatttttgta aaaaatggtt tatttcctaa ataaatatct 1380 ctttttcttt tttctcccag aaaatgttaa tctatgatcc agccaaacga atttctggca 1440 aaatggcact gaatcatcca tattttaatg atttggacaa tcagattaag aagatgtagc 1500 tttctgacaa aaagtttcca tatgttatgt caacagatag ttgtgttttt attgttaact 1560 cttgtctatt tttgtcttat atatatttct ttgttatcaa acttc 1605 24 124 DNA Homo sapiens CDS (1)...(123) 24 ata aat atc tct ttt tct ttt ttc tcc cag aaa atg tta atc tat gat 48 Ile Asn Ile Ser Phe Ser Phe Phe Ser Gln Lys Met Leu Ile Tyr Asp 1 5 10 15 cca gcc aaa cga att tct ggc aaa atg gca ctg aat cat cca tat ttt 96 Pro Ala Lys Arg Ile Ser Gly Lys Met Ala Leu Asn His Pro Tyr Phe 20 25 30 aat gat ttg gac aat cag att aag aag a 124 Asn Asp Leu Asp Asn Gln Ile Lys Lys 35 40 25 41 PRT Homo sapiens 25 Ile Asn Ile Ser Phe Ser Phe Phe Ser Gln Lys Met Leu Ile Tyr Asp 1 5 10 15 Pro Ala Lys Arg Ile Ser Gly Lys Met Ala Leu Asn His Pro Tyr Phe 20 25 30 Asn Asp Leu Asp Asn Gln Ile Lys Lys 35 40 26 30 RNA Artificial Sequence Artificially Synthesized Sequence 26 agcaucgagu cggccuuguu ggccuacugg 30 27 42 DNA Artificial Sequence Artificially Synthesized Primer Sequence 27 gcggctgaag acggcctatg tggccttttt tttttttttt tt 42 28 21 DNA Artificial Sequence Artificially Synthesized Primer Sequence 28 agcatcgagt cggccttgtt g 21 29 21 DNA Artificial Sequence Artificially Synthesized Primer Sequence 29 gcggctgaag acggcctatg t 21 30 433 PRT Homo sapiens 30 Met Glu Val Val Asp Pro Gln Gln Leu Gly Met Phe Thr Glu Gly Glu 1 5 10 15 Leu Met Ser Val Gly Met Asp Thr Phe Ile His Arg Ile Asp Ser Thr 20 25 30 Glu Val Ile Tyr Gln Pro Arg Arg Lys Arg Ala Lys Leu Ile Gly Lys 35 40 45 Tyr Leu Met Gly Asp Leu Leu Gly Glu Gly Ser Tyr Gly Lys Val Lys 50 55 60 Glu Val Leu Asp Ser Glu Thr Leu Cys Arg Arg Ala Val Lys Ile Leu 65 70 75 80 Lys Lys Lys Lys Leu Arg Arg Ile Pro Asn Gly Glu Ala Asn Val Lys 85 90 95 Lys Glu Ile Gln Leu Leu Arg Arg Leu Arg His Lys Asn Val Ile Gln 100 105 110 Leu Val Asp Val Leu Tyr Asn Glu Glu Lys Gln Lys Met Tyr Met Val 115 120 125 Met Glu Tyr Cys Val Cys Gly Met Gln Glu Met Leu Asp Ser Val Pro 130 135 140 Glu Lys Arg Phe Pro Val Cys Gln Ala His Gly Tyr Phe Cys Gln Leu 145 150 155 160 Ile Asp Gly Leu Glu Tyr Leu His Ser Gln Gly Ile Val His Lys Asp 165 170 175 Ile Lys Pro Gly Asn Leu Leu Leu Thr Thr Gly Gly Thr Leu Lys Ile 180 185 190 Ser Asp Leu Gly Val Ala Glu Ala Leu His Pro Phe Ala Ala Asp Asp 195 200 205 Thr Cys Arg Thr Ser Gln Gly Ser Pro Ala Phe Gln Pro Pro Glu Ile 210 215 220 Ala Asn Gly Leu Asp Thr Phe Ser Gly Phe Lys Val Asp Ile Trp Ser 225 230 235 240 Ala Gly Val Thr Leu Tyr Asn Ile Thr Thr Gly Leu Tyr Pro Phe Glu 245 250 255 Gly Asp Asn Ile Tyr Lys Leu Phe Glu Asn Ile Gly Lys Gly Ser Tyr 260 265 270 Ala Ile Pro Gly Asp Cys Gly Pro Pro Leu Ser Asp Leu Leu Lys Gly 275 280 285 Met Leu Glu Tyr Glu Pro Ala Lys Arg Phe Ser Ile Arg Gln Ile Arg 290 295 300 Gln His Ser Trp Phe Arg Lys Lys His Pro Pro Ala Glu Ala Pro Val 305 310 315 320 Pro Ile Pro Pro Ser Pro Asp Thr Lys Asp Arg Trp Arg Ser Met Thr 325 330 335 Val Val Pro Tyr Leu Glu Asp Leu His Gly Ala Asp Glu Asp Glu Asp 340 345 350 Leu Phe Asp Ile Glu Asp Asp Ile Ile Tyr Thr Gln Asp Phe Thr Val 355 360 365 Pro Gly Gln Val Pro Glu Glu Glu Ala Ser His Asn Gly Gln Arg Arg 370 375 380 Gly Leu Pro Lys Ala Val Cys Met Asn Gly Thr Glu Ala Ala Gln Leu 385 390 395 400 Ser Thr Lys Ser Arg Ala Glu Gly Arg Ala Pro Asn Pro Ala Arg Lys 405 410 415 Ala Cys Ser Ala Ser Ser Lys Ile Arg Arg Leu Ser Ala Cys Lys Gln 420 425 430 Gln 31 396 PRT Homo sapiens 31 Met Pro Arg Val Lys Ala Ala Gln Ala Gly Arg Gln Ser Ser Ala Lys 1 5 10 15 Arg His Leu Ala Glu Gln Phe Ala Val Gly Glu Ile Ile Thr Asp Met 20 25 30 Ala Lys Lys Glu Trp Lys Val Gly Leu Pro Ile Gly Gln Gly Gly Phe 35 40 45 Gly Cys Ile Tyr Leu Ala Asp Met Asn Ser Ser Glu Ser Val Gly Ser 50 55 60 Asp Ala Pro Cys Val Val Lys Val Glu Pro Ser Asp Asn Gly Pro Leu 65 70 75 80 Phe Thr Glu Leu Lys Phe Tyr Gln Arg Ala Ala Lys Pro Glu Gln Ile 85 90 95 Gln Lys Trp Ile Arg Thr Arg Lys Leu Lys Tyr Leu Gly Val Pro Lys 100 105 110 Tyr Trp Gly Ser Gly Leu His Asp Lys Asn Gly Lys Ser Tyr Arg Phe 115 120 125 Met Ile Met Asp Arg Phe Gly Ser Asp Leu Gln Lys Ile Tyr Glu Ala 130 135 140 Asn Ala Lys Arg Phe Ser Arg Lys Thr Val Leu Gln Leu Ser Leu Arg 145 150 155 160 Ile Leu Asp Ile Leu Glu Tyr Ile His Glu His Glu Tyr Val His Gly 165 170 175 Asp Ile Lys Ala Ser Asn Leu Leu Leu Asn Tyr Lys Asn Pro Asp Gln 180 185 190 Val Tyr Leu Val Asp Tyr Gly Leu Ala Tyr Arg Tyr Cys Pro Glu Gly 195 200 205 Val His Lys Glu Tyr Lys Glu Asp Pro Lys Arg Cys His Asp Gly Thr 210 215 220 Ile Glu Phe Thr Ser Ile Asp Ala His Asn Gly Val Ala Pro Ser Arg 225 230 235 240 Arg Gly Asp Leu Glu Ile Leu Gly Tyr Cys Met Ile Gln Trp Leu Thr 245 250 255 Gly His Leu Pro Trp Glu Asp Asn Leu Lys Asp Pro Lys Tyr Val Arg 260 265 270 Asp Ser Lys Ile Arg Tyr Arg Glu Asn Ile Ala Ser Leu Met Asp Lys 275 280 285 Cys Phe Pro Glu Lys Asn Lys Pro Gly Glu Ile Ala Lys Tyr Met Glu 290 295 300 Thr Val Lys Leu Leu Asp Tyr Thr Glu Lys Pro Leu Tyr Glu Asn Leu 305 310 315 320 Arg Asp Ile Leu Leu Gln Gly Leu Lys Ala Ile Gly Ser Lys Asp Asp 325 330 335 Gly Lys Leu Asp Leu Ser Val Val Glu Asn Gly Gly Leu Lys Ala Lys 340 345 350 Thr Ile Thr Lys Lys Arg Lys Lys Glu Ile Glu Glu Ser Lys Glu Pro 355 360 365 Gly Val Glu Asp Thr Glu Trp Ser Asn Thr Gln Thr Glu Glu Ala Ile 370 375 380 Gln Thr Arg Ser Arg Thr Arg Lys Arg Val Gln Lys 385 390 395 32 297 PRT Homo sapiens 32 Met Glu Asp Tyr Thr Lys Ile Glu Lys Ile Gly Glu Gly Thr Tyr Gly 1 5 10 15 Val Val Tyr Lys Gly Arg His Lys Thr Thr Gly Gln Val Val Ala Met 20 25 30 Lys Lys Ile Arg Leu Glu Ser Glu Glu Glu Gly Val Pro Ser Thr Ala 35 40 45 Ile Arg Glu Ile Ser Leu Leu Lys Glu Leu Arg His Pro Asn Ile Val 50 55 60 Ser Leu Gln Asp Val Leu Met Gln Asp Ser Arg Leu Tyr Leu Ile Phe 65 70 75 80 Glu Phe Leu Ser Met Asp Leu Lys Lys Tyr Leu Asp Ser Ile Pro Pro 85 90 95 Gly Gln Tyr Met Asp Ser Ser Leu Val Lys Ser Tyr Leu Tyr Gln Ile 100 105 110 Leu Gln Gly Ile Val Phe Cys His Ser Arg Arg Val Leu His Arg Asp 115 120 125 Leu Lys Pro Gln Asn Leu Leu Ile Asp Asp Lys Gly Thr Ile Lys Leu 130 135 140 Ala Asp Phe Gly Leu Ala Arg Ala Phe Gly Ile Pro Ile Arg Val Tyr 145 150 155 160 Thr His Glu Val Val Thr Leu Trp Tyr Arg Ser Pro Glu Val Leu Leu 165 170 175 Gly Ser Ala Arg Tyr Ser Thr Pro Val Asp Ile Trp Ser Ile Gly Thr 180 185 190 Ile Phe Ala Glu Leu Ala Thr Lys Lys Pro Leu Phe His Gly Asp Ser 195 200 205 Glu Ile Asp Gln Leu Phe Arg Ile Phe Arg Ala Leu Gly Thr Pro Asn 210 215 220 Asn Glu Val Trp Pro Glu Val Glu Ser Leu Gln Asp Tyr Lys Asn Thr 225 230 235 240 Phe Pro Lys Trp Lys Pro Gly Ser Leu Ala Ser His Val Lys Asn Leu 245 250 255 Asp Glu Asn Gly Leu Asp Leu Leu Ser Lys Met Leu Ile Tyr Asp Pro 260 265 270 Ala Lys Arg Ile Ser Gly Lys Met Ala Leu Asn His Pro Tyr Phe Asn 275 280 285 Asp Leu Asp Asn Gln Ile Lys Lys Met 290 295 33 403 PRT Homo sapiens 33 Met Asp Arg Ser Lys Glu Asn Cys Ile Ser Gly Pro Val Lys Ala Thr 1 5 10 15 Ala Pro Val Gly Gly Pro Lys Arg Val Leu Val Thr Gln Gln Phe Pro 20 25 30 Cys Gln Asn Pro Leu Pro Val Asn Ser Gly Gln Ala Gln Arg Val Leu 35 40 45 Cys Pro Ser Asn Ser Ser Gln Arg Ile Pro Leu Gln Ala Gln Lys Leu 50 55 60 Val Ser Ser His Lys Pro Val Gln Asn Gln Lys Gln Lys Gln Leu Gln 65 70 75 80 Ala Thr Ser Val Pro His Pro Val Ser Arg Pro Leu Asn Asn Thr Gln 85 90 95 Lys Ser Lys Gln Pro Leu Pro Ser Ala Pro Glu Asn Asn Pro Glu Glu 100 105 110 Glu Leu Ala Ser Lys Gln Lys Asn Glu Glu Ser Lys Lys Arg Gln Trp 115 120 125 Ala Leu Glu Asp Phe Glu Ile Gly Arg Pro Leu Gly Lys Gly Lys Phe 130 135 140 Gly Asn Val Tyr Leu Ala Arg Glu Lys Gln Ser Lys Phe Ile Leu Ala 145 150 155 160 Leu Lys Val Leu Phe Lys Ala Gln Leu Glu Lys Ala Gly Val Glu His 165 170 175 Gln Leu Arg Arg Glu Val Glu Ile Gln Ser His Leu Arg His Pro Asn 180 185 190 Ile Leu Arg Leu Tyr Gly Tyr Phe His Asp Ala Thr Arg Val Tyr Leu 195 200 205 Ile Leu Glu Tyr Ala Pro Leu Gly Thr Val Tyr Arg Glu Leu Gln Lys 210 215 220 Leu Ser Lys Phe Asp Glu Gln Arg Thr Ala Thr Tyr Ile Thr Glu Leu 225 230 235 240 Ala Asn Ala Leu Ser Tyr Cys His Ser Lys Arg Val Ile His Arg Asp 245 250 255 Ile Lys Pro Glu Asn Leu Leu Leu Gly Ser Ala Gly Glu Leu Lys Ile 260 265 270 Ala Asp Phe Gly Trp Ser Val His Ala Pro Ser Ser Arg Arg Thr Thr 275 280 285 Leu Cys Gly Thr Leu Asp Tyr Leu Pro Pro Glu Met Ile Glu Gly Arg 290 295 300 Met His Asp Glu Lys Val Asp Leu Trp Ser Leu Gly Val Leu Cys Tyr 305 310 315 320 Glu Phe Leu Val Gly Lys Pro Pro Phe Glu Ala Asn Thr Tyr Gln Glu 325 330 335 Thr Tyr Lys Arg Ile Ser Arg Val Glu Phe Thr Phe Pro Asp Phe Val 340 345 350 Thr Glu Gly Ala Arg Asp Leu Ile Ser Arg Leu Leu Lys His Asn Pro 355 360 365 Ser Gln Arg Pro Met Leu Arg Glu Val Leu Glu His Pro Trp Ile Thr 370 375 380 Ala Asn Ser Ser Lys Pro Ser Asn Cys Gln Asn Lys Glu Ser Ala Ser 385 390 395 400 Lys Gln Ser 34 344 PRT Homo sapiens 34 Met Ala Gln Lys Glu Asn Ser Tyr Pro Trp Pro Tyr Gly Arg Gln Thr 1 5 10 15 Ala Pro Ser Gly Leu Ser Thr Leu Pro Gln Arg Val Leu Arg Lys Glu 20 25 30 Pro Val Thr Pro Ser Ala Leu Val Leu Met Ser Arg Ser Asn Val Gln 35 40 45 Pro Thr Ala Ala Pro Gly Gln Lys Val Met Glu Asn Ser Ser Gly Thr 50 55 60 Pro Asp Ile Leu Thr Arg His Phe Thr Ile Asp Asp Phe Glu Ile Gly 65 70 75 80 Arg Pro Leu Gly Lys Gly Lys Phe Gly Asn Val Tyr Leu Ala Arg Glu 85 90 95 Lys Lys Ser His Phe Ile Val Ala Leu Lys Val Leu Phe Lys Ser Gln 100 105 110 Ile Glu Lys Glu Gly Val Glu His Gln Leu Arg Arg Glu Ile Glu Ile 115 120 125 Gln Ala His Leu His His Pro Asn Ile Leu Arg Leu Tyr Asn Tyr Phe 130 135 140 Tyr Asp Arg Arg Arg Ile Tyr Leu Ile Leu Glu Tyr Ala Pro Arg Gly 145 150 155 160 Glu Leu Tyr Lys Glu Leu Gln Lys Ser Cys Thr Phe Asp Glu Gln Arg 165 170 175 Thr Ala Thr Ile Met Glu Glu Leu Ala Asp Ala Leu Met Tyr Cys His 180 185 190 Gly Lys Lys Val Ile His Arg Asp Ile Lys Pro Glu Asn Leu Leu Leu 195 200 205 Gly Leu Lys Gly Glu Leu Lys Ile Ala Asp Phe Gly Trp Ser Val His 210 215 220 Ala Pro Ser Leu Arg Arg Lys Thr Met Cys Gly Thr Leu Asp Tyr Leu 225 230 235 240 Pro Pro Glu Met Ile Glu Gly Arg Met His Asn Glu Lys Val Asp Leu 245 250 255 Trp Cys Ile Gly Val Leu Cys Tyr Glu Leu Leu Val Gly Asn Pro Pro 260 265 270 Phe Glu Ser Ala Ser His Asn Glu Thr Tyr Arg Arg Ile Val Lys Val 275 280 285 Asp Leu Lys Phe Pro Ala Ser Val Pro Thr Gly Ala Gln Asp Leu Ile 290 295 300 Ser Lys Leu Leu Arg His Asn Pro Ser Glu Arg Leu Pro Leu Ala Gln 305 310 315 320 Val Ser Ala His Pro Trp Val Arg Ala Asn Ser Arg Arg Val Leu Pro 325 330 335 Pro Ser Ala Leu Gln Ser Val Ala 340 35 745 PRT Homo sapiens 35 Met Glu Arg Pro Pro Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu 1 5 10 15 Met Arg Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Cys Leu Tyr 20 25 30 Gln His Arg Glu Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg Leu 35 40 45 Glu Leu Ser Thr Lys Asn Arg Glu Arg Trp Cys His Glu Ile Gln Ile 50 55 60 Met Lys Lys Leu Asn His Ala Asn Val Val Lys Ala Cys Asp Val Pro 65 70 75 80 Glu Glu Leu Asn Ile Leu Ile His Asp Val Pro Leu Leu Ala Met Glu 85 90 95 Tyr Cys Ser Gly Gly Asp Leu Arg Lys Leu Leu Asn Lys Pro Glu Asn 100 105 110 Cys Cys Gly Leu Lys Glu Ser Gln Ile Leu Ser Leu Leu Ser Asp Ile 115 120 125 Gly Ser Gly Ile Arg Tyr Leu His Glu Asn Lys Ile Ile His Arg Asp 130 135 140 Leu Lys Pro Glu Asn Ile Val Leu Gln Asp Val Gly Gly Lys Ile Ile 145 150 155 160 His Lys Ile Ile Asp Leu Gly Tyr Ala Lys Asp Val Asp Gln Gly Ser 165 170 175 Leu Cys Thr Ser Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu Leu 180 185 190 Phe Glu Asn Lys Pro Tyr Thr Ala Thr Val Asp Tyr Trp Ser Phe Gly 195 200 205 Thr Met Val Phe Glu Cys Ile Ala Gly Tyr Arg Pro Phe Leu His His 210 215 220 Leu Gln Pro Phe Thr Trp His Glu Lys Ile Lys Lys Lys Asp Pro Lys 225 230 235 240 Cys Ile Phe Ala Cys Glu Glu Met Ser Gly Glu Val Arg Phe Ser Ser 245 250 255 His Leu Pro Gln Pro Asn Ser Leu Cys Ser Leu Ile Val Glu Pro Met 260 265 270 Glu Asn Trp Leu Gln Leu Met Leu Asn Trp Asp Pro Gln Gln Arg Gly 275 280 285 Gly Pro Val Asp Leu Thr Leu Lys Gln Pro Arg Cys Phe Val Leu Met 290 295 300 Asp His Ile Leu Asn Leu Lys Ile Val His Ile Leu Asn Met Thr Ser 305 310 315 320 Ala Lys Ile Ile Ser Phe Leu Leu Pro Pro Asp Glu Ser Leu His Ser 325 330 335 Leu Gln Ser Arg Ile Glu Arg Glu Thr Gly Ile Asn Thr Gly Ser Gln 340 345 350 Glu Leu Leu Ser Glu Thr Gly Ile Ser Leu Asp Pro Arg Lys Pro Ala 355 360 365 Ser Gln Cys Val Leu Asp Gly Val Arg Gly Cys Asp Ser Tyr Met Val 370 375 380 Tyr Leu Phe Asp Lys Ser Lys Thr Val Tyr Glu Gly Pro Phe Ala Ser 385 390 395 400 Arg Ser Leu Ser Asp Cys Val Asn Tyr Ile Val Gln Asp Ser Lys Ile 405 410 415 Gln Leu Pro Ile Ile Gln Leu Arg Lys Val Trp Ala Glu Ala Val His 420 425 430 Tyr Val Ser Gly Leu Lys Glu Asp Tyr Ser Arg Leu Phe Gln Gly Gln 435 440 445 Arg Ala Ala Met Leu Ser Leu Leu Arg Tyr Asn Ala Asn Leu Thr Lys 450 455 460 Met Lys Asn Thr Leu Ile Ser Ala Ser Gln Gln Leu Lys Ala Lys Leu 465 470 475 480 Glu Phe Phe His Lys Ser Ile Gln Leu Asp Leu Glu Arg Tyr Ser Glu 485 490 495 Gln Met Thr Tyr Gly Ile Ser Ser Glu Lys Met Leu Lys Ala Trp Lys 500 505 510 Glu Met Glu Glu Lys Ala Ile His Tyr Ala Glu Val Gly Val Ile Gly 515 520 525 Tyr Leu Glu Asp Gln Ile Met Ser Leu His Ala Glu Ile Met Glu Leu 530 535 540 Gln Lys Ser Pro Tyr Gly Arg Arg Gln Gly Asp Leu Met Glu Ser Leu 545 550 555 560 Glu Gln Arg Ala Ile Asp Leu Tyr Lys Gln Leu Lys His Arg Pro Ser 565 570 575 Asp His Ser Tyr Ser Asp Ser Thr Glu Met Val Lys Ile Ile Val His 580 585 590 Thr Val Gln Ser Gln Asp Arg Val Leu Lys Glu Leu Phe Gly His Leu 595 600 605 Ser Lys Leu Leu Gly Cys Lys Gln Lys Ile Ile Asp Leu Leu Pro Lys 610 615 620 Val Glu Val Ala Leu Ser Asn Ile Lys Glu Ala Asp Asn Thr Val Met 625 630 635 640 Phe Met Gln Gly Lys Arg Gln Lys Glu Ile Trp His Leu Leu Lys Ile 645 650 655 Ala Cys Thr Gln Ser Ser Ala Arg Ser Leu Val Gly Ser Ser Leu Glu 660 665 670 Gly Ala Val Thr Pro Gln Thr Ser Ala Trp Leu Pro Pro Thr Ser Ala 675 680 685 Glu His Asp His Ser Leu Ser Cys Val Val Thr Pro Gln Asp Gly Glu 690 695 700 Thr Ser Ala Gln Met Ile Glu Glu Asn Leu Asn Cys Leu Gly His Leu 705 710 715 720 Ser Thr Ile Ile His Glu Ala Asn Glu Glu Gln Gly Asn Ser Met Met 725 730 735 Asn Leu Asp Trp Ser Trp Leu Thr Glu 740 745 36 318 PRT Homo sapiens 36 Met Ser Lys Pro Pro Ala Pro Asn Pro Thr Pro Pro Arg Asn Leu Asp 1 5 10 15 Ser Arg Thr Phe Ile Thr Ile Gly Asp Arg Asn Phe Glu Val Glu Ala 20 25 30 Asp Asp Leu Val Thr Ile Ser Glu Leu Gly Arg Gly Ala Tyr Gly Val 35 40 45 Val Glu Lys Val Arg His Ala Gln Ser Gly Thr Ile Met Ala Val Lys 50 55 60 Arg Ile Arg Ala Thr Val Asn Ser Gln Glu Gln Lys Arg Leu Leu Met 65 70 75 80 Asp Leu Asp Ile Asn Met Arg Thr Val Asp Cys Phe Tyr Thr Val Thr 85 90 95 Phe Tyr Gly Ala Leu Phe Arg Glu Gly Asp Val Trp Ile Cys Met Glu 100 105 110 Leu Met Asp Thr Ser Leu Asp Lys Phe Tyr Arg Lys Val Leu Asp Lys 115 120 125 Asn Met Thr Ile Pro Glu Asp Ile Leu Gly Glu Ile Ala Val Ser Ile 130 135 140 Val Arg Ala Leu Glu His Leu His Ser Lys Leu Ser Val Ile His Arg 145 150 155 160 Asp Val Lys Pro Ser Asn Val Leu Ile Asn Lys Glu Gly His Val Lys 165 170 175 Met Cys Asp Phe Gly Ile Ser Gly Tyr Leu Val Asp Ser Val Ala Lys 180 185 190 Thr Met Asp Ala Gly Cys Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn 195 200 205 Pro Glu Leu Asn Gln Lys Gly Tyr Asn Val Lys Ser Asp Val Trp Ser 210 215 220 Leu Gly Ile Thr Met Ile Glu Met Ala Ile Leu Arg Phe Pro Tyr Glu 225 230 235 240 Ser Trp Gly Thr Pro Phe Gln Gln Leu Lys Gln Val Val Glu Glu Pro 245 250 255 Ser Pro Gln Leu Pro Ala Asp Arg Phe Ser Pro Glu Phe Val Asp Phe 260 265 270 Thr Ala Gln Cys Leu Arg Lys Asn Pro Ala Glu Arg Met Ser Tyr Leu 275 280 285 Glu Leu Met Glu His Pro Phe Phe Thr Leu His Lys Thr Lys Lys Thr 290 295 300 Asp Ile Ala Ala Phe Val Lys Lys Ile Leu Gly Glu Asp Ser 305 310 315 37 379 PRT Homo sapiens 37 Met Ala Ala Ala Ala Ala Gln Gly Gly Gly Gly Gly Glu Pro Arg Arg 1 5 10 15 Thr Glu Gly Val Gly Pro Gly Val Pro Gly Glu Val Glu Met Val Lys 20 25 30 Gly Gln Pro Phe Asp Val Gly Pro Arg Tyr Thr Gln Leu Gln Tyr Ile 35 40 45 Gly Glu Gly Ala Tyr Gly Met Val Ser Ser Ala Tyr Asp His Val Arg 50 55 60 Lys Thr Arg Val Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln Thr 65 70 75 80 Tyr Cys Gln Arg Thr Leu Arg Glu Ile Gln Ile Leu Leu Arg Phe Arg 85 90 95 His Glu Asn Val Ile Gly Ile Arg Asp Ile Leu Arg Ala Ser Thr Leu 100 105 110 Glu Ala Met Arg Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp 115 120 125 Leu Tyr Lys Leu Leu Lys Ser Gln Gln Leu Ser Asn Asp His Ile Cys 130 135 140 Tyr Phe Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala 145 150 155 160 Asn Val Leu His Arg Asp Leu Lys Pro Ser Asn Leu Leu Ser Asn Thr 165 170 175 Thr Cys Asp Leu Lys Ile Cys Asp Phe Gly Leu Ala Arg Ile Ala Asp 180 185 190 Pro Glu His Asp His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg 195 200 205 Trp Tyr Arg Ala Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr Lys 210 215 220 Ser Ile Asp Ile Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu Ser 225 230 235 240 Asn Arg Pro Ile Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His 245 250 255 Ile Leu Gly Ile Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile 260 265 270 Ile Asn Met Lys Ala Arg Asn Tyr Leu Gln Ser Leu Pro Ser Lys Thr 275 280 285 Lys Val Ala Trp Ala Lys Leu Phe Pro Lys Ser Asp Ser Lys Ala Leu 290 295 300 Asp Leu Leu Asp Arg Met Leu Thr Phe Asn Pro Asn Lys Arg Ile Thr 305 310 315 320 Val Glu Glu Ala Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp Pro 325 330 335 Thr Asp Glu Pro Val Ala Glu Glu Pro Phe Thr Phe Ala Met Glu Leu 340 345 350 Asp Asp Leu Pro Lys Glu Arg Leu Lys Glu Leu Ile Phe Gln Glu Thr 355 360 365 Ala Arg Phe Gln Pro Gly Val Leu Glu Ala Pro 370 375 38 648 PRT Homo sapiens 38 Met Glu His Ile Gln Gly Ala Trp Lys Thr Ile Ser Asn Gly Phe Gly 1 5 10 15 Phe Lys Asp Ala Val Phe Asp Gly Ser Ser Cys Ile Ser Pro Thr Ile 20 25 30 Val Gln Gln Phe Gly Tyr Gln Arg Arg Ala Ser Asp Asp Gly Lys Leu 35 40 45 Thr Asp Pro Ser Lys Thr Ser Asn Thr Ile Arg Val Phe Leu Pro Asn 50 55 60 Lys Gln Arg Thr Val Val Asn Val Arg Asn Gly Met Ser Leu His Asp 65 70 75 80 Cys Leu Met Lys Ala Leu Lys Val Arg Gly Leu Gln Pro Glu Cys Cys 85 90 95 Ala Val Phe Arg Leu Leu His Glu His Lys Gly Lys Lys Ala Arg Leu 100 105 110 Asp Trp Asn Thr Asp Ala Ala Ser Leu Ile Gly Glu Glu Leu Gln Val 115 120 125 Asp Phe Leu Asp His Val Pro Leu Thr Thr His Asn Phe Ala Arg Lys 130 135 140 Thr Phe Leu Lys Leu Ala Phe Cys Asp Ile Cys Gln Lys Phe Leu Leu 145 150 155 160 Asn Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Glu His Cys 165 170 175 Ser Thr Lys Val Pro Thr Met Cys Val Asp Trp Ser Asn Ile Arg Gln 180 185 190 Leu Leu Leu Phe Pro Asn Ser Thr Ile Gly Asp Ser Gly Val Pro Ala 195 200 205 Leu Pro Ser Leu Thr Met Arg Arg Met Arg Glu Ser Val Ser Arg Met 210 215 220 Pro Val Ser Ser Gln His Arg Tyr Ser Thr Pro His Ala Phe Thr Phe 225 230 235 240 Asn Thr Ser Ser Pro Ser Ser Glu Gly Ser Leu Ser Gln Arg Gln Arg 245 250 255 Ser Thr Ser Thr Pro Asn Val His Met Val Ser Thr Thr Leu Pro Val 260 265 270 Asp Ser Arg Met Ile Glu Asp Ala Ile Arg Ser His Ser Glu Ser Ala 275 280 285 Ser Pro Ser Ala Leu Ser Ser Ser Pro Asn Asn Leu Ser Pro Thr Gly 290 295 300 Trp Ser Gln Pro Lys Thr Pro Val Pro Ala Gln Arg Glu Arg Ala Pro 305 310 315 320 Val Ser Gly Thr Gln Glu Lys Asn Lys Ile Arg Pro Arg Gly Gln Arg 325 330 335 Asp Ser Ser Tyr Tyr Trp Glu Ile Glu Ala Ser Glu Val Met Leu Ser 340 345 350 Thr Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp 355 360 365 His Gly Asp Val Ala Val Lys Ile Leu Lys Val Val Asp Pro Thr Pro 370 375 380 Glu Gln Phe Gln Ala Phe Arg Asn Glu Val Ala Val Leu Arg Lys Thr 385 390 395 400 Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Met Thr Lys Asp Asn 405 410 415 Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr Lys His 420 425 430 Leu His Val Gln Glu Thr Lys Phe Gln Met Phe Gln Leu Ile Asp Ile 435 440 445 Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Asn Ile 450 455 460 Ile His Arg Asp Met Lys Ser Asn Asn Ile Phe Leu His Glu Gly Leu 465 470 475 480 Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp 485 490 495 Ser Gly Ser Gln Gln Val Glu Gln Pro Thr Gly Ser Val Leu Trp Met 500 505 510 Ala Pro Glu Val Ile Arg Met Gln Asp Asn Asn Pro Phe Ser Phe Gln 515 520 525 Ser Asp Val Tyr Ser Tyr Gly Ile Val Leu Tyr Glu Leu Met Thr Gly 530 535 540 Glu Leu Pro Tyr Ser His Ile Asn Asn Arg Asp Gln Ile Ile Phe Met 545 550 555 560 Val Gly Arg Gly Tyr Ala Ser Pro Asp Leu Ser Lys Leu Tyr Lys Asn 565 570 575 Cys Pro Lys Ala Met Lys Arg Leu Val Ala Asp Cys Val Lys Lys Val 580 585 590 Lys Glu Glu Arg Pro Leu Phe Pro Gln Ile Leu Ser Ser Ile Glu Leu 595 600 605 Leu Gln His Ser Leu Pro Lys Ile Asn Arg Ser Ala Ser Glu Pro Ser 610 615 620 Leu His Arg Ala Ala His Thr Glu Asp Ile Asn Ala Cys Thr Leu Thr 625 630 635 640 Thr Ser Pro Arg Leu Pro Val Phe 645 39 480 PRT Homo sapiens 39 Met Ser Asp Val Ala Ile Val Lys Glu Gly Trp Leu His Lys Arg Gly 1 5 10 15 Glu Tyr Ile Lys Thr Trp Arg Pro Arg Tyr Phe Leu Leu Lys Asn Asp 20 25 30 Gly Thr Phe Ile Gly Tyr Lys Glu Arg Pro Gln Asp Val Asp Gln Arg 35 40 45 Glu Ala Pro Leu Asn Asn Phe Ser Val Ala Gln Cys Gln Leu Met Lys 50 55 60 Thr Glu Arg Pro Arg Pro Asn Thr Phe Ile Ile Arg Cys Leu Gln Trp 65 70 75 80 Thr Thr Val Ile Glu Arg Thr Phe His Val Glu Thr Pro Glu Glu Arg 85 90 95 Glu Glu Trp Thr Thr Ala Ile Gln Thr Val Ala Asp Gly Leu Lys Lys 100 105 110 Gln Glu Glu Glu Glu Met Asp Phe Arg Ser Gly Ser Pro Ser Asp Asn 115 120 125 Ser Gly Ala Glu Glu Met Glu Val Ser Leu Ala Lys Pro Lys His Arg 130 135 140 Val Thr Met Asn Glu Phe Glu Tyr Leu Lys Leu Leu Gly Lys Gly Thr 145 150 155 160 Phe Gly Lys Val Ile Leu Val Lys Glu Lys Ala Thr Gly Arg Tyr Tyr 165 170 175 Ala Met Lys Ile Leu Lys Lys Glu Val Ile Val Ala Lys Asp Glu Val 180 185 190 Ala His Thr Leu Thr Glu Asn Arg Val Leu Gln Asn Ser Arg His Pro 195 200 205 Phe Leu Thr Ala Leu Lys Tyr Ser Phe Gln Thr His Asp Arg Leu Cys 210 215 220 Phe Val Met Glu Tyr Ala Asn Gly Gly Glu Leu Phe Phe His Leu Ser 225 230 235 240 Arg Glu Arg Val Phe Ser Glu Asp Arg Ala Arg Phe Tyr Gly Ala Glu 245 250 255 Ile Val Ser Ala Leu Asp Tyr Leu His Ser Glu Lys Asn Val Val Tyr 260 265 270 Arg Asp Leu Lys Leu Glu Asn Leu Met Leu Asp Lys Asp Gly His Ile 275 280 285 Lys Ile Thr Asp Phe Gly Leu Cys Lys Glu Gly Ile Lys Asp Gly Ala 290 295 300 Thr Met Lys Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val 305 310 315 320 Leu Glu Asp Asn Asp Tyr Gly Arg Ala Val Asp Trp Trp Gly Leu Gly 325 330 335 Val Val Met Tyr Glu Met Met Cys Gly Arg Leu Pro Phe Tyr Asn Gln 340 345 350 Asp His Glu Lys Leu Phe Glu Leu Ile Leu Met Glu Glu Ile Arg Phe 355 360 365 Pro Arg Thr Leu Gly Pro Glu Ala Lys Ser Leu Leu Ser Gly Leu Leu 370 375 380 Lys Lys Asp Pro Lys Gln Arg Leu Gly Gly Gly Ser Glu Asp Ala Lys 385 390 395 400 Glu Ile Met Gln His Arg Phe Phe Ala Gly Ile Val Trp Gln His Val 405 410 415 Tyr Glu Lys Lys Leu Ser Pro Pro Phe Lys Pro Gln Val Thr Ser Glu 420 425 430 Thr Asp Thr Arg Tyr Phe Asp Glu Glu Phe Thr Ala Gln Met Ile Thr 435 440 445 Ile Thr Pro Pro Asp Gln Asp Asp Ser Met Glu Cys Val Asp Ser Glu 450 455 460 Arg Arg Pro His Phe Pro Gln Phe Ser Tyr Ser Ala Ser Ser Thr Ala 465 470 475 480 40 724 PRT Homo sapiens 40 Met Ser Ala Glu Gly Tyr Gln Tyr Arg Ala Leu Tyr Asp Tyr Lys Lys 1 5 10 15 Glu Arg Glu Glu Asp Ile Asp Leu His Leu Gly Asp Ile Leu Thr Val 20 25 30 Asn Lys Gly Ser Leu Val Ala Leu Gly Phe Ser Asp Gly Gln Glu Ala 35 40 45 Arg Pro Glu Glu Ile Gly Trp Leu Asn Gly Tyr Asn Glu Thr Thr Gly 50 55 60 Glu Arg Gly Asp Phe Pro Gly Thr Tyr Val Glu Tyr Ile Gly Arg Lys 65 70 75 80 Lys Ile Ser Pro Pro Thr Pro Lys Pro Arg Pro Pro Arg Pro Leu Pro 85 90 95 Val Ala Pro Gly Ser Ser Lys Thr Glu Ala Asp Val Glu Gln Gln Ala 100 105 110 Leu Thr Leu Pro Asp Leu Ala Glu Gln Phe Ala Pro Pro Asp Ile Ala 115 120 125 Pro Pro Leu Leu Ile Lys Leu Val Glu Ala Ile Glu Lys Lys Gly Leu 130 135 140 Glu Cys Ser Thr Leu Tyr Arg Thr Gln Ser Ser Ser Asn Leu Ala Glu 145 150 155 160 Leu Arg Gln Leu Leu Asp Cys Asp Thr Pro Ser Val Asp Leu Glu Met 165 170 175 Ile Asp Val His Val Leu Ala Asp Ala Phe Lys Arg Tyr Leu Leu Asp 180 185 190 Leu Pro Asn Pro Val Ile Pro Ala Ala Val Tyr Ser Glu Met Ile Ser 195 200 205 Leu Ala Pro Glu Val Gln Ser Ser Glu Glu Tyr Ile Gln Leu Leu Lys 210 215 220 Lys Leu Ile Arg Ser Pro Ser Ile Pro His Gln Tyr Trp Leu Thr Leu 225 230 235 240 Gln Tyr Leu Leu Lys His Phe Phe Lys Leu Ser Gln Thr Ser Ser Lys 245 250 255 Asn Leu Leu Asn Ala Arg Val Leu Ser Glu Ile Phe Ser Pro Met Leu 260 265 270 Phe Arg Phe Ser Ala Ala Ser Ser Asp Asn Thr Glu Asn Leu Ile Lys 275 280 285 Val Ile Glu Ile Leu Ile Ser Thr Glu Trp Asn Glu Arg Gln Pro Ala 290 295 300 Pro Ala Leu Pro Pro Lys Pro Pro Lys Pro Thr Thr Val Ala Asn Asn 305 310 315 320 Gly Met Asn Asn Asn Met Ser Leu Gln Asn Ala Glu Trp Tyr Trp Gly 325 330 335 Asp Ile Ser Arg Glu Glu Val Asn Glu Lys Leu Arg Asp Thr Ala Asp 340 345 350 Gly Thr Phe Leu Val Arg Asp Ala Ser Thr Lys Met His Gly Asp Tyr 355 360 365 Thr Leu Thr Leu Arg Lys Gly Gly Asn Asn Lys Leu Ile Lys Ile Phe 370 375 380 His Arg Asp Gly Lys Tyr Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser 385 390 395 400 Val Val Glu Leu Ile Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr 405 410 415 Asn Pro Lys Leu Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln 420 425 430 Gln Asp Gln Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys 435 440 445 Leu His Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp 450 455 460 Arg Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys 465 470 475 480 Arg Thr Ala Ile Glu Ala Phe Asn Glu Thr Ile Lys Ile Phe Glu Glu 485 490 495 Gln Cys Gln Thr Gln Glu Arg Tyr Ser Lys Glu Tyr Ile Glu Lys Phe 500 505 510 Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met His Asn Tyr 515 520 525 Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp Ser Arg Arg Arg 530 535 540 Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu Tyr Arg Glu Ile Asp 545 550 555 560 Lys Arg Met Asn Ser Ile Lys Pro Asp Leu Ile Gln Leu Arg Lys Thr 565 570 575 Arg Asp Gln Tyr Leu Met Trp Leu Thr Gln Lys Gly Val Arg Gln Lys 580 585 590 Lys Leu Asn Glu Trp Leu Gly Asn Glu Asn Thr Glu Asp Gln Tyr Ser 595 600 605 Leu Val Glu Asp Asp Glu Asp Leu Pro His His Asp Glu Lys Thr Trp 610 615 620 Asn Val Gly Ser Ser Asn Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly 625 630 635 640 Lys Arg Asp Gly Thr Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys 645 650 655 Tyr Ala Cys Ser Val Val Val Asp Gly Glu Val Lys His Cys Val Ile 660 665 670 Asn Lys Thr Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr 675 680 685 Ser Ser Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val 690 695 700 Gln His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala 705 710 715 720 Gln Gln Arg Arg 41 3056 PRT Homo sapiens 41 Met Ser Leu Val Leu Asn Asp Leu Leu Ile Cys Cys Arg Gln Leu Glu 1 5 10 15 His Asp Arg Ala Thr Glu Arg Lys Lys Glu Val Glu Lys Phe Lys Arg 20 25 30 Leu Ile Arg Asp Pro Glu Thr Ile Lys His Leu Asp Arg His Ser Asp 35 40 45 Ser Lys Gln Gly Lys Tyr Leu Asn Trp Asp Ala Val Phe Arg Phe Leu 50 55 60 Gln Lys Tyr Ile Gln Lys Glu Thr Glu Cys Leu Arg Ile Ala Lys Pro 65 70 75 80 Asn Val Ser Ala Ser Thr Gln Ala Ser Arg Gln Lys Lys Met Gln Glu 85 90 95 Ile Ser Ser Leu Val Lys Tyr Phe Ile Lys Cys Ala Asn Arg Arg Ala 100 105 110 Pro Arg Leu Lys Cys Gln Glu Leu Leu Asn Tyr Ile Met Asp Thr Val 115 120 125 Lys Asp Ser Ser Asn Gly Ala Ile Tyr Gly Ala Asp Cys Ser Asn Ile 130 135 140 Leu Leu Lys Asp Ile Leu Ser Val Arg Lys Tyr Trp Cys Glu Ile Ser 145 150 155 160 Gln Gln Gln Trp Leu Glu Leu Phe Ser Val Tyr Phe Arg Leu Tyr Leu 165 170 175 Lys Pro Ser Gln Asp Val His Arg Val Leu Val Ala Arg Ile Ile His 180 185 190 Ala Val Thr Lys Gly Cys Cys Ser Gln Thr Asp Gly Leu Asn Ser Lys 195 200 205 Phe Leu Asp Phe Phe Ser Lys Ala Ile Gln Cys Ala Arg Gln Glu Lys 210 215 220 Ser Ser Ser Gly Leu Asn His Ile Leu Ala Ala Leu Thr Ile Phe Leu 225 230 235 240 Lys Thr Leu Ala Val Asn Phe Arg Ile Arg Val Cys Glu Leu Gly Asp 245 250 255 Glu Ile Leu Pro Thr Leu Leu Tyr Ile Trp Thr Gln His Arg Leu Asn 260 265 270 Asp Ser Leu Lys Glu Val Ile Ile Glu Leu Phe Gln Leu Gln Ile Tyr 275 280 285 Ile His His Pro Lys Gly Ala Lys Thr Gln Glu Lys Gly Ala Tyr Glu 290 295 300 Ser Thr Lys Trp Arg Ser Ile Leu Tyr Asn Leu Tyr Asp Leu Leu Val 305 310 315 320 Asn Glu Ile Ser His Ile Gly Ser Arg Gly Lys Tyr Ser Ser Gly Phe 325 330 335 Arg Asn Ile Ala Val Lys Glu Asn Leu Ile Glu Leu Met Ala Asp Ile 340 345 350 Cys His Gln Val Phe Asn Glu Asp Thr Arg Ser Leu Glu Ile Ser Gln 355 360 365 Ser Tyr Thr Thr Thr Gln Arg Glu Ser Ser Asp Tyr Ser Val Pro Cys 370 375 380 Lys Arg Lys Lys Ile Glu Leu Gly Trp Glu Val Ile Lys Asp His Leu 385 390 395 400 Gln Lys Ser Gln Asn Asp Phe Asp Leu Val Pro Trp Leu Gln Ile Ala 405 410 415 Thr Gln Leu Ile Ser Lys Tyr Pro Ala Ser Leu Pro Asn Cys Glu Leu 420 425 430 Ser Pro Leu Leu Met Ile Leu Ser Gln Leu Leu Pro Gln Gln Arg His 435 440 445 Gly Glu Arg Thr Pro Tyr Val Leu Arg Cys Leu Thr Glu Val Ala Leu 450 455 460 Cys Gln Asp Lys Arg Ser Asn Leu Glu Ser Ser Gln Lys Ser Asp Leu 465 470 475 480 Leu Lys Leu Trp Asn Lys Ile Trp Cys Ile Thr Phe Arg Gly Ile Ser 485 490 495 Ser Glu Gln Ile Gln Ala Glu Asn Phe Gly Leu Leu Gly Ala Ile Ile 500 505 510 Gln Gly Ser Leu Val Glu Val Asp Arg Glu Phe Trp Lys Leu Phe Thr 515 520 525 Gly Ser Ala Cys Arg Pro Ser Cys Pro Ala Val Cys Cys Leu Thr Leu 530 535 540 Ala Leu Thr Thr Ser Ile Val Pro Gly Ala Val Lys Met Gly Ile Glu 545 550 555 560 Gln Asn Met Cys Glu Val Asn Arg Ser Phe Ser Leu Lys Glu Ser Ile 565 570 575 Met Lys Trp Leu Leu Phe Tyr Gln Leu Glu Gly Asp Leu Glu Asn Ser 580 585 590 Thr Glu Val Pro Pro Ile Leu His Ser Asn Phe Pro His Leu Val Leu 595 600 605 Glu Lys Ile Leu Val Ser Leu Thr Met Lys Asn Cys Lys Ala Ala Met 610 615 620 Asn Phe Phe Gln Ser Val Pro Glu Cys Glu His His Gln Lys Asp Lys 625 630 635 640 Glu Glu Leu Ser Phe Ser Glu Val Glu Glu Leu Phe Leu Gln Thr Thr 645 650 655 Phe Asp Lys Met Asp Phe Leu Thr Ile Val Arg Glu Cys Gly Ile Glu 660 665 670 Lys His Gln Ser Ser Ile Gly Phe Ser Val His Gln Asn Leu Lys Glu 675 680 685 Ser Leu Asp Arg Cys Leu Leu Gly Leu Ser Glu Gln Leu Leu Asn Asn 690 695 700 Tyr Ser Ser Glu Ile Thr Asn Ser Glu Thr Leu Val Arg Cys Ser Arg 705 710 715 720 Leu Leu Val Gly Val Leu Gly Cys Tyr Cys Tyr Met Gly Val Ile Ala 725 730 735 Glu Glu Glu Ala Tyr Lys Ser Glu Leu Phe Gln Lys Ala Asn Ser Leu 740 745 750 Met Gln Cys Ala Gly Glu Ser Ile Thr Leu Phe Lys Asn Lys Thr Asn 755 760 765 Glu Glu Phe Arg Ile Gly Ser Leu Arg Asn Met Met Gln Leu Cys Thr 770 775 780 Arg Cys Leu Ser Asn Cys Thr Lys Lys Ser Pro Asn Lys Ile Ala Ser 785 790 795 800 Gly Phe Phe Leu Arg Leu Leu Thr Ser Lys Leu Met Asn Asp Ile Ala 805 810 815 Asp Ile Cys Lys Ser Leu Ala Ser Phe Ile Lys Lys Pro Phe Asp Arg 820 825 830 Gly Glu Val Glu Ser Met Glu Asp Asp Thr Asn Gly Asn Leu Met Glu 835 840 845 Val Glu Asp Gln Ser Ser Met Asn Leu Phe Asn Asp Tyr Pro Asp Ser 850 855 860 Ser Val Ser Asp Ala Asn Glu Pro Gly Glu Ser Gln Ser Thr Ile Gly 865 870 875 880 Ala Ile Asn Pro Leu Ala Glu Glu Tyr Leu Ser Lys Gln Asp Leu Leu 885 890 895 Phe Leu Asp Met Leu Lys Phe Leu Cys Leu Cys Val Thr Thr Ala Gln 900 905 910 Thr Asn Thr Val Ser Phe Arg Ala Ala Asp Ile Arg Arg Lys Leu Leu 915 920 925 Met Leu Ile Asp Ser Ser Thr Leu Glu Pro Thr Lys Ser Leu His Leu 930 935 940 His Met Tyr Leu Met Leu Leu Lys Glu Leu Pro Gly Glu Glu Tyr Pro 945 950 955 960 Leu Pro Met Glu Asp Val Leu Glu Leu Leu Lys Pro Leu Ser Asn Val 965 970 975 Cys Ser Leu Tyr Arg Arg Asp Gln Asp Val Cys Lys Thr Ile Leu Asn 980 985 990 His Val Leu His Val Val Lys Asn Leu Gly Gln Ser Asn Met Asp Ser 995 1000 1005 Glu Asn Thr Arg Asp Ala Gln Gly Gln Phe Leu Thr Val Ile Gly Ala 1010 1015 1020 Phe Trp His Leu Thr Lys Glu Arg Lys Tyr Ile Phe Ser Val Arg Met 1025 1030 1035 1040 Ala Leu Val Asn Cys Leu Lys Thr Leu Leu Glu Ala Asp Pro Tyr Ser 1045 1050 1055 Lys Trp Ala Ile Leu Asn Val Met Gly Lys Asp Phe Pro Val Asn Glu 1060 1065 1070 Val Phe Thr Gln Phe Leu Ala Asp Asn His His Gln Val Arg Met Leu 1075 1080 1085 Ala Ala Glu Ser Ile Asn Arg Leu Phe Gln Asp Thr Lys Gly Asp Ser 1090 1095 1100 Ser Arg Leu Leu Lys Ala Leu Pro Leu Lys Leu Gln Gln Thr Ala Phe 1105 1110 1115 1120 Glu Asn Ala Tyr Leu Lys Ala Gln Glu Gly Met Arg Glu Met Ser His 1125 1130 1135 Ser Ala Glu Asn Pro Glu Thr Leu Asp Glu Ile Tyr Asn Arg Lys Ser 1140 1145 1150 Val Leu Leu Thr Leu Ile Ala Val Val Leu Ser Cys Ser Pro Ile Cys 1155 1160 1165 Glu Lys Gln Ala Leu Phe Ala Leu Cys Lys Ser Val Lys Glu Asn Gly 1170 1175 1180 Leu Glu Pro His Leu Val Lys Lys Val Leu Glu Lys Val Ser Glu Thr 1185 1190 1195 1200 Phe Gly Tyr Arg Arg Leu Glu Asp Phe Met Ala Ser His Leu Asp Tyr 1205 1210 1215 Leu Val Leu Glu Trp Leu Asn Leu Gln Asp Thr Glu Tyr Asn Leu Ser 1220 1225 1230 Ser Phe Pro Phe Ile Leu Leu Asn Tyr Thr Asn Ile Glu Asp Phe Tyr 1235 1240 1245 Arg Ser Cys Tyr Lys Val Leu Ile Pro His Leu Val Ile Arg Ser His 1250 1255 1260 Phe Asp Glu Val Lys Ser Ile Ala Asn Gln Ile Gln Glu Asp Trp Lys 1265 1270 1275 1280 Ser Leu Leu Thr Asp Cys Phe Pro Lys Ile Leu Val Asn Ile Leu Pro 1285 1290 1295 Tyr Phe Ala Tyr Glu Gly Thr Arg Asp Ser Gly Met Ala Gln Gln Arg 1300 1305 1310 Glu Thr Ala Thr Lys Val Tyr Asp Met Leu Lys Ser Glu Asn Leu Leu 1315 1320 1325 Gly Lys Gln Ile Asp His Leu Phe Ile Ser Asn Leu Pro Glu Ile Val 1330 1335 1340 Val Glu Leu Leu Met Thr Leu His Glu Pro Ala Asn Ser Ser Ala Ser 1345 1350 1355 1360 Gln Ser Thr Asp Leu Cys Asp Phe Ser Gly Asp Leu Asp Pro Ala Pro 1365 1370 1375 Asn Pro Pro His Phe Pro Ser His Val Ile Lys Ala Thr Phe Ala Tyr 1380 1385 1390 Ile Ser Asn Cys His Lys Thr Lys Leu Lys Ser Ile Leu Glu Ile Leu 1395 1400 1405 Ser Lys Ser Pro Asp Ser Tyr Gln Lys Ile Leu Leu Ala Ile Cys Glu 1410 1415 1420 Gln Ala Ala Glu Thr Asn Asn Val Tyr Lys Lys His Arg Ile Leu Lys 1425 1430 1435 1440 Ile Tyr His Leu Phe Val Ser Leu Leu Leu Lys Asp Ile Lys Ser Gly 1445 1450 1455 Leu Gly Gly Ala Trp Ala Phe Val Leu Arg Asp Val Ile Tyr Thr Leu 1460 1465 1470 Ile His Tyr Ile Asn Gln Arg Pro Ser Cys Ile Met Asp Val Ser Leu 1475 1480 1485 Arg Ser Phe Ser Leu Cys Cys Asp Leu Leu Ser Gln Val Cys Gln Thr 1490 1495 1500 Ala Val Thr Tyr Cys Lys Asp Ala Leu Glu Asn His Leu His Val Ile 1505 1510 1515 1520 Val Gly Thr Leu Ile Pro Leu Val Tyr Glu Gln Val Glu Val Gln Lys 1525 1530 1535 Gln Val Leu Asp Leu Leu Lys Tyr Leu Val Ile Asp Asn Lys Asp Asn 1540 1545 1550 Glu Asn Leu Tyr Ile Thr Ile Lys Leu Leu Asp Pro Phe Pro Asp His 1555 1560 1565 Val Val Phe Lys Asp Leu Arg Ile Thr Gln Gln Lys Ile Lys Tyr Ser 1570 1575 1580 Arg Gly Pro Phe Ser Leu Leu Glu Glu Ile Asn His Phe Leu Ser Val 1585 1590 1595 1600 Ser Val Tyr Asp Ala Leu Pro Leu Thr Arg Leu Glu Gly Leu Lys Asp 1605 1610 1615 Leu Arg Arg Gln Leu Glu Leu His Lys Asp Gln Met Val Asp Ile Met 1620 1625 1630 Arg Ala Ser Gln Asp Asn Pro Gln Asp Gly Ile Met Val Lys Leu Val 1635 1640 1645 Val Asn Leu Leu Gln Leu Ser Lys Met Ala Ile Asn His Thr Gly Glu 1650 1655 1660 Lys Glu Val Leu Glu Ala Val Gly Ser Cys Leu Gly Glu Val Gly Pro 1665 1670 1675 1680 Ile Asp Phe Ser Thr Ile Ala Ile Gln His Ser Lys Asp Ala Ser Tyr 1685 1690 1695 Thr Lys Ala Leu Lys Leu Phe Glu Asp Lys Glu Leu Gln Trp Thr Phe 1700 1705 1710 Ile Met Leu Thr Tyr Leu Asn Asn Thr Leu Val Glu Asp Cys Val Lys 1715 1720 1725 Val Arg Ser Ala Ala Val Thr Cys Leu Lys Asn Ile Leu Ala Thr Lys 1730 1735 1740 Thr Gly His Ser Phe Trp Glu Ile Tyr Lys Met Thr Thr Asp Pro Met 1745 1750 1755 1760 Leu Ala Tyr Leu Gln Pro Phe Arg Thr Ser Arg Lys Lys Phe Leu Glu 1765 1770 1775 Val Pro Arg Phe Asp Lys Glu Asn Pro Phe Glu Gly Leu Asp Asp Ile 1780 1785 1790 Asn Leu Trp Ile Pro Leu Ser Glu Asn His Asp Ile Trp Ile Lys Thr 1795 1800 1805 Leu Thr Cys Ala Phe Leu Asp Ser Gly Gly Thr Lys Cys Glu Ile Leu 1810 1815 1820 Gln Leu Leu Lys Pro Met Cys Glu Val Lys Thr Asp Phe Cys Gln Thr 1825 1830 1835 1840 Val Leu Pro Tyr Leu Ile His Asp Ile Leu Leu Gln Asp Thr Asn Glu 1845 1850 1855 Ser Trp Arg Asn Leu Leu Ser Thr His Val Gln Gly Phe Phe Thr Ser 1860 1865 1870 Cys Leu Arg His Phe Ser Gln Thr Ser Arg Ser Thr Thr Pro Ala Asn 1875 1880 1885 Leu Asp Ser Glu Ser Glu His Phe Phe Arg Cys Cys Leu Asp Lys Lys 1890 1895 1900 Ser Gln Arg Thr Met Leu Ala Val Val Asp Tyr Met Arg Arg Gln Lys 1905 1910 1915 1920 Arg Pro Ser Ser Gly Thr Ile Phe Asn Asp Ala Phe Trp Leu Asp Leu 1925 1930 1935 Asn Tyr Leu Glu Val Ala Lys Val Ala Gln Ser Cys Ala Ala His Phe 1940 1945 1950 Thr Ala Leu Leu Tyr Ala Glu Ile Tyr Ala Asp Lys Lys Ser Met Asp 1955 1960 1965 Asp Gln Glu Lys Arg Ser Leu Ala Phe Glu Glu Gly Ser Gln Ser Thr 1970 1975 1980 Thr Ile Ser Ser Leu Ser Glu Lys Ser Lys Glu Glu Thr Gly Ile Ser 1985 1990 1995 2000 Leu Gln Asp Leu Leu Leu Glu Ile Tyr Arg Ser Ile Gly Glu Pro Asp 2005 2010 2015 Ser Leu Tyr Gly Cys Gly Gly Gly Lys Met Leu Gln Pro Ile Thr Arg 2020 2025 2030 Leu Arg Thr Tyr Glu His Glu Ala Met Trp Gly Lys Ala Leu Val Thr 2035 2040 2045 Tyr Asp Leu Glu Thr Ala Ile Pro Ser Ser Thr Arg Gln Ala Gly Ile 2050 2055 2060 Ile Gln Ala Leu Gln Asn Leu Gly Leu Cys His Ile Leu Ser Val Tyr 2065 2070 2075 2080 Leu Lys Gly Leu Asp Tyr Glu Asn Lys Asp Trp Cys Pro Glu Leu Glu 2085 2090 2095 Glu Leu His Tyr Gln Ala Ala Trp Arg Asn Met Gln Trp Asp His Cys 2100 2105 2110 Thr Ser Val Ser Lys Glu Val Glu Gly Thr Ser Tyr His Glu Ser Leu 2115 2120 2125 Tyr Asn Ala Leu Gln Ser Leu Arg Asp Arg Glu Phe Ser Thr Phe Tyr 2130 2135 2140 Glu Ser Leu Lys Tyr Ala Arg Val Lys Glu Val Glu Glu Met Cys Lys 2145 2150 2155 2160 Arg Ser Leu Glu Ser Val Tyr Ser Leu Tyr Pro Thr Leu Ser Arg Leu 2165 2170 2175 Gln Ala Ile Gly Glu Leu Glu Ser Ile Gly Glu Leu Phe Ser Arg Ser 2180 2185 2190 Val Thr His Arg Gln Leu Ser Glu Val Tyr Ile Lys Trp Gln Lys His 2195 2200 2205 Ser Gln Leu Leu Lys Asp Ser Asp Phe Ser Phe Gln Glu Pro Ile Met 2210 2215 2220 Ala Leu Arg Thr Val Ile Leu Glu Ile Leu Met Glu Lys Glu Met Asp 2225 2230 2235 2240 Asn Ser Gln Arg Glu Cys Ile Lys Asp Ile Leu Thr Lys His Leu Val 2245 2250 2255 Glu Leu Ser Ile Leu Ala Arg Thr Phe Lys Asn Thr Gln Leu Pro Glu 2260 2265 2270 Arg Ala Ile Phe Gln Ile Lys Gln Tyr Asn Ser Val Ser Cys Gly Val 2275 2280 2285 Ser Glu Trp Gln Leu Glu Glu Ala Gln Val Phe Trp Ala Lys Lys Glu 2290 2295 2300 Gln Ser Leu Ala Leu Ser Ile Leu Lys Gln Met Ile Lys Lys Leu Asp 2305 2310 2315 2320 Ala Ser Cys Ala Ala Asn Asn Pro Ser Leu Lys Leu Thr Tyr Thr Glu 2325 2330 2335 Cys Leu Arg Val Cys Gly Asn Trp Leu Ala Glu Thr Cys Leu Glu Asn 2340 2345 2350 Pro Ala Val Ile Met Gln Thr Tyr Leu Glu Lys Ala Val Glu Val Ala 2355 2360 2365 Gly Asn Tyr Asp Gly Glu Ser Ser Asp Glu Leu Arg Asn Gly Lys Met 2370 2375 2380 Lys Ala Phe Leu Ser Leu Ala Arg Phe Ser Asp Thr Gln Tyr Gln Arg 2385 2390 2395 2400 Ile Glu Asn Tyr Met Lys Ser Ser Glu Phe Glu Asn Lys Gln Ala Leu 2405 2410 2415 Leu Lys Arg Ala Lys Glu Glu Val Gly Leu Leu Arg Glu His Lys Ile 2420 2425 2430 Gln Thr Asn Arg Tyr Thr Val Lys Val Gln Arg Glu Leu Glu Leu Asp 2435 2440 2445 Glu Leu Ala Leu Arg Ala Leu Lys Glu Asp Arg Lys Arg Phe Leu Cys 2450 2455 2460 Lys Ala Val Glu Asn Tyr Ile Asn Cys Leu Leu Ser Gly Glu Glu His 2465 2470 2475 2480 Asp Met Trp Val Phe Arg Leu Cys Ser Leu Trp Leu Glu Asn Ser Gly 2485 2490 2495 Val Ser Glu Val Asn Gly Met Met Lys Arg Asp Gly Met Lys Ile Pro 2500 2505 2510 Thr Tyr Lys Phe Leu Pro Leu Met Tyr Gln Leu Ala Ala Arg Met Gly 2515 2520 2525 Thr Lys Met Met Gly Gly Leu Gly Phe His Glu Val Leu Asn Asn Leu 2530 2535 2540 Ile Ser Arg Ile Ser Met Asp His Pro His His Thr Leu Phe Ile Ile 2545 2550 2555 2560 Leu Ala Leu Ala Asn Ala Asn Arg Asp Glu Phe Leu Thr Lys Pro Glu 2565 2570 2575 Val Ala Arg Arg Ser Arg Ile Thr Lys Asn Val Pro Lys Gln Ser Ser 2580 2585 2590 Gln Leu Asp Glu Asp Arg Thr Glu Ala Ala Asn Arg Ile Ile Cys Thr 2595 2600 2605 Ile Arg Ser Arg Arg Pro Gln Met Val Arg Ser Val Glu Ala Leu Cys 2610 2615 2620 Asp Ala Tyr Ile Ile Leu Ala Asn Leu Asp Ala Thr Gln Trp Lys Thr 2625 2630 2635 2640 Gln Arg Lys Gly Ile Asn Ile Pro Ala Asp Gln Pro Ile Thr Lys Leu 2645 2650 2655 Lys Asn Leu Glu Asp Val Val Val Pro Thr Met Glu Ile Lys Val Asp 2660 2665 2670 His Thr Gly Glu Tyr Gly Asn Leu Val Thr Ile Gln Ser Phe Lys Ala 2675 2680 2685 Glu Phe Arg Leu Ala Gly Gly Val Asn Leu Pro Lys Ile Ile Asp Cys 2690 2695 2700 Val Gly Ser Asp Gly Lys Glu Arg Arg Gln Leu Val Lys Gly Arg Asp 2705 2710 2715 2720 Asp Leu Arg Gln Asp Ala Val Met Gln Gln Val Phe Gln Met Cys Asn 2725 2730 2735 Thr Leu Leu Gln Arg Asn Thr Glu Thr Arg Lys Arg Lys Leu Thr Ile 2740 2745 2750 Cys Thr Tyr Lys Val Val Pro Leu Ser Gln Arg Ser Gly Val Leu Glu 2755 2760 2765 Trp Cys Thr Gly Thr Val Pro Ile Gly Glu Phe Leu Val Asn Asn Glu 2770 2775 2780 Asp Gly Ala His Lys Arg Tyr Arg Pro Asn Asp Phe Ser Ala Phe Gln 2785 2790 2795 2800 Cys Gln Lys Lys Met Met Glu Val Gln Lys Lys Ser Phe Glu Glu Lys 2805 2810 2815 Tyr Glu Val Phe Met Asp Val Cys Gln Asn Phe Gln Pro Val Phe Arg 2820 2825 2830 Tyr Phe Cys Met Glu Lys Phe Leu Asp Pro Ala Ile Trp Phe Glu Lys 2835 2840 2845 Arg Leu Ala Tyr Thr Arg Ser Val Ala Thr Ser Ser Ile Val Gly Tyr 2850 2855 2860 Ile Leu Gly Leu Gly Asp Arg His Val Gln Asn Ile Leu Ile Asn Glu 2865 2870 2875 2880 Gln Ser Ala Glu Leu Val His Ile Asp Leu Gly Val Ala Phe Glu Gln 2885 2890 2895 Gly Lys Ile Leu Pro Thr Pro Glu Thr Val Pro Phe Arg Leu Thr Arg 2900 2905 2910 Asp Ile Val Asp Gly Met Gly Ile Thr Gly Val Glu Gly Val Phe Arg 2915 2920 2925 Arg Cys Cys Glu Lys Thr Met Glu Val Met Arg Asn Ser Gln Glu Thr 2930 2935 2940 Leu Leu Thr Ile Val Glu Val Leu Leu Tyr Asp Pro Leu Phe Asp Trp 2945 2950 2955 2960 Thr Met Asn Pro Leu Lys Ala Leu Tyr Leu Gln Gln Arg Pro Glu Asp 2965 2970 2975 Glu Thr Glu Leu His Pro Thr Leu Asn Ala Asp Asp Gln Glu Cys Lys 2980 2985 2990 Arg Asn Leu Ser Asp Ile Asp Gln Ser Phe Asp Lys Val Ala Glu Arg 2995 3000 3005 Val Leu Met Arg Leu Gln Glu Lys Leu Lys Gly Val Glu Glu Gly Thr 3010 3015 3020 Val Leu Ser Val Gly Gly Gln Val Asn Leu Leu Ile Gln Gln Ala Ile 3025 3030 3035 3040 Asp Pro Lys Asn Leu Ser Arg Leu Phe Pro Gly Trp Lys Ala Trp Val 3045 3050 3055 42 450 PRT Homo sapiens 42 Met Ser Ala Ile Gln Ala Ala Trp Pro Ser Gly Thr Glu Cys Ile Ala 1 5 10 15 Lys Tyr Asn Phe His Gly Thr Ala Glu Gln Asp Leu Pro Phe Cys Lys 20 25 30 Gly Asp Val Leu Thr Ile Val Ala Val Thr Lys Asp Pro Asn Trp Tyr 35 40 45 Lys Ala Lys Asn Lys Val Gly Arg Glu Gly Ile Ile Pro Ala Asn Tyr 50 55 60 Val Gln Lys Arg Glu Gly Val Lys Ala Gly Thr Lys Leu Ser Leu Met 65 70 75 80 Pro Trp Phe His Gly Lys Ile Thr Arg Glu Gln Ala Glu Arg Leu Leu 85 90 95 Tyr Pro Pro Glu Thr Gly Leu Phe Leu Val Arg Glu Ser Thr Asn Tyr 100 105 110 Pro Gly Asp Tyr Thr Leu Cys Val Ser Cys Asp Gly Lys Val Glu His 115 120 125 Tyr Arg Ile Met Tyr His Ala Ser Lys Leu Ser Ile Asp Glu Glu Val 130 135 140 Tyr Phe Glu Asn Leu Met Gln Leu Val Glu His Tyr Thr Ser Asp Ala 145 150 155 160 Asp Gly Leu Cys Thr Arg Leu Ile Lys Pro Lys Val Met Glu Gly Thr 165 170 175 Val Ala Ala Gln Asp Glu Phe Tyr Arg Ser Gly Trp Ala Leu Asn Met 180 185 190 Lys Glu Leu Lys Leu Leu Gln Thr Ile Gly Lys Gly Glu Phe Gly Asp 195 200 205 Val Met Leu Gly Asp Tyr Arg Gly Asn Lys Val Ala Val Lys Cys Ile 210 215 220 Lys Asn Asp Ala Thr Ala Gln Ala Phe Leu Ala Glu Ala Ser Val Met 225 230 235 240 Thr Gln Leu Arg His Ser Asn Leu Val Gln Leu Leu Gly Val Ile Val 245 250 255 Glu Glu Lys Gly Gly Leu Tyr Ile Val Thr Glu Tyr Met Ala Lys Gly 260 265 270 Ser Leu Val Asp Tyr Leu Arg Ser Arg Gly Arg Ser Val Leu Gly Gly 275 280 285 Asp Cys Leu Leu Lys Phe Ser Leu Asp Val Cys Glu Ala Met Glu Tyr 290 295 300 Leu Glu Gly Asn Asn Phe Val His Arg Asp Leu Ala Ala Arg Asn Val 305 310 315 320 Leu Val Ser Glu Asp Asn Val Ala Lys Val Ser Asp Phe Gly Leu Thr 325 330 335 Lys Glu Ala Ser Ser Thr Gln Asp Thr Gly Lys Leu Pro Val Lys Trp 340 345 350 Thr Ala Pro Glu Ala Leu Arg Glu Lys Lys Phe Ser Thr Lys Ser Asp 355 360 365 Val Trp Ser Phe Gly Ile Leu Leu Trp Glu Ile Tyr Ser Phe Gly Arg 370 375 380 Val Pro Tyr Pro Arg Ile Pro Leu Lys Asp Val Val Pro Arg Val Glu 385 390 395 400 Lys Gly Tyr Lys Met Asp Ala Pro Asp Gly Cys Pro Pro Ala Val Tyr 405 410 415 Glu Val Met Lys Asn Cys Trp His Leu Asp Ala Ala Met Arg Pro Ser 420 425 430 Phe Leu Gln Leu Arg Glu Gln Leu Glu His Ile Lys Thr His Glu Leu 435 440 445 His Leu 450 43 1142 PRT Homo sapiens 43 Met Ala Phe Cys Ala Lys Met Arg Ser Ser Lys Lys Thr Glu Val Asn 1 5 10 15 Leu Glu Ala Pro Glu Pro Gly Val Glu Val Ile Phe Tyr Leu Ser Asp 20 25 30 Arg Glu Pro Leu Arg Leu Gly Ser Gly Glu Tyr Thr Ala Glu Glu Leu 35 40 45 Cys Ile Arg Ala Ala Gln Ala Cys Arg Ile Ser Pro Leu Cys His Asn 50 55 60 Leu Phe Ala Leu Tyr Asp Glu Asn Thr Lys Leu Trp Tyr Ala Pro Asn 65 70 75 80 Arg Thr Ile Thr Val Asp Asp Lys Met Ser Leu Arg Leu His Tyr Arg 85 90 95 Met Arg Phe Tyr Phe Thr Asn Trp His Gly Thr Asn Asp Asn Glu Gln 100 105 110 Ser Val Trp Arg His Ser Pro Lys Lys Gln Lys Asn Gly Tyr Glu Lys 115 120 125 Lys Lys Ile Pro Asp Ala Thr Pro Leu Leu Asp Ala Ser Ser Leu Glu 130 135 140 Tyr Leu Phe Ala Gln Gly Gln Tyr Asp Leu Val Lys Cys Leu Ala Pro 145 150 155 160 Ile Arg Asp Pro Lys Thr Glu Gln Asp Gly His Asp Ile Glu Asn Glu 165 170 175 Cys Leu Gly Met Ala Val Leu Ala Ile Ser His Tyr Ala Met Met Lys 180 185 190 Lys Met Gln Leu Pro Glu Leu Pro Lys Asp Ile Ser Tyr Lys Arg Tyr 195 200 205 Ile Pro Glu Thr Leu Asn Lys Ser Ile Arg Gln Arg Asn Leu Leu Thr 210 215 220 Arg Met Arg Ile Asn Asn Val Phe Lys Asp Phe Leu Lys Glu Phe Asn 225 230 235 240 Asn Lys Thr Ile Cys Asp Ser Ser Val Ser Thr His Asp Leu Lys Val 245 250 255 Lys Tyr Leu Ala Thr Leu Glu Thr Leu Thr Lys His Tyr Gly Ala Glu 260 265 270 Ile Phe Glu Thr Ser Met Leu Leu Ile Ser Ser Glu Asn Glu Met Asn 275 280 285 Trp Phe His Ser Asn Asp Gly Gly Asn Val Leu Tyr Tyr Glu Val Met 290 295 300 Val Thr Gly Asn Leu Gly Ile Gln Trp Arg His Lys Pro Asn Val Val 305 310 315 320 Ser Val Glu Lys Glu Lys Asn Lys Leu Lys Arg Lys Lys Leu Glu Asn 325 330 335 Lys Asp Lys Lys Asp Glu Glu Lys Asn Lys Ile Arg Glu Glu Trp Asn 340 345 350 Asn Phe Ser Phe Phe Pro Glu Ile Thr His Ile Val Ile Lys Glu Ser 355 360 365 Val Val Ser Ile Asn Lys Gln Asp Asn Lys Lys Met Glu Leu Lys Leu 370 375 380 Ser Ser His Glu Glu Ala Leu Ser Phe Val Ser Leu Val Asp Gly Tyr 385 390 395 400 Phe Arg Leu Thr Ala Asp Ala His His Tyr Leu Cys Thr Asp Val Ala 405 410 415 Pro Pro Leu Ile Val His Asn Ile Gln Asn Gly Cys His Gly Pro Ile 420 425 430 Cys Thr Glu Tyr Ala Ile Asn Lys Leu Arg Gln Glu Gly Ser Glu Glu 435 440 445 Gly Met Tyr Val Leu Arg Trp Ser Cys Thr Asp Phe Asp Asn Ile Leu 450 455 460 Met Thr Val Thr Cys Phe Glu Lys Ser Glu Gln Val Gln Gly Ala Gln 465 470 475 480 Lys Gln Phe Lys Asn Phe Gln Ile Glu Val Gln Lys Gly Arg Tyr Ser 485 490 495 Leu His Gly Ser Asp Arg Ser Phe Pro Ser Leu Gly Asp Leu Met Ser 500 505 510 His Leu Lys Lys Gln Ile Leu Arg Thr Asp Asn Ile Ser Phe Met Leu 515 520 525 Lys Arg Cys Cys Gln Pro Lys Pro Arg Glu Ile Ser Asn Leu Leu Val 530 535 540 Ala Thr Lys Lys Ala Gln Glu Trp Gln Pro Val Tyr Pro Met Ser Gln 545 550 555 560 Leu Ser Phe Asp Arg Ile Leu Lys Lys Asp Leu Val Gln Gly Glu His 565 570 575 Leu Gly Arg Gly Thr Arg Thr His Ile Tyr Ser Gly Thr Leu Met Asp 580 585 590 Tyr Lys Asp Asp Glu Gly Thr Ser Glu Glu Lys Lys Ile Lys Val Ile 595 600 605 Leu Lys Val Leu Asp Pro Ser His Arg Asp Ile Ser Leu Ala Phe Phe 610 615 620 Glu Ala Ala Ser Met Met Arg Gln Val Ser His Lys His Ile Val Tyr 625 630 635 640 Leu Tyr Gly Val Cys Val Arg Asp Val Glu Asn Ile Met Val Glu Glu 645 650 655 Phe Val Glu Gly Gly Pro Leu Asp Leu Phe Met His Arg Lys Ser Asp 660 665 670 Val Leu Thr Thr Pro Trp Lys Phe Lys Val Ala Lys Gln Leu Ala Ser 675 680 685 Ala Leu Ser Tyr Leu Glu Asp Lys Asp Leu Val His Gly Asn Val Cys 690 695 700 Thr Lys Asn Leu Leu Leu Ala Arg Glu Gly Ile Asp Ser Glu Cys Gly 705 710 715 720 Pro Phe Ile Lys Leu Ser Asp Pro Gly Ile Pro Ile Thr Val Leu Ser 725 730 735 Arg Gln Glu Cys Ile Glu Arg Ile Pro Trp Ile Ala Pro Glu Cys Val 740 745 750 Glu Asp Ser Lys Asn Leu Ser Val Ala Ala Asp Lys Trp Ser Phe Gly 755 760 765 Thr Thr Leu Trp Glu Ile Cys Tyr Asn Gly Glu Ile Pro Leu Lys Asp 770 775 780 Lys Thr Leu Ile Glu Lys Glu Arg Phe Tyr Glu Ser Arg Cys Arg Pro 785 790 795 800 Val Thr Pro Ser Cys Lys Glu Leu Ala Asp Leu Met Thr Arg Cys Met 805 810 815 Asn Tyr Asp Pro Asn Gln Arg Pro Phe Phe Arg Ala Ile Met Arg Asp 820 825 830 Ile Asn Lys Leu Glu Glu Gln Asn Pro Asp Ile Val Ser Arg Lys Lys 835 840 845 Asn Gln Pro Thr Glu Val Asp Pro Thr His Phe Glu Lys Arg Phe Leu 850 855 860 Lys Arg Ile Arg Asp Leu Gly Glu Gly His Phe Gly Lys Val Glu Leu 865 870 875 880 Cys Arg Tyr Asp Pro Glu Asp Asn Thr Gly Glu Gln Val Ala Val Lys 885 890 895 Ser Leu Lys Pro Glu Ser Gly Gly Asn His Ile Ala Asp Leu Lys Lys 900 905 910 Glu Ile Glu Ile Leu Arg Asn Leu Tyr His Glu Asn Ile Val Lys Tyr 915 920 925 Lys Gly Ile Cys Thr Glu Asp Gly Gly Asn Gly Ile Lys Leu Ile Met 930 935 940 Glu Phe Leu Pro Ser Gly Ser Leu Lys Glu Tyr Leu Pro Lys Asn Lys 945 950 955 960 Asn Lys Ile Asn Leu Lys Gln Gln Leu Lys Tyr Ala Val Gln Ile Cys 965 970 975 Lys Gly Met Asp Tyr Leu Gly Ser Arg Gln Tyr Val His Arg Asp Leu 980 985 990 Ala Ala Arg Asn Val Leu Val Glu Ser Glu His Gln Val Lys Ile Gly 995 1000 1005 Asp Phe Gly Leu Thr Lys Ala Ile Glu Thr Asp Lys Glu Tyr Tyr Thr 1010 1015 1020 Val Lys Asp Asp Arg Asp Ser Pro Val Phe Trp Tyr Ala Pro Glu Cys 1025 1030 1035 1040 Leu Met Gln Ser Lys Phe Tyr Ile Ala Ser Asp Val Trp Ser Phe Gly 1045 1050 1055 Val Thr Leu His Glu Leu Leu Thr Tyr Cys Asp Ser Asp Ser Ser Pro 1060 1065 1070 Met Ala Leu Phe Leu Lys Met Ile Gly Pro Thr His Gly Gln Met Thr 1075 1080 1085 Val Thr Arg Leu Val Asn Thr Leu Lys Glu Gly Lys Arg Leu Pro Cys 1090 1095 1100 Pro Pro Asn Cys Pro Asp Glu Val Tyr Gln Leu Met Arg Lys Cys Trp 1105 1110 1115 1120 Glu Phe Gln Pro Ser Asn Arg Thr Ser Phe Gln Asn Leu Ile Glu Gly 1125 1130 1135 Phe Glu Ala Leu Leu Lys 1140 44 1338 PRT Homo sapiens 44 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr 35 40 45 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro 50 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala 65 70 75 80 Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 95 Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100 105 110 Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile 115 120 125 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 130 135 140 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 145 150 155 160 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 175 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 180 185 190 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 195 200 205 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220 Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 225 230 235 240 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys 260 265 270 Asn Lys Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser Asn Ser His 275 280 285 Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys 290 295 300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 305 310 315 320 Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Phe Ile Thr Val 325 330 335 Lys His Arg Lys Gln Gln Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340 345 350 Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val 355 360 365 Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu 370 375 380 Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala 385 390 395 400 Gly Asn Tyr Thr Ile Leu Leu Ser Ile Lys Gln Ser Asn Val Phe Lys 405 410 415 Asn Leu Thr Ala Thr Leu Ile Val Asn Val Lys Pro Gln Ile Tyr Glu 420 425 430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser 435 440 445 Arg Gln Ile Leu Thr Cys Thr Ala Tyr Gly Ile Pro Gln Pro Thr Ile 450 455 460 Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470 475 480 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe Ile Leu Asp Ala Asp Ser 485 490 495 Asn Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile Ile 500 505 510 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg 515 520 525 Ile Ser Gly Ile Tyr Ile Cys Ile Ala Ser Asn Lys Val Gly Thr Val 530 535 540 Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val Pro Asn Gly Phe His 545 550 555 560 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser 565 570 575 Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp Ile Leu Leu 580 585 590 Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser Ile Ser Lys Gln Lys 595 600 605 Met Ala Ile Thr Lys Glu His Ser Ile Thr Leu Asn Leu Thr Ile Met 610 615 620 Asn Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625 630 635 640 Val Tyr Thr Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile Arg 645 650 655 Asp Gln Glu Ala Pro Tyr Leu Leu Arg Asn Leu Ser Asp His Thr Val 660 665 670 Ala Ile Ser Ser Ser Thr Thr Leu Asp Cys His Ala Asn Gly Val Pro 675 680 685 Glu Pro Gln Ile Thr Trp Phe Lys Asn Asn His Lys Ile Gln Gln Glu 690 695 700 Pro Gly Ile Ile Leu Gly Pro Gly Ser Ser Thr Leu Phe Ile Glu Arg 705 710 715 720 Val Thr Glu Glu Asp Glu Gly Val Tyr His Cys Lys Ala Thr Asn Gln 725 730 735 Lys Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly Thr Ser 740 745 750 Asp Lys Ser Asn Leu Glu Leu Ile Thr Leu Thr Cys Thr Cys Val Ala 755 760 765 Ala Thr Leu Phe Trp Leu Leu Leu Thr Leu Leu Ile Arg Lys Met Lys 770 775 780 Arg Ser Ser Ser Glu Ile Lys Thr Asp Tyr Leu Ser Ile Ile Met Asp 785 790 795 800 Pro Asp Glu Val Pro Leu Asp Glu Gln Cys Glu Arg Leu Pro Tyr Asp 805 810 815 Ala Ser Lys Trp Glu Phe Ala Arg Glu Arg Leu Lys Leu Gly Lys Ser 820 825 830 Leu Gly Arg Gly Ala Phe Gly Lys Val Val Gln Ala Ser Ala Phe Gly 835 840 845 Ile Lys Lys Ser Pro Thr Cys Arg Thr Val Ala Val Lys Met Leu Lys 850 855 860 Glu Gly Ala Thr Ala Ser Glu Tyr Lys Ala Leu Met Thr Glu Leu Lys 865 870 875 880 Ile Leu Thr His Ile Gly His His Leu Asn Val Val Asn Leu Leu Gly 885 890 895 Ala Cys Thr Lys Gln Gly Gly Pro Leu Met Val Ile Val Glu Tyr Cys 900 905 910 Lys Tyr Gly Asn Leu Ser Asn Tyr Leu Lys Ser Lys Arg Asp Leu Phe 915 920 925 Phe Leu Asn Lys Asp Ala Ala Leu His Met Glu Pro Lys Lys Glu Lys 930 935 940 Met Glu Pro Gly Leu Glu Gln Gly Lys Lys Pro Arg Leu Asp Ser Val 945 950 955 960 Thr Ser Ser Glu Ser Phe Ala Ser Ser Gly Phe Gln Glu Asp Lys Ser 965 970 975 Leu Ser Asp Val Glu Glu Glu Glu Asp Ser Asp Gly Phe Tyr Lys Glu 980 985 990 Pro Ile Thr Met Glu Asp Leu Ile Ser Tyr Ser Phe Gln Val Ala Arg 995 1000 1005 Gly Met Glu Phe Leu Ser Ser Arg Lys Cys Ile His Arg Asp Leu Ala 1010 1015 1020 Ala Arg Asn Ile Leu Leu Ser Glu Asn Asn Val Val Lys Ile Cys Asp 1025 1030 1035 1040 Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asn Pro Asp Tyr Val Arg Lys 1045 1050 1055 Gly Asp Thr Arg Leu Pro Leu Lys Trp Met Ala Pro Glu Ser Ile Phe 1060 1065 1070 Asp Lys Ile Tyr Ser Thr Lys Ser Asp Val Trp Ser Tyr Gly Val Leu 1075 1080 1085 Leu Trp Glu Ile Phe Ser Leu Gly Gly Ser Pro Tyr Pro Gly Val Gln 1090 1095 1100 Met Asp Glu Asp Phe Cys Ser Arg Leu Arg Glu Gly Met Arg Met Arg 1105 1110 1115 1120 Ala Pro Glu Tyr Ser Thr Pro Glu Ile Tyr Gln Ile Met Leu Asp Cys 1125 1130 1135 Trp His Arg Asp Pro Lys Glu Arg Pro Arg Phe Ala Glu Leu Val Glu 1140 1145 1150 Lys Leu Gly Asp Leu Leu Gln Ala Asn Val Gln Gln Asp Gly Lys Asp 1155 1160 1165 Tyr Ile Pro Ile Asn Ala Ile Leu Thr Gly Asn Ser Gly Phe Thr Tyr 1170 1175 1180 Ser Thr Pro Ala Phe Ser Glu Asp Phe Phe Lys Glu Ser Ile Ser Ala 1185 1190 1195 1200 Pro Lys Phe Asn Ser Gly Ser Ser Asp Asp Val Arg Tyr Val Asn Ala 1205 1210 1215 Phe Lys Phe Met Ser Leu Glu Arg Ile Lys Thr Phe Glu Glu Leu Leu 1220 1225 1230 Pro Asn Ala Thr Ser Met Phe Asp Asp Tyr Gln Gly Asp Ser Ser Thr 1235 1240 1245 Leu Leu Ala Ser Pro Met Leu Lys Arg Phe Thr Trp Thr Asp Ser Lys 1250 1255 1260 Pro Lys Ala Ser Leu Lys Ile Asp Leu Arg Val Thr Ser Lys Ser Lys 1265 1270 1275 1280 Glu Ser Gly Leu Ser Asp Val Ser Arg Pro Ser Phe Cys His Ser Ser 1285 1290 1295 Cys Gly His Val Ser Glu Gly Lys Arg Arg Phe Thr Tyr Asp His Ala 1300 1305 1310 Glu Leu Glu Arg Lys Ile Ala Cys Cys Ser Pro Pro Pro Asp Tyr Asn 1315 1320 1325 Ser Val Val Leu Tyr Ser Thr Pro Pro Ile 1330 1335 45 309 PRT Homo sapiens 45 Met Asp Glu Lys Val Phe Thr Lys Glu Leu Asp Gln Trp Ile Glu Gln 1 5 10 15 Leu Asn Glu Cys Lys Gln Leu Ser Glu Ser Gln Val Lys Ser Leu Cys 20 25 30 Glu Lys Ala Lys Glu Ile Leu Thr Lys Glu Ser Asn Val Gln Glu Val 35 40 45 Arg Cys Pro Val Thr Val Cys Gly Asp Val His Gly Gln Phe His Asp 50 55 60 Leu Met Glu Leu Phe Arg Ile Gly Gly Lys Ser Pro Asp Thr Asn Tyr 65 70 75 80 Leu Phe Met Gly Asp Tyr Val Asp Arg Gly Tyr Tyr Ser Val Glu Thr 85 90 95 Val Thr Leu Leu Val Ala Leu Lys Val Arg Tyr Arg Glu Arg Ile Thr 100 105 110 Ile Leu Arg Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly 115 120 125 Phe Tyr Asp Glu Cys Leu Arg Lys Tyr Gly Asn Ala Asn Val Trp Lys 130 135 140 Tyr Phe Thr Asp Leu Phe Asp Tyr Leu Pro Leu Thr Ala Leu Val Asp 145 150 155 160 Gly Gln Ile Phe Cys Leu His Gly Gly Leu Ser Pro Ser Ile Asp Thr 165 170 175 Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 180 185 190 Gly Pro Met Cys Asp Leu Leu Trp Ser Asp Pro Asp Asp Arg Gly Gly 195 200 205 Trp Gly Ile Ser Pro Arg Gly Ala Gly Tyr Thr Phe Gly Gln Asp Ile 210 215 220 Ser Glu Thr Phe Asn His Ala Asn Gly Leu Thr Leu Val Ser Arg Ala 225 230 235 240 His Gln Leu Val Met Glu Gly Tyr Asn Trp Cys His Asp Arg Asn Val 245 250 255 Val Thr Ile Phe Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Gln 260 265 270 Ala Ala Ile Met Glu Leu Asp Asp Thr Leu Lys Tyr Ser Phe Leu Gln 275 280 285 Phe Asp Pro Ala Pro Arg Arg Gly Glu Pro His Val Thr Arg Arg Thr 290 295 300 Pro Asp Tyr Phe Leu 305 46 394 PRT Homo sapiens 46 Met Val Thr Met Glu Glu Leu Arg Glu Met Asp Cys Ser Val Leu Lys 1 5 10 15 Arg Leu Met Asn Arg Asp Glu Asn Gly Gly Gly Ala Gly Gly Ser Gly 20 25 30 Ser His Gly Thr Leu Gly Leu Pro Ser Gly Gly Lys Cys Leu Leu Leu 35 40 45 Asp Cys Arg Pro Phe Leu Ala His Ser Ala Gly Tyr Ile Leu Gly Ser 50 55 60 Val Asn Val Arg Cys Asn Thr Ile Val Arg Arg Arg Ala Lys Gly Ser 65 70 75 80 Val Ser Leu Glu Gln Ile Leu Pro Ala Glu Glu Glu Val Arg Ala Arg 85 90 95 Leu Arg Ser Gly Leu Tyr Ser Ala Val Ile Val Tyr Asp Glu Gly Ser 100 105 110 Pro Arg Ala Glu Ser Leu Arg Glu Asp Ser Thr Val Ser Leu Val Val 115 120 125 Gln Ala Leu Arg Arg Asn Ala Glu Arg Thr Asp Ile Cys Leu Leu Lys 130 135 140 Gly Gly Tyr Glu Arg Phe Ser Ser Glu Tyr Pro Glu Phe Cys Ser Lys 145 150 155 160 Thr Lys Ala Leu Ala Ala Ile Pro Pro Pro Val Pro Pro Ser Ala Thr 165 170 175 Glu Pro Leu Asp Leu Gly Cys Ser Ser Cys Gly Thr Pro Leu His Asp 180 185 190 Gln Gly Gly Pro Val Glu Ile Leu Pro Phe Leu Tyr Leu Gly Ser Ala 195 200 205 Tyr His Ala Ala Arg Arg Asp Met Leu Asp Ala Leu Gly Ile Thr Ala 210 215 220 Leu Leu Asn Val Ser Ser Asp Cys Pro Asn His Phe Glu Gly His Tyr 225 230 235 240 Gln Tyr Lys Cys Ile Pro Val Glu Asp Asn His Lys Ala Asp Ile Ser 245 250 255 Ser Trp Phe Met Glu Ala Ile Glu Tyr Ile Asp Ala Val Lys Asp Cys 260 265 270 Arg Gly Arg Val Leu Val His Cys Gln Ala Gly Ile Ser Arg Ser Ala 275 280 285 Thr Ile Cys Leu Ala Tyr Leu Met Met Lys Lys Arg Val Arg Leu Glu 290 295 300 Glu Ala Phe Glu Phe Val Lys Gln Arg Arg Ser Ile Ile Ser Pro Asn 305 310 315 320 Phe Ser Phe Met Gly Gln Leu Leu Gln Phe Glu Ser Gln Val Leu Ala 325 330 335 Thr Ser Cys Ala Ala Glu Ala Ala Ser Pro Ser Gly Pro Leu Arg Glu 340 345 350 Arg Gly Lys Thr Pro Ala Thr Pro Thr Ser Gln Phe Val Phe Ser Phe 355 360 365 Pro Val Ser Val Gly Val His Ser Ala Pro Ser Ser Leu Pro Tyr Leu 370 375 380 His Ser Pro Ile Thr Thr Ser Pro Ser Cys 385 390 47 185 PRT Homo sapiens 47 Met Ser Gly Ser Phe Glu Leu Ser Val Gln Asp Leu Asn Asp Leu Leu 1 5 10 15 Ser Asp Gly Ser Gly Cys Tyr Ser Leu Pro Ser Gln Pro Cys Asn Glu 20 25 30 Val Thr Pro Arg Ile Tyr Val Gly Asn Ala Ser Val Ala Gln Asp Ile 35 40 45 Pro Lys Leu Gln Lys Leu Gly Ile Thr His Val Leu Asn Ala Ala Glu 50 55 60 Gly Arg Ser Phe Met His Val Asn Thr Asn Ala Asn Phe Tyr Lys Asp 65 70 75 80 Ser Gly Ile Thr Tyr Leu Gly Ile Lys Ala Asn Asp Thr Gln Glu Phe 85 90 95 Asn Leu Ser Ala Tyr Phe Glu Arg Ala Ala Asp Phe Ile Asp Gln Ala 100 105 110 Leu Ala Gln Lys Asn Gly Arg Val Leu Val His Cys Arg Glu Gly Tyr 115 120 125 Ser Arg Ser Pro Thr Leu Val Ile Ala Tyr Leu Met Met Arg Gln Lys 130 135 140 Met Asp Val Lys Ser Ala Leu Ser Ile Val Arg Gln Asn Arg Glu Ile 145 150 155 160 Gly Pro Asn Asp Gly Phe Leu Ala Gln Leu Cys Gln Leu Asn Asp Arg 165 170 175 Leu Ala Lys Glu Gly Lys Leu Lys Pro 180 185 48 657 PRT Homo sapiens 48 Met Arg Arg Ala Val Cys Phe Pro Ala Leu Cys Leu Leu Leu Asn Leu 1 5 10 15 His Ala Ala Gly Cys Phe Ser Gly Asn Asn Asp His Phe Leu Ala Ile 20 25 30 Asn Gln Lys Lys Ser Gly Lys Pro Val Phe Ile Tyr Lys His Ser Gln 35 40 45 Asp Ile Glu Lys Ser Leu Asp Ile Ala Pro Gln Lys Ile Tyr Arg His 50 55 60 Ser Tyr His Ser Ser Ser Glu Ala Gln Val Ser Lys Arg His Gln Ile 65 70 75 80 Val Asn Ser Ala Phe Pro Arg Pro Ala Tyr Asp Pro Ser Leu Asn Leu 85 90 95 Leu Ala Met Asp Gly Gln Asp Leu Glu Val Glu Asn Leu Pro Ile Pro 100 105 110 Ala Ala Asn Val Ile Val Val Thr Leu Gln Met Asp Val Asn Lys Leu 115 120 125 Asn Ile Thr Leu Leu Arg Ile Phe Arg Gln Gly Val Ala Ala Ala Leu 130 135 140 Gly Leu Leu Pro Gln Gln Val His Ile Asn Arg Leu Ile Gly Lys Lys 145 150 155 160 Asn Ser Ile Glu Leu Phe Val Ser Pro Ile Asn Arg Lys Thr Gly Ile 165 170 175 Ser Asp Ala Leu Pro Ser Glu Glu Val Leu Arg Ser Leu Asn Ile Asn 180 185 190 Val Leu His Gln Ser Leu Ser Gln Phe Gly Ile Thr Glu Val Ser Pro 195 200 205 Glu Lys Asn Val Leu Gln Gly Gln His Glu Ala Asp Lys Ile Trp Ser 210 215 220 Lys Glu Gly Phe Tyr Ala Val Val Ile Phe Leu Ser Ile Phe Val Ile 225 230 235 240 Ile Val Thr Cys Leu Met Ile Leu Tyr Arg Leu Lys Glu Arg Phe Gln 245 250 255 Leu Ser Leu Arg Gln Asp Lys Glu Lys Asn Gln Glu Ile His Leu Ser 260 265 270 Pro Ile Thr Leu Gln Pro Ala Leu Ser Glu Ala Lys Thr Val His Ser 275 280 285 Met Val Gln Pro Glu Gln Ala Pro Lys Val Leu Asn Val Val Val Asp 290 295 300 Pro Gln Gly Arg Gly Ala Pro Glu Ile Arg Ala Thr Thr Ala Thr Ser 305 310 315 320 Val Cys Pro Ser Pro Phe Lys Met Lys Pro Ile Gly Leu Gln Glu Arg 325 330 335 Arg Gly Ser Asn Val Ser Leu Thr Leu Asp Met Ser Ser Leu Gly Asn 340 345 350 Ile Glu Pro Phe Val Ser Ile Pro Thr Pro Arg Glu Lys Val Ala Met 355 360 365 Glu Tyr Leu Gln Ser Ala Ser Arg Ile Leu Thr Arg Ser Gln Leu Arg 370 375 380 Asp Val Val Ala Ser Ser His Leu Leu Gln Ser Glu Phe Met Glu Ile 385 390 395 400 Pro Met Asn Phe Val Asp Pro Lys Glu Ile Asp Ile Pro Arg His Gly 405 410 415 Thr Lys Asn Arg Tyr Lys Thr Ile Leu Pro Asn Pro Leu Ser Arg Val 420 425 430 Cys Leu Arg Pro Lys Asn Val Thr Asp Ser Leu Ser Thr Tyr Ile Asn 435 440 445 Ala Asn Tyr Ile Arg Gly Tyr Ser Gly Lys Glu Lys Ala Phe Ile Ala 450 455 460 Thr Gln Gly Pro Met Ile Asn Thr Val Asp Asp Phe Trp Gln Met Val 465 470 475 480 Trp Gln Glu Asp Ser Pro Val Ile Val Met Ile Thr Lys Leu Lys Glu 485 490 495 Lys Asn Glu Lys Cys Val Leu Tyr Trp Pro Glu Lys Arg Gly Ile Tyr 500 505 510 Gly Lys Val Glu Val Leu Val Ile Ser Val Asn Glu Cys Asp Asn Tyr 515 520 525 Thr Ile Arg Asn Leu Val Leu Lys Gln Gly Ser His Thr Gln His Val 530 535 540 Lys His Tyr Trp Tyr Thr Ser Trp Pro Asp His Lys Thr Pro Asp Ser 545 550 555 560 Ala Gln Pro Leu Leu Gln Leu Met Leu Asp Val Glu Glu Asp Arg Leu 565 570 575 Ala Ser Gln Gly Arg Gly Pro Val Val Val His Cys Ser Ala Gly Ile 580 585 590 Gly Arg Thr Gly Cys Phe Ile Ala Thr Ser Ile Gly Cys Gln Gln Leu 595 600 605 Lys Glu Glu Gly Val Val Asp Ala Leu Ser Ile Val Cys Gln Leu Arg 610 615 620 Met Asp Arg Gly Gly Met Val Gln Thr Ser Glu Gln Tyr Glu Phe Val 625 630 635 640 His His Ala Leu Cys Leu Tyr Glu Ser Arg Leu Ser Ala Glu Thr Val 645 650 655 Gln 49 537 PRT Homo sapiens 49 Glu Arg Leu Leu Gly Arg Pro Gln Pro Ile Val Met Glu Ala Leu Asp 1 5 10 15 Glu Ala Glu Gly Leu Gln Asp Ser Gln Arg Glu Met Pro Pro Pro Pro 20 25 30 Pro Pro Ser Pro Pro Ser Asp Pro Ala Gln Lys Pro Pro Pro Arg Gly 35 40 45 Ala Gly Ser His Ser Leu Thr Val Arg Ser Ser Leu Cys Leu Phe Ala 50 55 60 Ala Ser Gln Phe Leu Leu Ala Cys Gly Val Leu Trp Phe Ser Gly Tyr 65 70 75 80 Gly His Met Trp Ser Gln Asn Ala Thr Asn Leu Val Ser Ser Leu Leu 85 90 95 Thr Leu Leu Lys Gln Leu Glu Pro Thr Ser Trp Leu Asp Ser Gly Thr 100 105 110 Trp Gly Val Pro Gly Leu Leu Leu Val Phe Leu Ser Val Gly Leu Val 115 120 125 Leu Val Thr Thr Leu Val Trp His Leu Leu Arg Thr Pro Pro Glu Pro 130 135 140 Pro Thr Pro Leu Pro Pro Glu Asp Arg Arg Gln Ser Val Ser Arg Gln 145 150 155 160 Pro Ser Phe Thr Tyr Ser Glu Trp Met Glu Glu Lys Ile Glu Asp Asp 165 170 175 Phe Leu Asp Leu Asp Pro Val Pro Glu Thr Pro Val Phe Asp Cys Val 180 185 190 Met Asp Ile Lys Pro Glu Ala Asp Pro Thr Ser Leu Thr Val Lys Ser 195 200 205 Met Gly Leu Gln Glu Arg Arg Gly Ser Asn Val Ser Leu Thr Leu Asp 210 215 220 Met Cys Thr Pro Gly Cys Asn Glu Glu Gly Phe Gly Tyr Leu Met Ser 225 230 235 240 Pro Arg Glu Glu Ser Ala Arg Glu Tyr Leu Leu Ser Ala Ser Arg Val 245 250 255 Leu Gln Ala Glu Glu Leu His Glu Lys Ala Leu Asp Pro Phe Leu Leu 260 265 270 Gln Ala Glu Phe Phe Glu Ile Pro Met Asn Phe Val Val Pro Lys Glu 275 280 285 Tyr Asp Ile Pro Gly Arg Cys Arg Lys Asn Arg Tyr Lys Thr Ile Leu 290 295 300 Pro Asn Pro His Ser Arg Val Cys Leu Thr Ser Pro Asp Pro Asp Asp 305 310 315 320 Pro Leu Ser Ser Tyr Ile Asn Ala Asn Tyr Ile Arg Gly Tyr Gly Gly 325 330 335 Glu Glu Lys Val Tyr Ile Ala Thr Gln Gly Pro Ile Val Ser Thr Val 340 345 350 Ala Asp Phe Trp Arg Met Val Trp Gln Glu His Thr Pro Ile Ile Val 355 360 365 Met Ile Thr Asn Ile Glu Glu Met Asn Glu Lys Cys Thr Glu Tyr Trp 370 375 380 Pro Glu Glu Gln Val Ala Tyr Asp Gly Val Glu Ile Thr Val Gln Lys 385 390 395 400 Val Ile His Thr Glu Asp Tyr Arg Leu Arg Leu Ile Ser Leu Lys Ser 405 410 415 Gly Thr Glu Glu Arg Gly Leu Lys His Tyr Trp Phe Thr Ser Trp Pro 420 425 430 Asp Gln Lys Thr Pro Asp Arg Ala Pro Pro Leu Leu His Leu Val Arg 435 440 445 Glu Val Glu Glu Ala Ala Gln Gln Glu Gly Pro His Cys Ala Pro Ile 450 455 460 Ile Val His Cys Ser Ala Gly Ile Gly Arg Thr Gly Cys Phe Ile Ala 465 470 475 480 Thr Ser Ile Cys Cys Gln Gln Leu Arg Gln Glu Gly Val Val Asp Ile 485 490 495 Leu Lys Thr Thr Cys Gln Leu Arg Gln Asp Arg Gly Gly Met Ile Gln 500 505 510 His Cys Glu Gln Tyr Gln Phe Val His His Val Met Ser Leu Tyr Glu 515 520 525 Lys Gln Leu Ser His Gln Ser Pro Glu 530 535 50 403 PRT Homo sapiens 50 Met Thr Ala Ile Ile Lys Glu Ile Val Ser Arg Asn Lys Arg Arg Tyr 1 5 10 15 Gln Glu Asp Gly Phe Asp Leu Asp Leu Thr Tyr Ile Tyr Pro Asn Ile 20 25 30 Ile Ala Met Gly Phe Pro Ala Glu Arg Leu Glu Gly Val Tyr Arg Asn 35 40 45 Asn Ile Asp Asp Val Val Arg Phe Leu Asp Ser Lys His Lys Asn His 50 55 60 Tyr Lys Ile Tyr Asn Leu Cys Ala Glu Arg His Tyr Asp Thr Ala Lys 65 70 75 80 Phe Asn Cys Arg Val Ala Gln Tyr Pro Phe Glu Asp His Asn Pro Pro 85 90 95 Gln Leu Glu Leu Ile Lys Pro Phe Cys Glu Asp Leu Asp Gln Trp Leu 100 105 110 Ser Glu Asp Asp Asn His Val Ala Ala Ile His Cys Lys Ala Gly Lys 115 120 125 Gly Arg Thr Gly Val Met Ile Cys Ala Tyr Leu Leu His Arg Gly Lys 130 135 140 Phe Leu Lys Ala Gln Glu Ala Leu Asp Phe Tyr Gly Glu Val Arg Thr 145 150 155 160 Arg Asp Lys Lys Gly Val Thr Ile Pro Ser Gln Arg Arg Tyr Val Tyr 165 170 175 Tyr Tyr Ser Tyr Leu Leu Lys Asn His Leu Asp Tyr Arg Pro Val Ala 180 185 190 Leu Leu Phe His Lys Met Met Phe Glu Thr Ile Pro Met Phe Ser Gly 195 200 205 Gly Thr Cys Asn Pro Gln Phe Val Val Cys Gln Leu Lys Val Lys Ile 210 215 220 Tyr Ser Ser Asn Ser Gly Pro Thr Arg Arg Glu Asp Lys Phe Met Tyr 225 230 235 240 Phe Glu Phe Pro Gln Pro Leu Pro Val Cys Gly Asp Ile Lys Val Glu 245 250 255 Phe Phe His Lys Gln Asn Lys Met Leu Lys Lys Asp Lys Met Phe His 260 265 270 Phe Trp Val Asn Thr Phe Phe Ile Pro Gly Pro Glu Glu Thr Ser Glu 275 280 285 Lys Val Glu Asn Gly Ser Leu Cys Asp Gln Glu Ile Asp Ser Ile Cys 290 295 300 Ser Ile Glu Arg Ala Asp Asn Asp Lys Glu Tyr Leu Val Leu Thr Leu 305 310 315 320 Thr Lys Asn Asp Leu Asp Lys Ala Asn Lys Asp Lys Ala Asn Arg Tyr 325 330 335 Phe Ser Pro Asn Phe Lys Val Lys Leu Tyr Phe Thr Lys Thr Val Glu 340 345 350 Glu Pro Ser Asn Pro Glu Ala Ser Ser Ser Thr Ser Val Thr Pro Asp 355 360 365 Val Ser Asp Asn Glu Pro Asp His Tyr Arg Tyr Ser Asp Thr Thr Asp 370 375 380 Ser Asp Pro Glu Asn Glu Pro Phe Asp Glu Asp Gln His Thr Gln Ile 385 390 395 400 Thr Lys Val 51 447 PRT Homo sapiens 51 Met Arg Ser Ser Thr Leu Gln Asp Pro Arg Arg Arg Asp Pro Gln Asp 1 5 10 15 Asp Val Tyr Val Asp Ile Thr Asp Arg Leu Arg Phe Ala Ile Leu Tyr 20 25 30 Ser Arg Pro Lys Ser Ala Ser Asn Val His Tyr Phe Ser Ile Asp Asn 35 40 45 Glu Leu Glu Tyr Glu Asn Phe Ser Glu Asp Phe Gly Pro Leu Asn Leu 50 55 60 Ala Met Val Tyr Arg Tyr Cys Cys Lys Ile Asn Lys Lys Leu Lys Ser 65 70 75 80 Ile Thr Met Leu Arg Lys Lys Ile Val His Phe Thr Gly Ser Asp Gln 85 90 95 Arg Lys Gln Ala Asn Ala Ala Phe Leu Val Gly Cys Tyr Met Val Ile 100 105 110 Tyr Leu Gly Arg Thr Pro Glu Ala Ala Tyr Arg Ile Leu Ile Phe Gly 115 120 125 Asp Thr Pro Tyr Ile Pro Phe Arg Asp Ala Ala Tyr Gly Ser Cys Asn 130 135 140 Phe Tyr Ile Thr Leu Leu Asp Cys Phe His Ala Val Lys Lys Ala Met 145 150 155 160 Gln Tyr Gly Phe Leu Asn Phe Asn Ser Phe Asn Leu Asp Glu Tyr Glu 165 170 175 His Tyr Glu Lys Ala Glu Asn Gly Asp Leu Asn Trp Ile Ile Pro Asp 180 185 190 Arg Phe Ile Ala Phe Cys Gly Pro His Ser Arg Ala Arg Leu Glu Ser 195 200 205 Gly Tyr His Gln His Ser Pro Glu Thr Tyr Ile Gln Tyr Phe Lys Asn 210 215 220 His Asn Val Thr Thr Ile Ile Arg Leu Asn Lys Arg Met Tyr Asp Ala 225 230 235 240 Lys Arg Phe Thr Asp Ala Gly Phe Asp His His Asp Leu Phe Phe Ala 245 250 255 Asp Gly Ser Thr Pro Thr Asp Ala Ile Val Lys Arg Phe Leu Asp Ile 260 265 270 Cys Glu Asn Ala Glu Gly Ala Ile Ala Val His Cys Lys Ala Gly Leu 275 280 285 Gly Arg Thr Gly Thr Leu Ile Ala Cys Tyr Ile Met Lys His Tyr Arg 290 295 300 Met Thr Ala Ala Glu Thr Ile Ala Trp Val Arg Ile Cys Arg Pro Gly 305 310 315 320 Leu Val Ile Gly Pro Gln Gln Gln Phe Leu Val Met Lys Gln Thr Ser 325 330 335 Leu Trp Leu Glu Gly Asp Tyr Phe Arg Gln Arg Leu Lys Gly Gln Glu 340 345 350 Asn Gly Gln His Arg Ala Ala Phe Ser Lys Leu Leu Ser Gly Val Asp 355 360 365 Asp Ile Ser Ile Asn Gly Val Glu Asn Gln Asp Gln Gln Glu Pro Lys 370 375 380 Pro Tyr Ser Asp Asp Asp Glu Ile Asn Gly Val Thr Gln Gly Asp Arg 385 390 395 400 Ser Arg Ala Leu Lys Arg Arg Arg Gln Ser Lys Thr Asn Asp Ile Leu 405 410 415 Leu Pro Ser Pro Leu Ala Val Leu Thr Phe Thr Leu Cys Ser Val Val 420 425 430 Ile Trp Trp Ile Val Cys Asp Tyr Ile Leu Pro Ile Leu Leu Phe 435 440 445 52 340 PRT Homo sapiens 52 Met Leu Glu Ala Pro Gly Pro Ser Asp Gly Cys Glu Leu Ser Asn Pro 1 5 10 15 Ser Ala Ser Arg Val Ser Cys Ala Gly Gln Met Leu Glu Val Gln Pro 20 25 30 Gly Leu Tyr Phe Gly Gly Ala Ala Ala Val Ala Glu Pro Asp His Leu 35 40 45 Arg Glu Ala Gly Ile Thr Ala Val Leu Thr Val Asp Ser Glu Glu Pro 50 55 60 Ser Phe Lys Ala Gly Pro Gly Val Glu Asp Leu Trp Arg Leu Phe Val 65 70 75 80 Pro Ala Leu Asp Lys Pro Glu Thr Asp Leu Leu Ser His Leu Asp Arg 85 90 95 Cys Val Ala Phe Ile Gly Gln Ala Arg Ala Glu Gly Arg Ala Val Leu 100 105 110 Val His Cys His Ala Gly Val Ser Arg Ser Val Ala Ile Ile Thr Ala 115 120 125 Phe Leu Met Lys Thr Asp Gln Leu Pro Phe Glu Lys Ala Tyr Glu Lys 130 135 140 Leu Gln Ile Leu Lys Pro Glu Ala Lys Met Asn Glu Gly Phe Glu Trp 145 150 155 160 Gln Leu Lys Leu Tyr Gln Ala Met Gly Tyr Glu Val Asp Thr Ser Ser 165 170 175 Ala Ile Tyr Lys Gln Tyr Arg Leu Gln Lys Val Thr Glu Lys Tyr Pro 180 185 190 Glu Leu Gln Asn Leu Pro Gln Glu Leu Phe Ala Val Asp Pro Thr Thr 195 200 205 Val Ser Gln Gly Leu Lys Asp Glu Val Leu Tyr Lys Cys Arg Lys Cys 210 215 220 Arg Arg Ser Leu Phe Arg Ser Ser Ser Ile Leu Asp His Arg Glu Gly 225 230 235 240 Ser Gly Pro Ile Ala Phe Ala His Lys Arg Met Thr Pro Ser Ser Met 245 250 255 Leu Thr Thr Gly Arg Gln Ala Gln Cys Thr Ser Tyr Phe Ile Glu Pro 260 265 270 Val Gln Trp Met Glu Ser Ala Leu Leu Gly Val Met Asp Gly Gln Leu 275 280 285 Leu Cys Pro Lys Cys Ser Ala Lys Leu Gly Ser Phe Asn Trp Tyr Gly 290 295 300 Glu Gln Cys Ser Cys Gly Arg Trp Ile Thr Pro Ala Phe Gln Ile His 305 310 315 320 Lys Asn Arg Val Asp Glu Met Lys Ile Leu Pro Val Leu Gly Ser Gln 325 330 335 Thr Gly Lys Ile 340 53 150 PRT Homo sapiens 53 Met Gly Val Gln Pro Pro Asn Phe Ser Trp Val Leu Pro Gly Arg Leu 1 5 10 15 Ala Gly Leu Ala Leu Pro Arg Leu Pro Ala His Tyr Gln Phe Leu Leu 20 25 30 Asp Leu Gly Val Arg His Leu Val Ser Leu Thr Glu Arg Gly Pro Pro 35 40 45 His Ser Asp Ser Cys Pro Gly Leu Thr Leu His Arg Leu Arg Ile Pro 50 55 60 Asp Phe Cys Pro Pro Ala Pro Asp Gln Ile Asp Arg Phe Val Gln Ile 65 70 75 80 Val Asp Glu Ala Asn Ala Arg Gly Glu Ala Val Gly Val His Cys Ala 85 90 95 Leu Gly Phe Gly Arg Thr Gly Thr Met Leu Ala Cys Tyr Leu Val Lys 100 105 110 Glu Arg Gly Leu Ala Ala Gly Asp Ala Ile Ala Glu Ile Arg Arg Leu 115 120 125 Arg Pro Gly Pro Ile Glu Thr Tyr Glu Gln Glu Lys Ala Val Phe Gln 130 135 140 Phe Tyr Gln Arg Thr Lys 145 150 54 322 PRT Homo sapiens 54 Gly Leu Met Leu Arg Arg Leu Arg Lys Gly Asn Leu Pro Ile Arg Ser 1 5 10 15 Ile Ile Pro Asn His Ala Asp Lys Glu Arg Phe Ala Thr Arg Cys Lys 20 25 30 Ala Ala Thr Val Leu Leu Tyr Asp Glu Ala Thr Ala Glu Trp Gln Pro 35 40 45 Glu Pro Gly Ala Pro Ala Ser Val Leu Gly Leu Leu Leu Gln Lys Leu 50 55 60 Arg Asp Asp Gly Cys Gln Ala Tyr Tyr Leu Gln Gly Gly Phe Asn Lys 65 70 75 80 Phe Gln Thr Glu Tyr Ser Glu His Cys Glu Thr Asn Val Asp Ser Ser 85 90 95 Ser Ser Pro Ser Ser Ser Pro Pro Thr Ser Val Leu Gly Leu Gly Gly 100 105 110 Leu Arg Ile Ser Ser Asp Cys Ser Asp Gly Glu Ser Asp Arg Glu Leu 115 120 125 Pro Ser Ser Ala Thr Glu Ser Asp Gly Ser Pro Val Pro Ser Ser Gln 130 135 140 Pro Ala Phe Pro Val Gln Ile Leu Pro Tyr Leu Tyr Leu Gly Cys Ala 145 150 155 160 Lys Asp Ser Thr Asn Leu Asp Val Leu Gly Lys Tyr Gly Ile Lys Tyr 165 170 175 Ile Leu Asn Val Thr Pro Asn Leu Pro Asn Ala Phe Glu His Gly Gly 180 185 190 Glu Phe Thr Tyr Lys Gln Ile Pro Ile Ser Asp His Trp Ser Gln Asn 195 200 205 Leu Ser Gln Phe Phe Pro Glu Ala Ile Ser Phe Ile Asp Glu Ala Arg 210 215 220 Ser Lys Lys Cys Gly Val Leu Val His Cys Leu Ala Gly Ile Ser Arg 225 230 235 240 Ser Val Thr Val Thr Val Ala Tyr Leu Met Gln Lys Met Asn Leu Ser 245 250 255 Leu Asn Asp Ala Tyr Asp Phe Val Lys Arg Lys Lys Ser Asn Ile Ser 260 265 270 Pro Asn Phe Asn Phe Met Gly Gln Leu Leu Asp Phe Glu Arg Thr Leu 275 280 285 Gly Leu Ser Ser Pro Cys Asp Asn His Ala Ser Ser Glu Gln Leu Tyr 290 295 300 Phe Ser Thr Pro Thr Asn His Asn Leu Phe Pro Leu Asn Thr Leu Glu 305 310 315 320 Ser Thr 55 521 PRT Homo sapiens 55 Met Ser Glu Pro Lys Ala Ile Asp Pro Lys Leu Ser Thr Thr Asp Arg 1 5 10 15 Val Val Lys Ala Val Pro Phe Pro Pro Ser His Arg Leu Thr Ala Lys 20 25 30 Glu Val Phe Asp Asn Asp Gly Lys Pro Arg Val Asp Ile Leu Lys Ala 35 40 45 His Leu Met Lys Glu Gly Arg Leu Glu Glu Ser Val Ala Leu Arg Ile 50 55 60 Ile Thr Glu Gly Ala Ser Ile Leu Arg Gln Glu Lys Asn Leu Leu Asp 65 70 75 80 Ile Asp Ala Pro Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Phe 85 90 95 Asp Leu Met Lys Leu Phe Glu Val Gly Gly Ser Pro Ala Asn Thr Arg 100 105 110 Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Tyr Phe Ser Ile Glu 115 120 125 Cys Val Leu Tyr Leu Trp Ala Leu Lys Ile Leu Tyr Pro Lys Thr Leu 130 135 140 Phe Leu Leu Arg Gly Asn His Glu Cys Arg His Leu Thr Glu Tyr Phe 145 150 155 160 Thr Phe Lys Gln Glu Cys Lys Ile Lys Tyr Ser Glu Arg Val Tyr Asp 165 170 175 Ala Cys Met Asp Ala Phe Asp Cys Leu Pro Leu Ala Ala Leu Met Asn 180 185 190 Gln Gln Phe Leu Cys Val His Gly Gly Leu Ser Pro Glu Ile Asn Thr 195 200 205 Leu Asp Asp Ile Arg Lys Leu Asp Arg Phe Lys Glu Pro Pro Ala Tyr 210 215 220 Gly Pro Met Cys Asp Ile Leu Trp Ser Asp Pro Leu Glu Asp Phe Gly 225 230 235 240 Asn Glu Lys Thr Gln Glu His Phe Thr His Asn Thr Val Arg Gly Cys 245 250 255 Ser Tyr Phe Tyr Ser Tyr Pro Ala Val Cys Glu Phe Leu Gln His Asn 260 265 270 Asn Leu Leu Ser Ile Leu Arg Ala His Glu Ala Gln Asp Ala Gly Tyr 275 280 285 Arg Met Tyr Arg Lys Ser Gln Thr Thr Gly Phe Pro Ser Leu Ile Thr 290 295 300 Ile Phe Ser Ala Pro Asn Tyr Leu Asp Val Tyr Asn Asn Lys Ala Ala 305 310 315 320 Val Leu Lys Tyr Glu Asn Asn Val Met Asn Ile Arg Gln Phe Asn Cys 325 330 335 Ser Pro His Pro Tyr Trp Leu Pro Asn Phe Met Asp Val Phe Thr Trp 340 345 350 Ser Leu Pro Phe Val Gly Glu Lys Val Thr Glu Met Leu Val Asn Val 355 360 365 Leu Asn Ile Cys Ser Asp Asp Glu Leu Gly Ser Glu Glu Asp Gly Phe 370 375 380 Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys Ile 385 390 395 400 Arg Ala Ile Gly Lys Met Ala Arg Val Phe Ser Val Leu Arg Glu Glu 405 410 415 Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly Met Leu 420 425 430 Pro Ser Gly Val Leu Ser Gly Gly Lys Gln Thr Leu Gln Ser Ala Thr 435 440 445 Val Glu Ala Ile Glu Ala Asp Glu Ala Ile Lys Gly Phe Ser Pro Gln 450 455 460 His Lys Ile Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg Ile Asn 465 470 475 480 Glu Arg Met Pro Pro Arg Arg Asp Ala Met Pro Ser Asp Ala Asn Leu 485 490 495 Asn Ser Ile Asn Lys Ala Leu Thr Ser Glu Thr Asn Gly Thr Asp Ser 500 505 510 Asn Gly Ser Asn Ser Ser Asn Ile Gln 515 520 56 1267 PRT Homo sapiens 56 Asp Leu Ser Arg Ser His Cys His Val Tyr Leu Ala His Leu Glu Asn 1 5 10 15 Ser Phe Gly Pro Ser Gly Ala Arg Glu Gly Ser Leu Ser Ser Gln Asp 20 25 30 Ser Arg Thr Glu Ser Ala Ser Leu Ser Gln Ser Gln Val Asn Gly Phe 35 40 45 Phe Ala Ser His Leu Gly Asp Gln Thr Trp Gln Glu Ser Gln His Gly 50 55 60 Ser Pro Ser Pro Ser Val Ile Ser Lys Ala Thr Glu Lys Glu Thr Phe 65 70 75 80 Thr Asp Ser Asn Gln Ser Lys Thr Lys Lys Pro Gly Ile Ser Asp Val 85 90 95 Thr Asp Tyr Ser Asp Arg Gly Asp Ser Asp Met Asp Glu Ala Thr Tyr 100 105 110 Ser Ser Ser Gln Asp His Gln Thr Pro Lys Gln Glu Ser Ser Ser Ser 115 120 125 Val Asn Thr Ser Asn Lys Met Asn Phe Lys Thr Phe Pro Ser Ser Pro 130 135 140 Pro Arg Ser Gly Asp Ile Phe Glu Val Glu Leu Ala Lys Asn Asp Asn 145 150 155 160 Ser Leu Gly Ile Ser Val Thr Gly Gly Val Asn Thr Ser Val Arg His 165 170 175 Gly Gly Ile Tyr Val Lys Ala Val Ile Pro Gln Gly Ala Ala Glu Ser 180 185 190 Asp Gly Arg Ile His Lys Gly Asp Arg Val Leu Ala Val Asn Gly Val 195 200 205 Ser Leu Glu Gly Ala Thr His Lys Gln Ala Val Glu Thr Leu Arg Asn 210 215 220 Thr Gly Gln Val Val His Leu Leu Leu Glu Lys Gly Gln Ser Pro Thr 225 230 235 240 Ser Lys Glu His Val Pro Val Thr Pro Gln Cys Thr Leu Ser Asp Gln 245 250 255 Asn Ala Gln Gly Gln Gly Pro Glu Lys Val Lys Lys Thr Thr Gln Val 260 265 270 Lys Asp Tyr Ser Phe Val Thr Glu Glu Asn Thr Phe Glu Val Lys Leu 275 280 285 Phe Lys Asn Ser Ser Gly Leu Gly Phe Ser Phe Ser Arg Glu Asp Asn 290 295 300 Leu Ile Pro Glu Gln Ile Asn Ala Ser Ile Val Arg Val Lys Lys Leu 305 310 315 320 Phe Pro Gly Gln Pro Ala Ala Glu Ser Gly Lys Ile Asp Val Gly Asp 325 330 335 Val Ile Leu Lys Val Asn Gly Ala Ser Leu Lys Gly Leu Ser Gln Gln 340 345 350 Glu Val Ile Ser Ala Leu Arg Gly Thr Ala Pro Glu Val Phe Leu Leu 355 360 365 Leu Cys Arg Pro Pro Pro Gly Val Leu Pro Glu Ile Asp Thr Ala Leu 370 375 380 Leu Thr Pro Leu Gln Ser Pro Ala Gln Val Leu Pro Asn Ser Ser Lys 385 390 395 400 Asp Ser Ser Gln Pro Ser Cys Val Glu Gln Ser Thr Ser Ser Asp Glu 405 410 415 Asn Glu Met Ser Asp Lys Ser Lys Lys Gln Cys Lys Ser Pro Ser Arg 420 425 430 Lys Asp Ser Tyr Ser Asp Ser Ser Gly Ser Gly Glu Asp Asp Leu Val 435 440 445 Thr Ala Pro Ala Asn Ile Ser Asn Ser Thr Trp Ser Ser Ala Leu His 450 455 460 Gln Thr Leu Ser Asn Met Val Ser Gln Ala Gln Ser His His Glu Ala 465 470 475 480 Pro Arg Val Lys Lys Ile Pro Phe Val Pro Cys Phe Thr Ile Leu Arg 485 490 495 Lys Arg Pro Asn Lys Pro Glu Phe Glu Asp Ser Asn Pro Ser Pro Leu 500 505 510 Pro Pro Asp Met Ala Pro Gly Gln Ser Tyr Gln Pro Gln Ser Glu Ser 515 520 525 Ala Ser Ser Ser Ser Met Asp Lys Tyr His Ile His His Ile Ser Glu 530 535 540 Pro Thr Arg Gln Glu Asn Trp Thr Pro Leu Lys Asn Asp Leu Glu Asn 545 550 555 560 His Leu Glu Asp Phe Glu Leu Glu Val Glu Leu Leu Ile Thr Leu Ile 565 570 575 Lys Ser Glu Lys Gly Ser Leu Gly Phe Thr Val Thr Lys Gly Asn Gln 580 585 590 Arg Ile Gly Cys Tyr Val His Asp Val Ile Gln Asp Pro Ala Lys Ser 595 600 605 Asp Gly Arg Leu Lys Pro Gly Asp Arg Leu Ile Lys Val Asn Asp Thr 610 615 620 Asp Val Thr Asn Met Thr His Thr Asp Ala Val Asn Leu Leu Arg Gly 625 630 635 640 Ser Lys Thr Val Arg Leu Val Ile Gly Arg Val Leu Glu Leu Pro Arg 645 650 655 Ile Pro Met Leu Pro His Leu Leu Pro Asp Ile Thr Leu Thr Cys Asn 660 665 670 Lys Glu Glu Leu Gly Phe Ser Leu Cys Gly Gly His Asp Ser Leu Tyr 675 680 685 Gln Val Val Tyr Ile Ser Asp Ile Asn Pro Arg Ser Val Ala Ala Ile 690 695 700 Glu Gly Asn Leu Gln Leu Leu Asp Val Ile His Tyr Val Asn Gly Val 705 710 715 720 Ser Thr Gln Gly Met Thr Leu Glu Glu Val Asn Arg Ala Leu Asp Met 725 730 735 Ser Leu Pro Ser Leu Val Leu Lys Ala Thr Arg Asn Asp Leu Pro Val 740 745 750 Val Pro Ser Ser Lys Arg Ser Ala Val Ser Ala Pro Lys Ser Thr Lys 755 760 765 Gly Asn Gly Ser Tyr Ser Val Gly Ser Cys Ser Gln Pro Ala Leu Thr 770 775 780 Pro Asn Asp Ser Phe Ser Thr Val Ala Gly Glu Glu Ile Asn Glu Ile 785 790 795 800 Ser Tyr Pro Lys Gly Lys Cys Ser Thr Tyr Gln Ile Lys Gly Ser Pro 805 810 815 Asn Leu Thr Leu Pro Lys Glu Ser Tyr Ile Gln Glu Asp Asp Ile Tyr 820 825 830 Asp Asp Ser Gln Glu Ala Glu Val Ile Gln Ser Leu Leu Asp Val Val 835 840 845 Asp Glu Glu Ser Gln Asn Leu Leu Asn Glu Asn Asn Ala Ala Gly Tyr 850 855 860 Ser Cys Gly Pro Gly Thr Leu Lys Met Asn Gly Lys Leu Ser Glu Glu 865 870 875 880 Arg Thr Glu Asp Thr Asp Cys Asp Gly Ser Pro Leu Pro Glu Tyr Phe 885 890 895 Thr Glu Ala Thr Lys Met Asn Gly Cys Glu Glu Tyr Cys Glu Glu Lys 900 905 910 Val Lys Ser Glu Ser Leu Ile Gln Lys Pro Gln Glu Lys Lys Thr Asp 915 920 925 Asp Asp Glu Ile Thr Trp Gly Asn Asp Glu Leu Pro Ile Glu Arg Thr 930 935 940 Asn His Glu Asp Ser Asp Lys Asp His Ser Phe Leu Thr Asn Asp Glu 945 950 955 960 Leu Ala Val Leu Pro Val Val Lys Val Leu Pro Ser Gly Lys Tyr Thr 965 970 975 Gly Ala Asn Leu Lys Ser Val Ile Arg Val Leu Arg Val Ala Arg Ser 980 985 990 Gly Ile Pro Ser Lys Glu Leu Glu Asn Leu Gln Glu Leu Lys Pro Leu 995 1000 1005 Asp Gln Cys Leu Ile Gly Gln Thr Lys Glu Asn Arg Arg Lys Asn Arg 1010 1015 1020 Tyr Lys Asn Ile Leu Pro Tyr Asp Ala Thr Arg Val Pro Leu Gly Asp 1025 1030 1035 1040 Glu Gly Gly Tyr Ile Asn Ala Ser Phe Ile Lys Ile Pro Val Gly Lys 1045 1050 1055 Glu Glu Phe Val Tyr Ile Ala Cys Gln Gly Pro Leu Pro Thr Thr Val 1060 1065 1070 Gly Asp Phe Trp Gln Met Ile Trp Glu Gln Lys Ser Thr Val Ile Ala 1075 1080 1085 Met Met Thr Gln Glu Val Glu Gly Glu Lys Ile Lys Cys Gln Arg Tyr 1090 1095 1100 Trp Pro Asn Ile Leu Gly Lys Thr Thr Met Val Ser Asn Arg Leu Arg 1105 1110 1115 1120 Leu Ala Leu Val Arg Met Gln Gln Leu Lys Gly Phe Val Val Arg Ala 1125 1130 1135 Met Thr Leu Glu Asp Ile Gln Thr Arg Glu Val Arg His Ile Ser His 1140 1145 1150 Leu Asn Phe Thr Ala Trp Pro Asp His Asp Thr Pro Ser Gln Pro Asp 1155 1160 1165 Asp Leu Leu Thr Phe Ile Ser Tyr Met Arg His Ile His Arg Ser Gly 1170 1175 1180 Pro Ile Ile Thr His Cys Ser Ala Gly Ile Gly Arg Ser Gly Thr Leu 1185 1190 1195 1200 Ile Cys Ile Asp Val Val Leu Gly Leu Ile Ser Gln Asp Leu Asp Phe 1205 1210 1215 Asp Ile Ser Asp Leu Val Arg Cys Met Arg Leu Gln Arg His Gly Met 1220 1225 1230 Val Gln Thr Glu Asp Gln Tyr Ile Phe Cys Tyr Gln Val Ile Leu Tyr 1235 1240 1245 Val Leu Thr Arg Leu Gln Ala Glu Glu Glu Gln Lys Gln Gln Pro Gln 1250 1255 1260 Leu Leu Lys 1265 57 551 PRT Homo sapiens 57 Met Asn Glu Ser Pro Asp Pro Thr Asp Leu Ala Gly Val Ile Ile Glu 1 5 10 15 Leu Gly Pro Asn Asp Ser Pro Gln Thr Ser Glu Phe Lys Gly Ala Thr 20 25 30 Glu Glu Ala Pro Ala Lys Glu Ser Pro His Thr Ser Glu Phe Lys Gly 35 40 45 Ala Ala Arg Val Ser Pro Ile Ser Glu Ser Val Leu Ala Arg Leu Ser 50 55 60 Lys Phe Glu Val Glu Asp Ala Glu Asn Val Ala Ser Tyr Asp Ser Lys 65 70 75 80 Ile Lys Lys Ile Val His Ser Ile Val Ser Ser Phe Ala Phe Gly Leu 85 90 95 Phe Gly Val Phe Leu Val Leu Leu Asp Val Thr Leu Ile Leu Ala Asp 100 105 110 Leu Ile Phe Thr Asp Ser Lys Leu Tyr Ile Pro Leu Glu Tyr Arg Ser 115 120 125 Ile Ser Leu Ala Ile Ala Leu Phe Phe Leu Met Asp Val Leu Leu Arg 130 135 140 Val Phe Val Glu Arg Arg Gln Gln Tyr Phe Ser Asp Leu Phe Asn Ile 145 150 155 160 Leu Asp Thr Ala Ile Ile Val Ile Leu Leu Leu Val Asp Val Val Tyr 165 170 175 Ile Phe Phe Asp Ile Lys Leu Leu Arg Asn Ile Pro Arg Trp Thr His 180 185 190 Leu Leu Arg Leu Leu Arg Leu Ile Ile Leu Leu Arg Ile Phe His Leu 195 200 205 Phe His Gln Lys Arg Gln Leu Glu Lys Leu Ile Arg Arg Arg Val Ser 210 215 220 Glu Asn Lys Arg Arg Tyr Thr Arg Asp Gly Phe Asp Leu Asp Leu Thr 225 230 235 240 Tyr Val Thr Glu Arg Ile Ile Ala Met Ser Phe Pro Ser Ser Gly Arg 245 250 255 Gln Ser Phe Tyr Arg Asn Pro Ile Lys Glu Val Val Arg Phe Leu Asp 260 265 270 Lys Lys His Arg Asn His Tyr Arg Val Tyr Asn Leu Cys Ser Glu Arg 275 280 285 Ala Tyr Asp Pro Lys His Phe His Asn Arg Val Val Arg Ile Met Ile 290 295 300 Asp Asp His Asn Val Pro Thr Leu His Gln Met Val Val Phe Thr Lys 305 310 315 320 Glu Val Asn Glu Trp Met Ala Gln Asp Leu Glu Asn Ile Val Ala Ile 325 330 335 His Cys Lys Gly Gly Thr Asp Arg Thr Gly Thr Met Val Cys Ala Phe 340 345 350 Leu Ile Ala Ser Glu Ile Cys Ser Thr Ala Lys Glu Ser Leu Tyr Tyr 355 360 365 Phe Gly Glu Arg Arg Thr Asp Lys Thr His Ser Glu Lys Phe Gln Gly 370 375 380 Val Glu Thr Pro Ser Gln Lys Arg Tyr Val Ala Tyr Phe Ala Gln Val 385 390 395 400 Lys His Leu Tyr Asn Trp Asn Leu Pro Pro Arg Arg Ile Leu Phe Ile 405 410 415 Lys His Phe Ile Ile Tyr Ser Ile Pro Arg Tyr Val Arg Asp Leu Lys 420 425 430 Ile Gln Ile Glu Met Glu Lys Lys Val Val Phe Ser Thr Ile Ser Leu 435 440 445 Gly Lys Cys Ser Val Leu Asp Asn Ile Thr Thr Asp Lys Ile Leu Ile 450 455 460 Asp Val Phe Asp Gly Pro Pro Leu Tyr Asp Asp Val Lys Val Gln Phe 465 470 475 480 Phe Tyr Ser Asn Leu Pro Thr Tyr Tyr Asp Asn Cys Ser Phe Tyr Phe 485 490 495 Trp Leu His Thr Ser Phe Ile Glu Asn Asn Arg Leu Tyr Leu Pro Lys 500 505 510 Asn Glu Leu Asp Asn Leu His Lys Gln Lys Ala Arg Arg Ile Tyr Pro 515 520 525 Ser Asp Phe Ala Val Glu Ile Leu Phe Gly Glu Lys Met Thr Ser Ser 530 535 540 Asp Val Val Ala Gly Ser Asp 545 550 58 323 PRT Homo sapiens 58 Met Ala Asp Leu Asp Lys Leu Asn Ile Asp Ser Ile Ile Gln Arg Leu 1 5 10 15 Leu Glu Val Arg Gly Ser Lys Pro Gly Lys Asn Val Gln Leu Gln Glu 20 25 30 Asn Glu Ile Arg Gly Leu Cys Leu Lys Ser Arg Glu Ile Phe Leu Ser 35 40 45 Gln Pro Ile Leu Leu Glu Leu Glu Ala Pro Leu Lys Ile Cys Gly Asp 50 55 60 Ile His Gly Gln Tyr Tyr Asp Leu Leu Arg Leu Phe Glu Tyr Gly Gly 65 70 75 80 Phe Pro Pro Glu Ser Asn Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg 85 90 95 Gly Lys Gln Ser Leu Glu Thr Ile Cys Leu Leu Leu Ala Tyr Lys Ile 100 105 110 Lys Tyr Pro Glu Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala 115 120 125 Ser Ile Asn Arg Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr 130 135 140 Asn Ile Lys Leu Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro 145 150 155 160 Ile Ala Ala Ile Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu 165 170 175 Ser Pro Asp Leu Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro 180 185 190 Thr Asp Val Pro Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp 195 200 205 Pro Asp Lys Asp Val Leu Gly Trp Gly Glu Asn Asp Arg Gly Val Ser 210 215 220 Phe Thr Phe Gly Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp 225 230 235 240 Leu Asp Leu Ile Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu 245 250 255 Phe Phe Ala Lys Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr 260 265 270 Cys Gly Glu Phe Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr 275 280 285 Leu Met Cys Ser Phe Gln Ile Leu Lys Pro Ala Glu Lys Lys Lys Pro 290 295 300 Asn Ala Thr Arg Pro Val Thr Pro Pro Arg Gly Met Ile Thr Lys Gln 305 310 315 320 Ala Lys Lys 59 319 PRT Homo sapiens 59 Asp Lys Leu Asn Ile Asp Ser Ile Ile Gln Arg Leu Leu Glu Val Arg 1 5 10 15 Gly Ser Lys Pro Gly Lys Asn Val Gln Leu Gln Glu Asn Glu Ile Arg 20 25 30 Gly Leu Cys Leu Lys Ser Arg Glu Ile Phe Leu Ser Gln Pro Ile Leu 35 40 45 Leu Glu Leu Glu Ala Pro Leu Lys Ile Cys Gly Asp Ile His Gly Gln 50 55 60 Tyr Tyr Asp Leu Leu Arg Leu Phe Glu Tyr Gly Gly Phe Pro Pro Glu 65 70 75 80 Ser Asn Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Lys Gln Ser 85 90 95 Leu Glu Thr Ile Cys Leu Leu Leu Ala Tyr Lys Ile Lys Tyr Pro Glu 100 105 110 Asn Phe Phe Leu Leu Arg Gly Asn His Glu Cys Ala Ser Ile Asn Arg 115 120 125 Ile Tyr Gly Phe Tyr Asp Glu Cys Lys Arg Arg Tyr Asn Ile Lys Leu 130 135 140 Trp Lys Thr Phe Thr Asp Cys Phe Asn Cys Leu Pro Ile Ala Ala Ile 145 150 155 160 Val Asp Glu Lys Ile Phe Cys Cys His Gly Gly Leu Ser Pro Asp Leu 165 170 175 Gln Ser Met Glu Gln Ile Arg Arg Ile Met Arg Pro Thr Asp Val Pro 180 185 190 Asp Gln Gly Leu Leu Cys Asp Leu Leu Trp Ser Asp Pro Asp Lys Asp 195 200 205 Val Leu Gly Trp Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly 210 215 220 Ala Glu Val Val Ala Lys Phe Leu His Lys His Asp Leu Asp Leu Ile 225 230 235 240 Cys Arg Ala His Gln Val Val Glu Asp Gly Tyr Glu Phe Phe Ala Lys 245 250 255 Arg Gln Leu Val Thr Leu Phe Ser Ala Pro Asn Tyr Cys Gly Glu Phe 260 265 270 Asp Asn Ala Gly Ala Met Met Ser Val Asp Glu Thr Leu Met Cys Ser 275 280 285 Phe Gln Ile Leu Lys Pro Ala Glu Lys Lys Lys Pro Asn Ala Thr Arg 290 295 300 Pro Val Thr Pro Pro Arg Gly Met Ile Thr Lys Gln Ala Lys Lys 305 310 315 60 309 PRT Homo sapiens 60 Met Asp Glu Lys Val Phe Thr Lys Glu Leu Asp Gln Trp Ile Glu Gln 1 5 10 15 Leu Asn Glu Cys Lys Gln Leu Ser Glu Ser Gln Val Lys Ser Leu Cys 20 25 30 Glu Lys Ala Lys Glu Ile Leu Thr Lys Glu Ser Asn Val Gln Glu Val 35 40 45 Arg Cys Pro Val Thr Val Cys Gly Asp Val His Gly Gln Phe His Asp 50 55 60 Leu Met Glu Leu Phe Arg Ile Gly Gly Lys Ser Pro Asp Thr Asn Tyr 65 70 75 80 Leu Phe Met Gly Asp Tyr Val Asp Arg Gly Tyr Tyr Ser Val Glu Thr 85 90 95 Val Thr Leu Leu Val Ala Leu Lys Val Arg Tyr Arg Glu Arg Ile Thr 100 105 110 Ile Leu Arg Gly Asn His Glu Ser Arg Gln Ile Thr Gln Val Tyr Gly 115 120 125 Phe Tyr Asp Glu Cys Leu Arg Lys Tyr Gly Asn Ala Asn Val Trp Lys 130 135 140 Tyr Phe Thr Asp Leu Phe Asp Tyr Leu Pro Leu Thr Ala Leu Val Asp 145 150 155 160 Gly Gln Ile Phe Cys Leu His Gly Gly Leu Ser Pro Ser Ile Asp Thr 165 170 175 Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 180 185 190 Gly Pro Met Cys Asp Leu Leu Trp Ser Asp Pro Asp Asp Arg Gly Gly 195 200 205 Trp Gly Ile Ser Pro Arg Gly Ala Gly Tyr Thr Phe Gly Gln Asp Ile 210 215 220 Ser Glu Thr Phe Asn His Ala Asn Gly Leu Thr Leu Val Ser Arg Ala 225 230 235 240 His Gln Leu Val Met Glu Gly Tyr Asn Trp Cys His Asp Arg Asn Val 245 250 255 Val Thr Ile Phe Ser Ala Pro Asn Tyr Cys Tyr Arg Cys Gly Asn Gln 260 265 270 Ala Ala Ile Met Glu Leu Asp Asp Thr Leu Lys Tyr Ser Phe Leu Gln 275 280 285 Phe Asp Pro Ala Pro Arg Arg Gly Glu Pro His Val Thr Arg Arg Thr 290 295 300 Pro Asp Tyr Phe Leu 305 61 20 DNA Artificial Sequence Artificially Synthesized Primer Sequence 61 tacggaagtg ttacttctgc 20 62 20 DNA Artificial Sequence Artificially Synthesized Primer Sequence 62 tgtgggaggt tttttctcta 20 63 17 DNA Artificial Sequence Artificially Synthesized Primer Sequence 63 gttttcccag tcacgac 17 64 17 DNA Artificial Sequence Artificially Synthesized Primer Sequence 64 caggaaacag ctatgac 17 

What is claimed is:
 1. An isolated nucleic acid of any one of (a) to (d) below: (a) a nucleic acid encoding a protein comprising the amino acid sequence of any one of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, (b) a nucleic acid comprising a coding region in the nucleotide sequence of any one of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21, (c) a nucleic acid encoding a protein that comprises the amino acid sequence of any one of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, in which one or more amino acids are replaced, deleted, inserted and/or added and that is functionally equivalent to the protein comprising the amino acid sequence of any one of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, and (d) a nucleic acid that hybridizes under stringent conditions with the nucleic acid comprising the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21, and that encodes a protein finctionally equivalent to the protein comprising the amino acid sequence of any one of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or
 22. 2. An isolated nucleic acid encoding the amino acid sequence of any one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22 or a fragment thereof.
 3. A vector into which the nucleic acid of claim 1 is inserted.
 4. A vector into which the nucleic acid of claim 2 is inserted.
 5. A transformant harboring the nucleic acid of claim
 1. 6. A transformant harboring the nucleic acid of claim
 2. 7. A transformant harboring the vector of claim
 3. 8. A transformant harboring the vector of claim
 4. 9. A substan t ially purified polypeptide encoded by the nucleic acid of claim
 1. 10. A substantially purified polypeptide encoded by the nucleic acid of claim
 2. 11. A method for producing a polypeptide, the method comprising the steps of culturing the transformant of claim 7 and recovering a polypeptide expressed from the transformant or the culture supernatant thereof.
 12. A method for producing a polypeptide, the method comprising the steps of culturing the transformant of claim 8 and recovering a polypeptide expressed from the transformant or the culture supernatant thereof.
 13. An antibody against the polypeptide of claim
 9. 14. An antibody against the polypeptide of claim
 10. 15. A polynucleotide that hybridizes with the nucleic acid comprising the nucleotide sequence of any one of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, or 21 or the complementary strand thereof and that comprises at least 15 nucleotides.
 16. A method for identifying a compound that binds to the polypeptide of claim 9, the method comprising the steps of: (a) contacting a test sample with the polypeptide or a partial peptide thereof, (b) detecting a binding activity of the test sample to the polypeptide or the partial peptide thereof, and (c) selecting a compound comprising the binding activity to the polypeptide or the partial peptide thereof, thereby identifying a compound that binds to the polypeptide of claim
 9. 17. A method for identifying a compound that binds to the polypeptide of claim 10, the method comprising the steps of: (a) contacting a test sample with the polypeptide or a partial peptide thereof, (b) detecting a binding activity of the test sample to the polypeptide or the partial peptide thereof, and (c) selecting a compound comprising the binding activity to the polypeptide or the partial peptide thereof, thereby identifying a compound that binds to the polypeptide of claim
 10. 